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Prion diseases are a group of rare, fatal neurodegenerative diseases, also known as transmissible 
spongiform encephalopathies (TSEs), that affect both animals and humans and include bovine 
spongiform encephalopathy (BSE) in cattle, scrapie in sheep, chronic wasting disease in deer and elk 
and Creutzfeldt-Jakob disease (CJD) in humans. TSEs are usually rapidly progressive and clinical 
symptoms comprise dementia and loss of movement coordination. A common hallmark of TSEs is the 
accumulation of an abnormal isoform (PrPSc) of the host-encoded prion protein (PrPc) in the brains of 
affected animals and humans. PrPc is a highly conserved cell surface sialoglycoprotein that is 
expressed in several cell types, mainly neuronal cells, but its normal physiological function is still not 
known. However, PrPc is elementary for the acquisition and the replication of prion diseases. Several 
inhibitors of the PrPSc formation have been reported, but none of them showed great potency in an in 
vivo application. Thus, the identification of the 37kDa/67kDa laminin receptor (LRP/LR) as the cell 
surface receptor for prions opened a new direction for the development of a TSE therapy.  
 
In the 1980s, the appearance of a new form of a neurological disease in the UK attracted attention of 
the scientific community. Since then, more than 180.000 BSE cases have been reported in the UK. The 
route of transmission of BSE is still not proven, but transmission of BSE to humans has been shown to 
cause the new variant of Creutzfeldt-Jakob disease (vCJD). Currently, no treatment to slow down or 
stop the disease process in humans with any form of CJD is established. In June 2004, the PRION-1 
clinical trial (3 years) was started to assess the activity and safety of Quinacrine in human prion 
disease since there are no other drugs available which are considered suitable for human evaluation. 
However, several strategies have been investigated to find an anti-prion treatment including 
development of a vaccination therapy and screening for potent chemical compounds.  
 
The discovery that the 37kDa/67kDa laminin receptor (LRP/LR) acts as the cell surface receptor for 
the cellular prion protein (PrPc) opened a new perspective for the development of an anti-prion 
therapy. In scrapie-infected neuronal cells, which represent a widely used and well characterized in 
vitro model for transmissible spongiform encephalopathies, the accumulation of PrPSc has been 
prevented by transfection of (i) antisense LRP RNA, (ii) small interfering RNAs targeting the LRP 
mRNA and (iii) incubation with the polyclonal anti-LRP antibody W3. Furthermore, the knock down 
of surface LRP/LR resulted in a reduction of the cellular PrP levels, suggesting an interference with 
the PrP internalization process. Thus, LRP/LR is required for the PrPSc propagation in vitro and 
involved in the PrPc metabolism. 
 
Due to the existence of several LR genes, a major step to investigate the role of the 37kDa/67kDa 
laminin receptor in scrapie pathogenesis in vivo is the generation of transgenic mice exhibiting a lower 
level of LRP/LR. Hemizygous transgenic mice that express LRP/LR antisense RNA under the control 
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of the neuron-specific enolase (NSE) promoter were generated and showed a reduced LRP/LR protein 
level in the cerebellum and the hippocampus. Intracerebral inoculation of these transgenic mice with 
the scrapie agent will show, whether the accumulation of pathogenic PrPSc in the brain is delayed or 
prevented due to a reduced LRP/LR level.  
 
A further therapeutic anti-prion approach is given by LRP/LR deletion mutants that can be secreted to 
the cell culture medium and might act as decoys. Previously, it has been demonstrated that a 
transmembrane deletion mutant is able to prevent PrPc binding and internalization. In vitro studies 
using an N-terminally truncated LRP mutant, representing the extracellular domain of LRP/LR 
(LRP102-295::FLAG), revealed a reduced binding of (i) recombinant cellular PrP to mouse 
neuroblastoma cells, (ii) infectious moPrP 27-30 to BHK21 cells and (iii) interfered with the PrPSc 
propagation in chronically scrapie-infected mouse neuroblastoma cells. Furthermore, a cell free 
binding assay demonstrated the direct binding of the LRP102-295::FLAG mutant to both PrPc and 
PrPSc. These results together with the finding that that endogenous LRP levels remain unaffected by 
the expression of the mutant indicate that the secreted LRP102-295::FLAG mutant may act in a trans-
dominant negative manner as a decoy by trapping PrP molecules. Thus, the LRP mutant might 
represent a potential therapeutic tool for the treatment of TSEs. 
 
To investigate the therapeutic potential of the LRP102-295::FLAG decoy mutant in vivo transgenic 
mice were generated ectopically expressing LRP102-295::FLAG in the brain. Animals showed no 
phenotype and transgene expression was detected in cortical and cerebellar brain regions. An 
intracerebral prion inoculation of these mice will prove whether the expression of the LRP102-
295::FLAG mutant can impair the PrPSc accumulation in the brain and can thus, act as a alternative 
therapeutic tool in prion diseases. 
 
Since there is no efficient TSE-treatment available, great expenses have been driven to discover an 
effective prion disease treatment. The recent finding that experimental introduction of RNA can be 
used to interfere with the function of an endogenous gene (RNA interference) provided a new tool for 
the development of gene-specific therapeutics. In order to evaluate a gene transfer therapeutic TSE 
strategy, human immunodeficiency virus (HIV)-derived vectors that express short hairpin RNA 
(shRNA) directed against the LRP mRNA were used. Following integration of LRP-shRNA-
expressing lentiviral vectors into the genome of neuronal cells efficient LRP/LR downregulation was 
observed. In scrapie infected neuronal cells, downregulation of the LRP gene expression resulted in a 
diminishment of PrPSc propagation, providing a further therapeutic strategy in the development of a 
TSE treatment. 
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1 Prion diseases 
 
Prion diseases or transmissible spongiform encephalopathies (TSEs) are incurable neurodegenerative 
disorders, which occur both in humans and animals. Human TSEs include Kuru (Gajdusek and Zigas, 
1957), Gerstmann-Sträussler-Scheinker syndrome (GSS) (Gerstmann et al., 1936), fatal familial 
insomnia (FFI) (Lugaresi et al., 1986) and Creutzfeldt-Jakob disease (CJD) (Creutzfeldt, 1920), which 
is the most prominent prion disease in humans. In animals, scrapie in sheep and goats (McGowan 
1922), feline spongiform encephalopathy (FSE) in cats (Wyatt, 1990), transmissible mink 
encephalopathy (TME) (Burger and Hartsough, 1965), chronic wasting disease in wild ruminants 
(CWD) (Williams and Young, 1980), bovine spongiform encephalopathy (BSE) in cattle (Wells et al., 
1987) and encephalopathies of a number of zoo animals (exotic ungulate encephalopathy, EUE) 
(Jeffrey and Wells, 1988; Kirkwood et al., 1990) have been described. A hallmark of all prion diseases 
is the accumulation of an abnormal, partially proteinase-resistant isoform of the cellular prion protein 
(PrPc), which is a cell-surface glycosylphosphatidylinositol (GPI) anchored protein (Stahl and 
Prusiner, 1991). PrPc is highly conserved among mammals (Schätzl et al., 1995) and is expressed in 
many tissues, notably high levels in the brain of animals and humans (Kretzschmar et al., 1986; 
Moudjou et al., 2001). The conversion of the host-encoded PrPc into the abnormal disease-causing 
isoform (PrPSc) involves a conformational change and is important in the pathogenesis of these 
diseases (Prusiner, 1994). Several hypotheses about the nature of the infectious agent have been 
proposed. Initially, the agent was thought to be a slow virus (Sigurdsson, 1954; Thormar, 1971) 
because of several criteria: a long incubation period of month to decades until the onset of disease, 
limitation of the infection to a single host and pathoanatomical changes in a single organ or tissue. 
Further research revealed that the agent differed substantially from viruses and was extremely resistant 
to ultraviolett and ionizing radiation and treatment with nucleases. Such findings led to the suggestion 
that the transmissible agent may be devoid of nucleic acid (Alper et al., 1967). In 1967, J.S.Griffith 
postulated the hypothesis that the causative agent might be a protein (Griffith, 1967). The theory of a 
self-propagating proteinaceous agent (Prusiner, 1982) was proposed after the isolation of a protease-
resistant sialoglycoprotein specifically associated with infectivity, designated the prion protein (PrP) 
(Bolton et al., 1982). The term prion, which was devised by Stanley Prusiner, is the abbreviation for 
“proteinaceous infectious particle” and was defined as “small proteinaceous infectious particle that 
resists inactivation by procedures which modify nucleic acids” (Prusiner, 1982). 
 
 
1.1 History of prion diseases 
 
During the18th century scrapie was first recognized in sheep and earned its name due to the itching and 
rubbing of affected sheep. In the 1920s, Hans Gerhard Creutzfeldt and Alfons Maria Jakob described 
the first case of a progressive neurological disturbance in humans (Creutzfeldt, 1920; Jakob, 1921) 
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(Table 1) and in 1922 the eponym “Creutzfeldt-Jakob disease” was first used to characterize a number 
of neurodegenerative diseases. In 1936, scrapie was demonstrated to be transmissible by inoculation 
between sheep following prolonged incubation periods (Cuillé and Chelle, 1936) (Table 1). In the 
1950s, a similar disease known as Kuru was identified among the Fore people, a tribe of remote 
highland natives of Papua New Guinea (Gajdusek and Zigas, 1957) (Table 1). Two years later, in 
1959, the neuropathological similarities between both Kuru and scrapie (Hadlow, 1959) and Kuru and 
CJD (Klatzo et al., 1959) were observed (Table 1). In the 1960s, the term transmissible spongiform 
encephalopathy (TSE) was applied after the discovery of the transmissible ability of both Kuru 
(Gajdusek et al., 1966) and Creutzfeldt-Jakob disease (CJD) (Gibbs et al., 1968) to chimpanzees 
(Table 1). In 1976 Daniel Carleton Gajdusek was awarded the Nobel Prize for medicine for his work 
on “slow virus” infection. Reports in the early 1980s of a spongiform encephalopathy in captive mule 
and elk from the USA did not attract much attention (Williams and Young, 1980). In April 1985, 
english farmers reported for the first time that cattle showing random fear and aggression and 
uncoordinated movements. Postmortem analysis of their brains revealed multiple lesions that had 
turned the gray matter into a spongelike mass (Wells et al., 1987) (Table 1). The appearance of bovine 
spongiform encephalopathy (BSE) in cattle in the UK in 1987 rapidly evolved into a major epidemic 
(Wilesmith, 1988). Renewed interest and research on this disease gave rise to considerable concern 
about the possibility of transmission the infectious agent from animal species to human. This fear was 
emphasized by the appearance of spongiform encephalopathies in captive zoo animals and in domestic 
housecats in the UK. About a decade after the first BSE case was recognized, a new form of the 
degenerative brain disorder known as Creutzfeldt-Jakob disease (CJD) appeared in UK, named new 
variant CJD (vCJD) (Will et al., 1996) (Table 1). By February 2006 a total number of 159 vCJD 
patients have been registered in the UK (www.vetolavie.chez.tiscali.fr), and it has been shown that 
these are linked to BSE (Hill et al., 1997) (Table 1). 
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Year   Research discovery 
Mid 18th century First description of scrapie  
1920     First description of CJD (Creutzfeldt, 1920) 
1936   Report of experimental transmission of scrapie (Cuillé and Chelle, 1936) 
1955-1957  Discovery of Kuru in New Guinea (Gajdusek and Zigas, 1957) 
1959   Similarities between Kuru and scrapie noted (Hadlow, 1959) 
   Similarities between Kuru and CJD noted (Klatzo et al., 1959) 
1961   Experimental transmission of scrapie to mice (Chandler, 1961) 
1966   Experimental transmission of Kuru to chimpanzees (Gajdusek et al., 1966) 
1967   First notification of the protein-only hypothesis (Griffith, 1967) 
1968   Experimental transmission of CJD to chimpanzees (Gibbs et al., 1968) 
1974   First documentation of iatrogenic prion transmission (Duffy et al., 1974) 
1982   Manifestation of the prion concept (Prusiner, 1982) 
1985 Cloning of the PrPc encoding gene (Chesebro et al., 1985; Oesch et al., 1985) 
1986  PrPc and PrPSc isoforms shown to be encoded by the same host gene (Basler et 
al., 1986) 
1987  First report of BSE in cattle (Wells et al., 1987) 
1993   Prnp0/0 mice are resistant to scrapie inoculation (Bueler et al., 1993) 
1996   Identification of new variant CJD (Will et al., 1996) 
1997   First evidence that vCJD is caused by the BSE agent (Hill et al., 1997) 
1999   Discovery of the PrPc homolog Dpl (Moore et al., 1999) 
2000  Resolution of the structure of the human prion protein by NMR (Zahn et al., 
2000) 
2001  Identification of the crystal structure of human prion protein (Knaus et al., 
2001) 
Identification of pharmacotherapeutics for prion diseases (Korth et al., 2001) 
2002   Interaction of cell-surface prion protein with glycosaminoglycans (Pan et al., 
2002) 
2003    Cell-free conversion of bacterial recombinant PrP (Kirby et al., 2003) 
2004 Proof that PrPc is sufficient for spontaneous formation of prions (Legname et 
al., 2004) 
2005  Effective treatment of scrapie-infected mice using a mucosal anti-PrP 
vaccination (Goni et al., 2005) 
 
 
  Table 1. Chronology of essential prion research 
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1.2 Human prion diseases 
 
Human transmissible spongiform encephalopathies (Table 2) are a group of rapidly progressive 
disorders characterized by a defined spectrum of clinical abnormalities.  
          
 
 TSE       Year of first report 
 Creutzfeldt-Jakob disease (CJD)     1920 
 Sporadic Creutzfeldt-Jakob disease (sCJD)   1921 
 Familial Creutzfeldt-Jakob disease (fCJD)   1924 
 Iatrogenic Creutzfeldt-Jakob disease (iCJD)   1974 
 New variant Creutzfeldt-Jakob disease (vCJD)   1996 
 Gerstmann-Sträussler-Scheinker syndrome (GSS)  1928 
Kuru        1957 
Fatal familial insomnia (FFI)     1986 
Sporadic fatal insomnia (sFI)     1999 
 
They all share a spongiform degeneration of the brain and a variable amyloid plaque formation. Four 
categories of human prion diseases have been described and can present as sporadic, inherited or 
iatrogenic disorders: Kuru, Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker syndrome and 
fatal insomnia (Table 3). 
 
Kuru (means “trembling with fear” in the native language), the prototype of human spongiform 
encephalopathy, is restricted to the ‘Fore’ people in the Eastern Highlands of New Guinea, where 
prions were transmitted by ritualistic cannibalism (Gajdusek, 1977). Among the natives the disease 
was originally termed “negi nagi” (meaning a silly person) which led to the designation as the 
‘laughing death’ (Klatzo et al., 1959). The disease occurred mostly in children and women, because 
they consumed the brain of deceased family members. In 1959, the government banned the 
cannibalistic practice.  
 
Creutzfeldt-Jakob disease (CJD) presents as a sporadic (classical), hereditary (familial) or iatrogenic 
(acquired) illness. Approximately 85% of all CJD cases occur sporadically, geographically 
ubiquitously with an incidence rate of 0.5-2 cases per one million people per year. The median age of 
the onset of disease represents the seventh decade (64 years) and men and women are equally affected 
(Kretzschmar, 1993; Ravilochan et al., 1983). Typically, memory loss and progressive dementia with 
cerebellar degeneration are diagnosed in classical CJD patients. Homozygosity for amino acid 
Methionin or Valin at position 129 has been identified as a predisposing factor in the majority of 
sporadic and iatrogenic CJD cases (Collinge et al., 1991; Palmer et al., 1991). 
  Table 2. Human prion diseases 
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Iatrogenic CJD (iCJD) is a very rare disease and has resulted from neurosurgery, corneal grafting, 
human dura mater implants or exposure, and the use of human growth hormone (hGH) and pituitary-
derived gonadotropin (hGNH). Iatrogenic CJD was first recognized in 1974 in a US patient who 
received a corneal transplant from a donor later proven to have died from CJD (Duffy et al., 1974). 
Today, the most common source of iCJD has been contaminated human growth hormone and a total of 
131 cases of iCJD following treatment with hGH have been reported (February 2006, 
www.eurocjd.ed.ac.uk) in the UK, France and the Netherlands.  
 
Familial CJD (fCJD), representing 5-15% of all CJD cases, is classified into many haplotypes based 
on the Prn-p mutation and codon 129 on the mutant allele (Lee et al., 1999). The majority of familial 
CJD cases (>70%) have been associated with a codon 200 mutation in the Prn-p gene (E200K) 
(Bertoni et al., 1992; Goldfarb et al., 1990; Goldgaber et al., 1989) or with a codon 178 mutation 
(D178N) (Goldfarb et al., 1991; Haltia et al., 1991; Nieto et al., 1991) (Figure 1). The symptoms of 
the familial form of CJD vary, depending on the type of PrP mutation involved (Mastrianni et al., 
2001).  
 
In contrast to CJD, Gerstmann-Sträussler-Scheinker syndrome (GSS) is almost always described in 
a familial context. Only a few sporadic cases resembling GSS have been described (Masters et al., 
1981). GSS is a rare form of prion disease and occurs at a rate of one per 100 million people per year 
worldwide (Ghetti et al., 1995). The syndrome was first described in 1928 by the Austrian neurologist 
Josef Gerstmann (1887-1969), followed by a more detailed report in collaboration with his colleagues 
Erwin Sträussler and Isaak Scheinker (Gerstmann et al., 1936). Most of the patients show first 
symptoms in the fourth or fifth decade of life. Investigations have shown that missense mutations are 
present in the Prn-p gene of GSS patients. To date, six mutations have been identified at codons 102 
(P102L) (Hsiao et al., 1989), 105 (P105L) (Yamada et al., 1993), 117 (A117V) (Doh-ura et al., 1989), 
131 (G131V) (Panegyres et al., 2001), 198 (F198S) (Dlouhy et al., 1992) and 217 (Q217R) (Hsiao et 
al., 1992), but the majority of affected families with GSS have a point mutation at codon 102 (Figure 
1). 
 
Fatal familial insomnia (FFI) was first described in 1986 in a 53 years old man (Lugaresi et al., 
1986). Since then, it has been reported in several European countries (Almer et al., 1999; Carota et al., 
1996; Padovani et al., 1998), Australia (McLean et al., 1997) and Japan (Nagayama et al., 1996). The 
occurrence of fatal familial insomnia is associated with the same codon 178 mutation (D178N) also 
observed in a subtype of familial CJD (Medori et al., 1992). The phenotype caused by the D178N 
mutation depends on a polymorphism at codon 129. The Met 129-Asn 178 allele segregates with FFI, 
while the Val 129-Asn 178 allele segregates with fCJD (Goldfarb et al., 1992).  
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Recently, the first cases of a sporadic form of fatal insomnia (sFI) have been reported in a 44-year-old 
man and a 58-year old woman (Mastrianni et al., 1999; Scaravilli et al., 2000). Both patients were 
homozygous for methionine at codon 129, but had no mutations in the prion protein gene. 
 
 
  
Figure 1. Pathogenic mutations and polymorphic variants of the human prion protein  
Prn-p mutations can be divided into two groups: (i) point mutations resulting in amino acid substitutions 
or production of a stop-codon (one case) in the prion protein and (ii) insertions encoding additional 
integral copies of an octapeptide repeat or deletion of an octapeptide repeat. (adopted from Collinge, 
2001).  
 
In 1995 and early 1996, a small number of remarkably young CJD patients were diagnosed in the 
United Kingdom (UK). Due to its similarity to sCJD, this human disease was termed “new variant of 
CJD” (vCJD) (Will et al., 1996). In contrast to sCJD, the median age of onset of the disease in vCJD  
patients is 28 years (sCJD 68 years) and the clinical course is prolonged (median 14 month, sCJD 6 
months). The appearance of vCJD in the United Kingdom and the experimental evidence that vCJD is 
caused by the same prion strain that causes BSE raised the possibility that an epidemic of vCJD might 
occur (Cousens et al., 1997; Ghani et al., 1998). Laboratory transmission studies in transgenic mice 
demonstrated that the characteristics of vCJD, including incubation period and neuropathological 
changes, are very similar in BSE and vCJD (Scott et al., 1999). The favored hypothesis for 
transmission of BSE to humans is a dietary exposure to prion-contaminated bovine tissues (likely 
CNS) in the 1980s (Will, 1999). Variant CJD is difficult to distinguish from other neurological 
disorders, so that a definitive diagnosis has relied on neuropathology. It has been demonstrated that 
vCJD can be diagnosed by PrPSc-immunostaining on a tonsil biopsy (Collinge, 1996; Hill et al., 1999). 
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To date, vCJD disease has only been recognized in individuals homozygous for methionine at codon 
129 in the Prn-p gene (Collinge et al., 1996). 
The human genotype at codon 129 of the Prn-p gene is known be a key determinant in human 
transmissible spongiform encephalopathies. This polymorphism modulates phenotype and disease 
susceptibility to acquired or sporadic prion infection (Cervenakova et al., 1998). The large majority of 
prion-disease-affected individuals are homozygous at codon 129 for either methionine or valine 
(Collinge et al., 1991; Palmer et al., 1991; Windl et al., 1996). The prevalence of Met/Met is only 
39% in the normal Caucasian population while the frequency for Met/Val is about 50% and for 
Val/Val 11% (Collinge et al., 1991). The protective effect of Prn-p codon 129 heterozygosity is seen 
in some of the inherited prion diseases (Baker et al., 1991; Hsiao et al., 1992).  
 
 
Disease       Mechanism of pathogenesis 
Kuru       infection through ritualistic cannibalism 
Sporadic Creutzfeldt-Jakob disease (sCJD)  somatic mutation  
Familial Creutzfeldt-Jakob disease (fCJD)  germline mutation in the Prn-p gene 
Iatrogenic Creutzfeldt-Jakob disease (iCJD)  infection from prion-contaminated       
medication, grafts and instruments 
New variant Creutzfeldt-Jakob disease (vCJD)  infection from bovine prions 
Gerstmann-Sträussler-Scheinker syndrome (GSS) germline mutation in the Prn-p gene 
Fatal familial insomnia (FFI)    germline mutation in the Prn-p gene 
Sporadic fatal insomnia (sFI)    not known 
 
 
 
1.3 Animal prion diseases 
 
Transmissible spongiform encephalopathies (TSEs) have also been described in different animal 
species (Table 4). 
 
Scrapie was first recognized as a disease of sheep in Great Britain over 200 years ago and is known as 
the prototype of prion diseases in animals. It is a slowly progressive disease and causes degeneration 
of the central nervous system (McGowan, 1922). The name “scrapie” is derived from the tendency of 
affected sheep to scrape off their wool. Although the worldwide distribution is unknown, Australia and 
New Zealand are the only countries being scrapie-free.  
 
The first case of bovine spongiform encephalopathy (BSE) was diagnosed in 1987 (Table 4) (Wells 
et al., 1987). BSE has a long incubation period of four to five years and is characterized by a 
spongiform degeneration of the brain with severe and fatal neurological symptoms. Between 
  Table 3. Pathogenesis of human prion diseases  
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November 1996 and February 2006 180857 cases of BSE were confirmed in the UK 
(www.vetolavie.chez.tiscali.fr). Epidemiological studies suggest that the source of BSE was cattle 
food that was contaminated by the scrapie agent (from meat and bone meal from sheep) due to an 
improper sterilization procedure. In July 1988, the UK banned the use of ruminant sources in the 
preparation of animal feed, but sale from UK to other countries was allowed. Six years later, the 
European Union (EU) banned mammalian meat and bone meal to ruminants (cattle, sheep). Starting in 
1996, bans prevented the sale of food and food products containing beef from the UK to other 
countries. However, in 1999, the EU repealed the ban for meat fulfilling specific requirements. Since 
then, cattle were continuously monitored for BSE.  
 
Transmissible mink encephalopathy (TME) has sporadically appeared in farmed mink and was first 
reported in 1947 in Wisconsin and Minnesota (USA) (Table 4). Epidemiological studies revealed that 
the disease is causally linked to the ingestion of prion-contaminated meat, potentially scrapie (Marsh 
and Bessen, 1993). To investigate potential food-borne sources of TME, mink were intracerebrally 
exposed to sheep scrapie brain homogenate and showed high susceptibility to the sheep scrapie 
(Hanson et al., 1971). Nevertheless, mink did not develop disease from ingesting scrapie brain (Marsh 
and Hanson, 1979). However, further experiments demonstrated that TME was transmitted to cattle 
and that brain from these cattle transmitted the TME agent efficiently to mink (Marsh et al., 1991). 
 
Feline spongiform encephalopathy (FSE) has been described in captive cheetah, puma, ocelot, tiger 
and lion (Table 4) and was likely due to the ingestion of BSE-infected material (Kirkwood and 
Cunningham, 1994). In addition, domestic cats have also been diagnosed with FSE (Ryder et al., 
2001). By February 2006, there were a total of 89 confirmed cases peaking at 1994 
(www.defra.gov.uk). Cases have mainly been confined to the UK, but there have been sporadic cases 
reported in Northern Ireland, Norway, Lichtenstein and Switzerland (www.defra.gov.uk). The most 
widely accepted hypothesis for transmission of the infectious agent is that the affected domestic cats 
were exposed to BSE material present in contaminated commercial cat food.  
 
Chronic wasting disease (CWD) is the only prion disease known affecting free ranging wildlife 
including elk, white-tailed deer and mule deer. The disease was first recognized in captive mule deer 
(Odocoileus hemionus) 39 years ago in Colorado (Table 4), but not diagnosed as a TSE until 1978 
(Williams and Young, 1980). Typically, affected animals are 3-5 years old. The origin of CWD in 
captive or free-ranging deer remains enigmatic (Miller et al., 2000; Williams and Miller, 2002), 
because these animals had never been fed with meat- or bone-meal (Williams and Young, 1992). The 
mode of transmission of CWD is unknown.  
 
In parallel to the first BSE cases, cases of spongiform encephalopathy in hoofed zoo species (exotic 
ungulate encephalopathy, EUE) were diagnosed in British zoos (Table 4). The exotic zoo ruminants 
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that died of TSE include greater kudu, eland, nyala, gemsbok, Arabian oryx, a scimitar-horned oryx 
and a bison (Kirkwood and Cunningham, 1994). The affected exotic ruminants appear to be linked to 
the BSE epidemic via the consumption of contaminated feed (Kirkwood and Cunningham, 1994). 
 
The first case of a spontaneously developed spongiform encephalopathy in a rhesus monkey (Macaca 
mulatta) (primate spongiform encephalopathy, PSE) was reported in 1996 in France (Table 4). 
Immunohistochemistry revealed severe vacuolation of neurons related to those seen in the brains of 
CJD patients (Bons et al., 1996). In the 1990s, further TSE cases of primates (lemurs) were reported. 
Indeed, lemurs experimentally infected with BSE showed similar neuropathology and distribution of 
PrPSc as spontaneously infected zoo lemurs (Bons et al., 1999) 
 
 
Species    TSE      Year of first report 
sheep, goats   Scrapie       1732 
european minks   Transmissible mink encephalopathy (TME)  1947 
captive mule and elk  Chronic wasting diseases (CWD)   1980 
captive cats   Feline spongiform encephalopathy (FSE)  1986 
domestic cats   Feline spongiform encephalopathy (FSE)  1990 
cattle    Bovine spongiform encephalopathy (BSE)  1987 
zoo antelopes   Exotic ungulate encephalopathy (EUE)   1986 
non-human primates  Primate spongiform encephalopathy (PSE)  1996 
 
 
2 The prion protein (PrP) 
 
The prion protein (PrPc) is a normal cellular glycolipid anchored protein and is highly conserved 
among mammalian species (Schätzl et al., 1995; Wopfner et al., 1999). It has been identified in 
various animals including birds (Harris et al., 1993), pisces (Gibbs and Bolis, 1997) and marsupials 
(Windl et al., 1995), and may be present in all vertebrates. PrP mRNA is constitutively expressed in 
the brains of adult animals with a high expression in neurons (Kretzschmar et al., 1986). Substantial 
amounts have also been found in heart (Brown et al., 1990), skeletal muscle (Bosque et al., 2002; 
Brown et al., 1998), lymphoid tissue and leukocytes (Liu et al., 2001; Paltrinieri et al., 2004), 
intestinal tissues (Morel et al., 2004) and uterus and testis (Tanji et al., 1995). In 1986, the human PrP 
gene (Prn-p) has been mapped to 20p12-pter (short arm of chromosome 20) (Liao et al., 1986; 
Robakis et al., 1986; Sparkes et al., 1986). The conformation of the cellular isoform of murine PrP 
was first determined by nuclear magnetic resonance (NMR) studies (Riek et al., 1996). Since then, 
NMR measurements on the prion protein from various species, e.g. Syrian hamster (Donne et al., 
   Table 4. Animal prion diseases  
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1997), human (Zahn et al., 2000), cattle (Lopez Garcia et al., 2000), sheep, cat, dog and pig (Lysek et 
al., 2005) as well as chicken, turtle, frog (Calzolai et al., 2005) and elk (Gossert et al., 2005), were 
performed and revealed that they all have global architecture similarities. The prion protein has a 
flexible, unstructured N-terminal region and a well-ordered C-terminal globular domain, which 
includes three α-helices and two antiparallel β-sheet structures (Riek et al., 1996). The N-terminal 
region contains a segment of several octapeptide-repeat regions that preferentially bind copper 
(Hornshaw et al., 1995) (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Genomic organization of the Syrian hamster cellular prion protein  
 Cellular PrP (PrPc) is a GPI-anchored protein of 254 amino acid residues. During PrPc processing a 
22 amino acid N-terminal signal peptide is removed and 23 C-terminal residues are cleaved upon 
the addition of the glycosylphosphatidylinositol anchor to Ser-231. The C-terminus is highly 
structured and possesses two glycosylation sites (Asn-181 and Asn-197) and cysteine residues 179 
and 214 act as sites to form a disulfide bound. The N-terminal region contains a series of 5 
octapeptide repeats that have been implicated in the binding of metal ions. (www.chemsoc.org, 
modified) 
 
Infrared spectroscopy and circular dichroism demonstrated that the secondary structure of PrPc is 
mainly composed of α-helices (42%), whereas PrPSc consists mainly of β-sheets (Cohen et al., 1994). 
In Syrian hamster and mice, PrPc is synthesized as a precursor of 254 amino acids (aa) while the 
human Prn-p encodes a prion protein 253 aa in length. During trafficking within the cell the N-
terminal signal peptide (22 amino acids) is cleaved off in the endoplasmatic reticulum (Hope et al., 
1986) and 23 C-terminal residues demerge upon addition of the GPI anchor at serine (Ser) 231 (Stahl 
et al., 1987). The hamster prion protein has two glycosylations sites at Asparagines (Asn) 181 and Asn 
197, and a disulphide bond is formed between Cysteine (Cys) 179 and Cys 214 (Turk et al., 1988). 
Cell culture studies revealed that PrPc constitutively cycles between the cell surface and an endocytic 
GPI anchor 
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compartment with a transit time of approximately 60 minutes. More than 95% of the internalized 
protein is recycled back to the cell surface, where it is anchored via the GPI moiety (Shyng et al., 
1993). 
 
 
2.1 Role of PrPc 
 
The exact physiological role of the cellular prion protein PrPc remains still obscure, although some 
possible biological functions have been described. The proposed functions include a neuroprotective 
function due to antiapoptotic activity (Bounhar et al., 2001; Diarra-Mehrpour et al., 2004), a 
functional role in copper metabolism due to its copper-binding capacity (Brown et al., 1997), 
involvement in signal transduction (Koch et al., 1991; Mouillet-Richard et al., 2000), memory 
formation (Coitinho et al., 2003) and neuritogenesis (Graner et al., 2000). Mice lacking PrP (Prnp0/0) 
showed no obvious phenotype (Bueler et al., 1992), although they have abnormalities in synaptic 
physiology (Collinge et al., 1994) and in circadian rhythm and sleep (Tobler et al., 1996). Prnp0/0 mice 
were shown to be completely resistant to prion disease (Bueler et al., 1993). Several lines of PrP 
knockout mice have been generated to unveil the function of PrPc (Weissmann and Flechsig, 2003).  
 
The molecular mechanism of PrP protection against oxidative stress is still unclear, but PrP may 
reduce copper-mediated oxidative stress due to its copper-binding activity (Vassallo and Herms, 
2003). PrPc binds copper via conserved histidine residues within the N-terminal region of the protein 
that contains an octapeptide repeat region (Brown et al., 1997). It has been proposed that PrPc acts as a 
sensor for copper and triggers intracellular calcium signals that finally modulate synaptic transmission 
(Vassallo and Herms, 2003). Since PrP knockout mice exhibit approx. 50% lower copper 
concentration in synaptosomal fractions than wild-type mice, it was suggested that PrPc might regulate 
the copper concentration in the synaptic region and may play a role in the re-uptake of copper into the 
presynapse (Kretzschmar et al., 2000).  
 
Furthermore, it has been shown that PrPc harbors a copper/zinc-dependent superoxide-dismutase 
(SOD) that provides PrPc with antioxidant activity. By deletion of the octapeptide repeat region 
involved in copper binding, the SOD activity was abolished (Brown et al., 1999). In vivo experiments 
revealed that protein and lipid oxidation is increased in skeletal muscle, heart and liver in Prnp0/0 mice 
suggesting a PrPc function related to cellular antioxidant defenses (Klamt et al., 2001). 
 
PrPc is known to be attached to the plasma membrane through a glycosylphosphatidylinositol (GPI) 
anchor and may act as a cell-surface receptor mediating cell-surface signaling or cell adhesion. 
Recently, a coupling of PrPc to the non-receptor tyrosine kinase Fyn was observed (Mouillet-Richard 
et al., 2000). Fyn tyrosine kinase is a member of the Src family of tyrosine kinases and is required for 
morphological differentiation of oligodendrocytes (Osterhout et al., 1999).  
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Furthermore, several experimental findings suggest a major role for PrPc in cell survival or cell death. 
In a yeast two-hybrid system, PrPc was demonstrated to interact selectively with the Bcl-2 protein 
(Kurschner and Morgan, 1995), that is a suppressor of the programmed cell death. Recently, the 
antiapoptotic activity of PrP has been shown in a human breast carcinoma cell line (Diarra-Mehrpour 
et al., 2004).  
 
Despite all knowledge, there is some controversy around the protective function of PrPc. It has been 
demonstrated that in some cell lines overexpression of PrPc increase the susceptibility of these cells to 
staurosporine-induced apoptosis (Paitel et al., 2002; Paitel et al., 2003). In addition, it was proposed 
that endogenous cellular prion protein sensitizes neurons to apoptotic stimuli through a p53-dependent 
caspase 3 mediated activation (Paitel et al., 2003; Paitel et al., 2004). But there are several possibilities 
to explain this discrepancy. First, in some cases overexpression of PrP may interfere with the cellular 
protein synthesis machinery leading to saturation following toxicity. Second, overexpression of PrP 
may lead to the formation of topological forms of toxic PrP and third, overexpressed PrP may be 
converted into a lethal protein or into an aberrant isoform.  
 
 
2.2 Trafficking of PrPc 
 
PrP is predominantly found on the cell surface where it is attached by a GPI anchor (Stahl et al., 
1987). The biosynthetic pathway of PrP is similar to that of other membrane proteins. PrPc is 
synthesized in the rough endoplasmatic reticulum (rER) and is further trafficking along the secretory 
pathway to the cell surface. Biosynthesis of PrPc includes cleavage of the N-terminal signal peptide, 
addition of N-linked oligosaccharide chains, formation of a disulfide bound, attachment of the GPI-
anchor and cleavage of the C-terminal hydrophobic peptide (Haraguchi et al., 1989; Stahl et al., 1987; 
Turk et al., 1988) followed by traveling to the plasma membrane. PrPc is associated with lipid rafts 
(Naslavsky et al., 1997), which are special membrane domains that are rich in cholesterol and 
sphingolipids (Simons and Ikonen, 1997) and thought to represent sites for signal transduction events. 
Previously published studies suggest, that misfolded or improperly matured PrP is retro-translocated 
from the ER into the cytosol and degraded by the proteasome (Bonifacino and Weissman, 1998; Ma 
and Lindquist, 2001; Ma and Lindquist, 2002; Ma et al., 2002; Tsai et al., 2002; Yedidia et al., 2001).  
 
Most PrPc molecules are attached to the cell surface, but at the endoplasmatic reticulum membrane PrP 
can be synthesized in several topological forms. These topological forms are ordinary generated 
during the PrP biosynthesis and span the membrane once, with either the N-terminus or the C-terminus 
on the cytoplasmic side of the lipid bilayer, designated NtmPrP and CtmPrP (Harris, 2003) (Figure 3). 
The possibility that alternative topological variants of PrP may play a role in prion diseases arose a 
great interest. In fact, it has been demonstrated that CtmPrP is a key neurotoxic intermediate in certain 
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prion diseases and might cause neurodegeneration (Hegde et al., 1998; Hegde et al., 1999; Stewart et 
al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Topological forms of PrP  
The majority of newly synthesized PrPc is attached to the cell surface through a C-terminal glycosyl-
phosphatidylinositol (GPI). During PrP biosynthesis in the endoplasmatic reticulum, the prion protein 
can also be synthesized in different topological form including two transmembrane forms designated 
NtmPrP and CtmPrP. The transmembrane species span the lipid bilayer once via a highly conserved 
hydrophobic region (amino acid 111-134) with either the N- or C-terminus on the extracytoplasmic 
side of the membrane. (Harris, 2003, modified) 
 
PrPc is constitutively internalized into an endocytic compartment and the majority is recycled to the 
cell surface (Shyng et al., 1993). It has been shown that copper rapidly and reversibly stimulates 
endocytosis of PrPc from the cell surface (Pauly and Harris, 1998). Furthermore, it has been 
demonstrated that PrPc, which is internalized in response to copper, is delivered to early endosomes 
(Brown and Harris, 2003). The mechanism of PrPc internalization is currently under investigation, and 
caveolae, rafts and clathrin-coated pits have been shown to be involved (Figure 4). Localization 
studies of PrPc indicated that PrPc clusters in caveolae or caveolae-like domains (CLDs) (Vey et al., 
1996). It has also been shown that PrPc is present in detergent insoluble glycosphingolipid-rich 
membrane domains (DIGs) in mouse brain (Parkin et al., 1999). Furthermore, in Chinese ovary 
hamster (CHO) cells caveolin-related endocytosis has been implicated (Peters et al., 2003). 
Interestingly, some GPI-anchored proteins may use endosomal organelles that contain caveolin-1 
(termed caveosomes), which is distinct from classical endosomes, to traffic to the Golgi (Nichols, 
2002). 
A more commonly studied pathway for the endocytic uptake of PrPc involves clathrin-coated pits 
(Figure 4). Initial experiments using a chicken homologue of PrPc indicated that internalization of PrPc 
is dependent on clathrin-mediated endocytosis (Shyng et al., 1994). Later on it has been demonstrated 
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that the N-terminal region of the prion protein is essential for its internalization via clathrin-coated pits 
(Shyng et al., 1995). More recently, it was shown that the N-terminal region is not only important for 
endocytosis but also for delivery of PrPc to the cell surface (Nunziante et al., 2003). In neurons, it has 
been shown that PrPc is located in the Golgi and in endosomal intracytoplasmic organelles (Laine et 
al., 2001). Recent immunoelectron microscopy experiments in neuronal cells have demonstrated, that 
PrPc is rapidly endocytosed and predominantly found in clathrin-coated pits (Sunyach et al., 2003). 
Investigation of the vesicular transport revealed, that different Rab proteins are associated with 
endosomes (Sonnichsen et al., 2000) that are implicated in the endocytic transport of PrPc. 
Finally, non-clathrin and non-caveolin but raft-dependent endocytosis has been proposed to participate 
in the internalization of PrPc (Figure 4). The association of GPI-anchored proteins with cholesterol-
rich rafts is generally a dynamic phenomenon and might facilitate maturation and correct folding of 
PrPc (Sarnataro et al., 2004). Overall, PrPc may use distinct intracellular routes for internalization but 
there is growing evidence for a role of classical endosomal organelles in PrPc intracellular trafficking. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Cellular trafficking of PrPc  
 At the cell surface, PrPc can be constitutively internalized into an endocytic compartment from which 
most molecules are recycled to the plasma membrane. (i) In neuronal cells, PrPc internalization seems to 
depend on clathrin-mediated endocytosis. Rab5 positive endosomes have been shown to participate in the 
trafficking of PrPc. (ii) Caveolin-related endocytosis and trafficking have also been suggested for PrPc, 
particularly in CHO cells. (iii) Like other GPI-anchored proteins PrPc is associated with rafts. Therefore, 
a non-clathrin and non-caveolin, but raft-dependent endocytosis has been implicated to participate in the 
internalization of PrPc. (adopted from Campana et al., 2005) 
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2.3 Characteristics of PrPSc 
 
In TSEs, the cellular prion protein PrPc can be converted into a pathogenic isoform referred to as PrPSc 
that shows great resistance to radiation and nucleases (Alper et al., 1967). The high proportion of β-
sheets in PrPSc (Figure 5) renders it insoluble and markedly resistant to proteases (Cohen and Prusiner, 
1998).  
 
 
 
 
 
 
 
 Figure 5. Models of the three-dimensional structures of PrP isoforms 
The structure of the normal prion protein, known as cellular PrPc (A), contains 
mostly α-helical structures (brown ribbons) and a small portion of flattened β-sheet 
(blue arrows). The increase in β-sheet upon conversion into the prion form is 
illustrated in (B) by the theoretical structural model of PrPSc. The 90-160 region of 
amino acid sequence has been modeled onto α-helical architecture (blue arrows) 
while the C-terminal helices are preserved as in PrPc (brown ribbons). (adopted 
from F. Cohen, University of California, San Francisco) 
 
Digestion with proteases result in a 27-30kDa fragment, often termed PrPres (Bolton et al., 1982). 
PrP27-30 is unusual stable at high temperatures and can only be inactivated by protein denaturants that 
modify the structure of PrP27-30 (Prusiner et al., 1993). During prion diseases PrP27-30 accumulates 
into rod-shaped polymers that are insoluble in aqueous and organic solvents as well as nonionic 
detergents. In contrast, PrPSc (the full-length infectious conformer of PrPc) has a tendency to form 
aggregates but not amyloid fibrils (McKinley et al., 1991) (Table 5). 
 
 
        PrP isoform           PrPc       PrPSc               PrP27-30 
         
        infectivity      non infectious              infectious  infectious 
        protease status     sensitive          partially resistant              resistant 
        solubility       soluble   insoluble              insoluble 
        aggregation status     monomer   aggregates          amyloid fibrils 
        secondary structure   α-helices (42%),              α-helices (30%),        α-helices (21%), 
      β-sheets (3%)                       β-sheets (45%)        β-sheets (54%) 
 
Table 5. Properties of different PrP isoforms 
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Prusiner, 1991 
Lansbury and Caughey, 1995 
2.4 Conversion of PrPc to PrPSc 
 
Given the same primary structure of PrPc and PrPSc (Basler et al., 1986), the different properties of 
PrPc and PrPSc seemed likely to involve post-translational modifications. Extensive biochemical 
investigations have failed to reveal any covalent difference between PrPc and PrPSc (Stahl et al., 1993). 
By contrast, spectroscopic studies demonstrated a conformational difference between PrPc and PrPSc. It 
was shown, that PrPc has a high α-helical content of approx. 40%, with little or no β-sheets (approx. 
3%), whereas PrPSc contains approx. 30% α-helices and approx. 45% β-sheets (Pan et al., 1993) 
(Table 5). PrPSc formation is supposed to occur via the interaction between PrPc and PrPSc, which is 
able to convert the host protein into a likeness of itself (Griffith, 1967; Prusiner, 1982). The 
mechanism by which PrPSc triggers further PrPSc production is unknown, although two major models 
have been proposed (Figure 6). The catalytic model (Prusiner, 1991) proposes that the presence of 
PrPSc catalyzes the conversion of PrPc to PrPSc. Alternatively, it has been proposed that the formation 
of PrPSc is a nucleation-dependent process (Lansbury and Caughey, 1995). The conversion between 
PrPc and PrPSc is reversible, but the PrPSc monomer is less stable than PrPc and several monomeric 
PrPSc molecules are stabilized by binding to PrPc or other PrPSc aggregates. The cell-free in vitro 
conversion process was shown to be consistent with the nucleated polymerization mechanism of PrPSc 
formation and inconsistent with the heterodimer mechanism (Caughey et al., 1995).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Conversion models of PrPc to PrPSc 
(A) The “refolding (or catalytic) model” postulates that PrPSc is inherently more stable than PrPc, but 
kinetically inaccessible. But PrPSc could promote conversion of a PrPc molecule to the more stable PrPSc 
conformation. Infectivity then relies on the ability of the PrPSc molecule to bind to and catalyze the 
conversion of existing intermediate molecules. (B) The nucleation-polymerization or “seeding” model 
proposes, that PrPc and PrPSc are in a reversible thermodynamic equilibrium, but the PrPSc monomer is 
less stable than PrPc. Only if several monomeric PrPSc molecules are mounted into a higly ordered seed, 
further monomeric PrPSc can be recruited and form amyloid aggregates. Fragmentation of PrPSc 
aggregates increases the number of seeds, which can recruit further PrPSc, and thus results in replication 
of the agent. (adopted from Aguzzi and Polymenidou, 2004) 
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However, the precise subcellular localization of PrPSc propagation remains controversial. But there is 
evidence, that either late-endosome-like organelles or lysosomes are involved (Arnold et al., 1995; 
Mayer et al., 1992). Recent studies report the involvement of rafts in different diseases (Fantini et al., 
2002) and a role in pathogen invasion (van der Goot and Harder, 2001). A role for lipid rafts in the 
formation of PrPSc is deduced from the finding that both PrPc and PrPSc are present in rafts isolated 
from infected cells (Baron and Caughey, 2003; Botto et al., 2004). Although the exact mechanisms of 
how rafts control the formation of PrPSc are unidentified, there exist three different models. Firstly, 
rafts might be involved in targeting PrPc to the specific compartments in which PrPSc 
transconformation occurs. Secondly, rafts might contain factors comprising the transconformation 
machinery. And thirdly, rafts might provide the membrane environment for the transconformation 
process by concentrating PrPc and PrPSc within defined parts of the plasma membrane (Campana et al., 
2005). 
 
 
2.5 The prion-like protein Doppel (Dpl) 
 
In 1999, a novel gene 16kb downstream from the mouse prion protein gene (Prn-p), located on 
chromosome 2, was identified and termed Prn-d (prion protein dublet). The human Prn-d gene is 
localized similarly, 27kb downstream of Prn-p on 20pter-p12 (Moore et al., 1999). The Prn-d gene 
generates two major transcripts of 1.7kb and 2.7kb and encodes a 179 amino acid residue PrP-like 
protein designated “Doppel” (Dpl). Like PrP, Dpl is expressed during embryogenesis, in heart and 
testis, but in contrast to PrP, it is minimally expressed in the adult central nervous system (CNS). The 
Dpl and PrP proteins show approx. 25% sequence identity.  
 
 
 
 
 
 
 
 
 
Figure 7. Organization of murine Dpl and PrP  
PrP and Dpl are both GPI-anchored proteins and show structural similarities. Like PrPc, Dpl is a protein 
with two N-glycosylation sites and a globular C-terminus containing three α-helices and two short β-
strands. Dpl is distinguished from PrPc by a shorter N-terminal region, a kink in helix B and a different 
location and stoichiometry of the Cu2+-binding site. (adopted from Whyte et al., 2003) 
CHO : glycosolation sites 
GPI  :  glycosylphosphatidylinositol addition sites 
TM region : transmembrane region 
α-helices A, B and C 
 
cleavable signal peptide 
 
octapeptide-repeat regions 
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However, Doppel lacks the flexible N-terminal octapetide repeat region of PrPc that binds copper ions 
and the highly conserved region between amino acid 106 and 126 that is thought to be essential for 
prion replication (Weissmann and Aguzzi, 1999) (Figure 7). Investigation of the physiological 
functions of Dpl revealed, that Dpl deficiency resulted in male sterility in mice (Behrens et al., 2002). 
Furthermore, ectopic expression of Dpl in the brain of PrP knockout mice has been proposed to cause 
neurotoxicity (Moore et al., 1999; Rossi et al., 2001). 
Very little is known about potential binding partners of Doppel. Very recently, it was shown that Dpl 
binds the full-length 37kDa laminin receptor precursor protein (LRP) (Yin et al., 2004). In addition, 
Yin et al. claimed that the middle segment of LRP (residues 100-220) is sufficient for the binding of 
LRP to Dpl (Yin et al., 2004). However, a LRP mutant lacking the first 43 amino acids (LRP44-295) 
did not interact with Dpl (Hundt and Weiss, 2004). These contradictory results might be explained by 
the fact that the binding site in the middle segment of LRP (residues 100-220) is not properly exposed 
in a N-terminal deleted LRP mutant. In a yeast two-hybrid system, Dpl also failed to interact with 
itself and the cellular prion protein (Hundt and Weiss, 2004), suggesting that Dpl might play no 
essential role in prion diseases.  
Together with the findings that (i) expression of Dpl in the CNS of mice did not modulate TSEs (Tuzi 
et al., 2002), (ii) Dpl expression was not modified in scrapie-infected cells and in the brain of CJD 
patients (Peoc'h et al., 2003) and (iii) Dpl is dispensable for prion disease progression and PrPSc 
(Behrens et al., 2001) generation an essential function of Dpl in prion diseases is unlikely. 
 
 
3 Prion-like elements in yeast, fungi and aplysia 
 
Prion-like proteins are found naturally in many plants and animals. Hence, scientists reasoned that 
such proteins provide some evolutionary advantage to their host. In yeast Saccaromyces cerevisiae 
(Weissmann, 1994) and in the filamentosus fungus Podospora anserina (Coustou et al., 1997) genetic 
elements with an unusual pattern of inheritance were described.  
In yeast, the prion-like genetic elements were named [PSI+] and [URE3] and are associated with the 
proteins Sup35p* and Ure2p*, respectively (Wickner, 1994; Masison and Wickner, 1995; Wickner et 
al., 1995), equivalent to mammalian prions such as PrPSc. The corresponding non-prion-associated 
genetic elements are termed [psi-] and [ure3], the protein determinants Sup35p and Ure2p, 
respectively. Sup35p is an essential subunit of the translation release factor that recognizes termination 
codons and releases the complete peptide from the last tRNA (Hawthorne and Mortimer, 1968), while 
Ure2p acts as a negative regulator of nitrogen metabolism (Coschigano and Magasanik, 1991; 
Courchesne and Magasanik, 1988). [PSI+] results in expression of the prion form Sup35p* causing a 
reduction of translational fidelity leading to read-trough of stop-codons (Cox et al., 1988). [URE3] 
leads to expression of Ure2p*, promoting the uptake of ureidosuccinate (Lacroute, 1971).  
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Genomic searches led to the identification of further prion proteins, Rnq1p (Sondheimer and 
Lindquist, 2000) and New1p (Michelitsch and Weissman, 2000). Like other prions, Rnq1 and New1p 
exist in two heritable states, a soluble form and an aggregated form, [RNQ+] (also known as the 
epigenetic element [PIN+]) and [NU+], respectively.  
Recently, it was demonstrated that in the sea slug Aplysia californica CPEB (cytoplasmic 
polyadenylation element binding protein) has prion-like properties, forming small aggregates or 
multimers in its active state (Si et al., 2003). CPEB was initially identified in Xenopus oocytes as a 
translational regulator that activates dormant mRNAs by elongating their poly (A) tails (Hake and 
Richter, 1994). Si et al. speculated that in Aplysia CPEB has at least two conformational states: one 
inactive and one active. The prion-like state of neuronal CPEB might be more active, might have 
altered substrate specificity, or might be devoid of the inhibitory function of the basal state. The prion-
like state would thereby promote expression of several proteins establishing new synaptic connections 
and thus, maintain long-term synaptic changes associated with memory storage (Si et al., 2003). 
 
 
4 Prion strains 
3 
Initially, prion strains were isolated based on different clinical symptoms in goats with scrapie 
(Pattison and Millson, 1961). Newly, prion strains are distinguishable by their biological properties 
such as behavior of the affected animals, incubation period, neuropathological profiles, plaque 
morphology and proteinase K susceptibility of PrPSc. To date, different scrapie strains have been 
isolated from natural sheep scrapie by passage into mice (Table 6). Well studied are two strains of 
transmissible mink encephalopathie (TME) termed drowsy (DY) and hyper (HY) prions. These prion 
strains were isolated from mink by passage in Syrian hamsters. Studies of the DY and HY prion 
strains showed, that two strains produced PrP27-30 molecules of different molecular sizes (Bessen and 
Marsh, 1994). Furthermore, new strains have been produced upon passage from one species to another 
(Kimberlin et al., 1987). Interestingly, several human PrPSc types have been isolated that are 
associated with different phenotypes of CJD (Collinge et al., 1996; Parchi et al., 1996). Three PrPSc 
types among cases of sporadic and itrogenic CJD and a type 4 in all cases of vCJD were described by 
Collinge and colleagues (Collinge et al., 1996). Knowing that vCJD is associated with a PrPSc type that 
is distinct from those seen in classical CJD, molecular strain typing can be applied to molecular 
diagnosis of Creutzfeldt-Jakob disease. This technique may also be applicable to determine whether 
BSE has been transmitted to other species, and thereby possesses implications for epidemiological 
studies. (Hill et al., 1997). 
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 Species     TSE strain 
  
mouse-adapted scrapie   139A, RML, Chandler, ME7, 
      22L, 87V, C506-M3, 79A, 111A 
 mouse-adapted BSE   301C, 301V, 6PB1 
 mouse-adapted CJD   Fukuoka-1 
 hamster-adapted scrapie   263K, 22A-H, ME7-H, Sc237 
 hamster-adapted BSE   BSE-H 
 hamster-adapted TME   DY, HY 
 
 
5 Prion transmission barriers 
 
Early studies proposed that transmission of prion diseases between different mammalian species is 
restricted by a “species barrier” (Pattison, 1965). By the use of experimental mouse models it has been 
illustrated that the “species barrier” limits or even prevents the interspecies transmission of prion 
diseases. For example, mice are normally resistant to an infection with the 263K strain of hamster 
prion, but become susceptible to that strain of PrPSc by transgenic introduction of the hamster PrP gene 
(Scott et al., 1989). To study TSE transmission different mouse models were created, including 
transgenic mice expressing human PrP (Telling et al., 1994), bovine PrP (Buschmann et al., 2000) and 
ovine PrP (Crozet et al., 2001; Vilotte et al., 2001). These transgenic mice showed a strongly reduced 
species barrier following inoculation of human, bovine or sheep prions, respectively, allowing 
transmission of natural prion disease to wild-type mice. A second approach to facilitate the 
transmission of TSEs in mice was the overexpression of murine PrP in mice. Transmission studies in 
tga20 mice, that express 10-fold higher levels of PrPc than wild-type mice, revealed a significant 
reduction of the incubation periods following inoculation with natural scrapie isolates (Vilotte et al., 
2001). Furthermore, prion inoculation of tga20 mice has been shown to shorten the incubation period 
by the half (Fischer et al., 1996; Thackray et al., 2002). Recent studies of TSE transmissions in mice 
revealed further complexity of the genetic control of prion diseases. Genetic loci other than Prn-p 
influencing the incubation periods of mouse-adapted scrapie strains were identified on chromosomes 
2, 11, 12 and 9 (Lloyd et al., 2001; Stephenson et al., 2000).  
 
 
6 In search of binding proteins and receptors for prions 
 
More than 10 years ago the existence of a cellular receptor for prions was proposed. It was reasoned 
that the cellular prion protein PrPc would require a transmembrane protein to connect with the 
Table 6. Established TSE strains in mice and hamsters 
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intracellular space (Shyng et al., 1994). Employing complementary hydropathy, a 66kDa membrane 
protein that binds PrPc both in vitro and in vivo was found (Martins et al., 1997) and it was reasoned 
that this protein might act as a cellular prion protein receptor. By the same group, years later the 
66kDa protein was identified as stress-inducible-protein1 (STI1), phasing a role in neurite outgrowth 
and neuroprotection (Zanata et al., 2002). Using the yeast two-hybrid technology in Saccharomyces 
cerevisiae, the 37kDa laminin receptor precursor (LRP) was identified interacting with the cellular 
prion protein PrPc (Rieger et al., 1997). Moreover, it has been shown that several glycosaminoglycans 
(GAG) bind to PrPc (Pan et al., 2002; Priola and Caughey, 1994) and stimulate the PrPres formation in 
a cell-free system (Wong et al., 2001). Heparan sulfates are a component of amyloid plaques in prion 
diseases (Snow et al., 1990). Different proteins (Figure 8, Table 7) have been shown to interact with 
the cellular prion protein including laminin (Graner et al., 2000), which is an extracellular matrix 
protein, N-CAM (Schmitt-Ulms et al., 2001), a cell surface component with an important role in 
neuronal aggregation, and the laminin receptor (Rieger et al., 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
      Figure 8. Representation of the binding domains of PrPc ligands on the human PrPc molecule 
Numbers below the boxes correspond to the amino acids in each domain. Double arrows indicate the 
binding site for each PrPc-binding molecule, which is also represented by amino acid numbers in 
parentheses. (adopted from Lee et al., 2003) 
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PrPc binding molecules  proposed subcellular binding sites 
 
 Synapsin 1b    intracellular vesicles (Spielhaupter and Schätzl, 2001) 
 Grb2     intracellular vesicles (Spielhaupter and Schätzl, 2001) 
 Pint 1     unknown (Spielhaupter and Schätzl, 2001) 
 Caveolin-1    caveolae raft (Mouillet-Richard et al., 2000) 
 CK2     caveolae raft (Meggio et al., 2000) 
 STI 1     cell surface (Zanata et al., 2002) 
 Bcl-2     unknown (Kurschner and Morgan, 1995) 
 p75    caveolae raft (Della-Bianca et al., 2001) 
 Laminin   cell surface (Graner et al., 2000) 
 GAG     cell surface (Pan et al., 2002) 
 N-CAM   caveolae-like domain (Schmitt-Ulms et al., 2001) 
 Hsp60     unknown (Edenhofer et al., 1996) 
 Nrf2     unknown (Yehiely et al., 1997) 
 Aplp1     cell surface (Yehiely et al., 1997) 
 Laminin receptor   cell surface (Gauczynski et al., 2001b) 
 NRAGE   cytosol (Bragason and Palsdottir, 2005) 
 
 
6.1 Molecular chaperones 
 
Misfolded proteins can lead to intracellular aggregate formation, disruption of multiple cellular 
processes and cell death. In prion diseases, it is proposed that the conversion of PrPc to PrPSc is 
mediated by molecular chaperones. In a yeast two-hybrid screen the chaperonin Hsp60 was identified 
as an interaction partner for the Syrian hamster prion protein (Edenhofer et al., 1996). In vitro binding 
studies with recombinant PrP confirmed the specificity of the PrP-Hsp60 interaction. Interestingly, 
heat shock protein Hsp104 has been linked to the function of prion-like elements in yeast (Chernoff et 
al., 1995). Furthermore, Hsp104 and GroEL, the bacterial homologue of Hsp60, were found to 
promote conversion of PrPc into the proteinase K resistant state. Other heat shock proteins such as 
GroES, Hsp40, Hsp70 and Hsp90 don’t seem to influence the conversion process (DebBurman et al., 
1997).  
 
 
 
 
  Table 7. Binding partners for the cellular prion protein and subcellular binding sites 
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6.2 Protein X 
 
Protein X represents a prominent protein proposed to participate in the conversion mechanism of PrPc 
to PrPSc, although its identity is still unknown. Protein X might act as a molecular chaperone in the 
formation of PrPSc (Telling et al., 1995). Evidence for the participation of protein X in prion 
propagation arose from transmission studies in transgenic mice. Transgenic mice expressing high 
levels of human prion protein (Tg(HuPrP)Prnp+/+) failed to develop CNS dysfunctions following 
inoculation with human CJD prions (PrPCJD), whereas mice expressing a chimeric human/mouse PrP 
transgene (Tg(MHu2M)Prnp+/+) were highly susceptible to human prions (Telling et al., 1994). One 
explanation for the difference in susceptibility of (Tg(MHu2M)Prnp+/+) and (Tg(HuPrP)Prnp+/+) mice 
to human prions might be that mouse chaperones catalyzing the refolding of PrPc into PrPSc might 
readily interact with the MHu2MPrPc/HuPrPCJD complex but not with HuPrPc/HuPrPCJD. Another 
possibility might be that sequences at the N- or C-terminus of HuPrP inhibit the formation of PrPSc in 
murine cells (Telling et al., 1994). Overall, it was concluded that different susceptibilities of 
Tg(HuPrP) and Tg(MHu2M) mice to human prions indicate that additional species-specific factors 
might be involved in prion replication (Telling et al., 1994).  
The fact that N-terminal truncations of PrPc still permits the formation of PrPSc suggested that the 
binding site for the protein X is located in the C-terminal segment of PrP (residues 169-230) (Fischer 
et al., 1996; Rogers et al., 1993). The finding that substitution of a basic residue at positions 167, 171 
or 218 of human PrP, respectively, prevented PrPSc formation, suggests that these mutant PrPs might 
act as “dominant negatives” by binding protein X and rendering it unavailable for prion propagation 
(Kaneko et al., 1997).  
 
 
6.3 The 37kDa/67kDa laminin receptor (LRP/LR) 
 
In a yeast two-hybrid screen, the 37kDa laminin receptor precursor (LRP) was identified as an 
interaction partner for the prion protein (Rieger et al., 1997). Further in vitro studies on neuronal and 
non-neuronal cells validated that the laminin receptor LRP/LR act as the receptor for the cellular prion 
protein (Gauczynski et al., 2001b). Yeast two-hybrid studies and cell biological mapping analysis 
identified domains on PrP and LRP involved in the PrP-LRP interaction (Figure 9). Two binding 
domains for LRP on PrP were identified: a direct binding domain (PrPLRPbd1, aa144-179) and an 
indirect binding domain (PrPLRPbd2, aa53-93), which depends on the presence of heparan sulfate 
proteoglycans (HSPGs), functioning as co-factors or co-receptors for the binding of PrPc to LRP/LR 
(Hundt et al., 2001) (Figure 9). Furthermore, the yeast two-hybrid system localized the direct PrP-
binding domain on LRP between amino acid residues 161 and 179 (Hundt et al., 2001) and a second 
HSPG-dependent binding site, that might be located between amino acid 180 and 285 (Figure 9).  
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Figure 9. Model for the function of the 37kDa/67kDa LRP/LR as a receptor for PrP 
The PrP molecule binds directly to LRP/LR via PrPLRPbd1 (aa144-179) and indirectly via PrPLRPbd2 
(aa53-93). Direct binding of LRP/LR to PrP occurs via the direct binding site on LRP/LR (aa161-179), 
whereas the indirect HSPG-dependent binding domain may reside between aa 180 and 285. (adopted 
from Hundt et al., 2001) 
 
HSPGs are multifunctional macromolecules characterized by a core polypeptide to which 
glycosaminoglycans (GAGs) are covalently attached and have been also shown to be associated with 
Aβ deposits in Alzheimer’s disease (AD) (Snow et al., 1994). In addition, cell surface proteoglycans 
are known to act as cellular receptors for some bacteria and several animal viruses (Rostand and Esko, 
1997), including foot-and-mouth disease type O virus (Jackson et al., 1996), HSV types 1 and 2 (Shieh 
et al., 1992) and dengue virus (Chen et al., 1997). Furthermore, HSPGs were identified as primary 
receptor for AAV (Summerford and Samulski, 1998) and shown to mediate HIV-cell attachment and 
virus entry (Patel et al., 1993). HSPGs play also a crucial role in regulating key developmental 
signaling pathways, such as the Wnt, TGF-β (transforming growth factor-β) and FGF (fibroblast 
growth factor) pathways (Lin, 2004).  
 
The 37kDa LRP is thought to be the precursor of the 67kDa high-affinity laminin receptor (LR), 
which was first isolated from melanoma cells due to its high binding capacity to laminin (Rao et al., 
1983). Although LRP consists of a transmembrane domain (amino acid residue 86-101, Castronovo et 
al., 1991), it is abundantly localized in the cytoplasm (Romanov et al., 1994). In mammalian cells, it 
has been demonstrated that both the 37kDa LRP and the 67kDa LR are present in plasma membrane 
fractions (Gauczynski et al., 2001b). The exact mechanism by which the 37kDa precursor forms the 
mature 67kDa isoform is up to now still unclear. Data from the yeast two-hybrid analysis showed that 
LRP failed to interact with itself (Hundt et al., 2001), which is an argument against the hypothesis of a 
direct homodimerization. Analysis of the membrane-bound 67kDa LR indicated, that acylation of LRP 
is involved in the processing of the receptor (Landowski et al., 1995). Additional studies suggested 
that the 67kDa LR is a heterodimer stabilized by fatty acid-mediated interactions (Buto et al., 1998). 
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Mammalian genomes contain multiple copies of the LRP gene, particularly 6 copies in the mouse and 
26 copies in the human genome (Jackers et al., 1996b). Sequencing revealed that over 50% of the 
37kDa LRP gene copies were pseudogenes most probably generated by retropositional events. The 
finding of multiple pseudogenes for the 37kDa LRP might suggest that the accumulation of several 
copies of this gene might have given a survival advantage to the cell in the course of evolution 
(Jackers et al., 1996a).  
Interestingly, the 37kDa LRP appears to be a multifunctional protein involved in the translational 
machinery (Auth and Brawerman, 1992) and has also been identified as p40 ribosome-associated 
protein (Makrides et al., 1988). LRP has also been found in the nucleus, where it is tightly associated 
with nuclear structures (Sato et al., 1996). The 37kDa/67kDa LRP/LR has been described to act as a 
receptor for laminin, elastin and carbohydrates (Ardini et al., 1998) as well as a receptor for 
Venezuelan equine encephalitis virus (VEE) (Ludwig et al., 1996), Sindbis virus (Wang et al., 1992) 
and Dengue virus (Tio et al., 2005). Due to the co-localization of LRP/LR and PrP on the surface of 
mammalian cells, a possible role of LRP/LR for PrP binding and internalization was assumed. Using a 
cell-binding assay with recombinant PrP a LRP/LR dependent binding of PrP has been shown 
(Gauczynski et al., 2001b). The strict LRP/LR specificity for the PrP binding could be confirmed in 
competition assays with different anti-LRP antibodies. Furthermore, it has been demonstrated, that the 
PrP internalization process represents an active receptor-mediated event (Gauczynski et al., 2001b). 
Due to the identification of various LRP/LR isoforms, additional studies have been performed to 
detect the isoforms that are present in the central nervous system and bind PrP. Therefore, mouse brain 
fractions enriched in the laminin receptor were purified and overlay assays with recombinant PrP were 
performed (Simoneau et al., 2003). Several LRP/LR isoforms corresponding to different maturation 
states of the receptor were identified, including a 44kDa, 60kDa, 67kDa and a 220kDa form. 
Furthermore, it has been demonstrated, that all of these isoforms were able to bind PrP, supporting a 
physiological role for the laminin receptor/PrP interaction in the brain (Simoneau et al., 2003). A 
closer insight into the fine cellular distribution of LRP/LR in the central nervous system was obtained 
by using immunohistochemistry in adult rat brain (Baloui et al., 2004). It has been shown that the 
67kDa LR is the major receptor form, which is expressed within the cytoplasm and at the plasma 
membrane in most neurons and in a subset of glia cells. In contrast, the 37kDa LRP is much less 
abundant in adult than in postnatal central nervous system and its expression is restricted to a subclass 
of cortical interneurons known to be particularly sensitive to abnormal prion accumulation and rapidly 
degenerate during early stages of CJD (Belichenko et al., 1999). In addition, recent studies showed 
that LRP/LR is not only involved in the PrPc metabolism, but has also a crucial role in prion 
propagation. Using antisense LRP RNA and small interfering (si) RNAs specific for LRP mRNA, 
PrPSc levels in scrapie-infected neuronal cells were reduced indicating a necessity for the laminin 
receptor LRP/LR for PrPSc propagation in cultured cells (Leucht et al., 2003).  
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Due to the facts that a (natural) infection with prions mostly occur via an oral route and that LRP/LR 
acts as receptor for prion proteins (Gauczynski et al., 2001b), potential binding sites for PrP in the 
intestinal mucosa were examined. Studies of the tissue expression of LR in human duodenal and 
jejunal biopsy samples led to the discovery that this receptor is expressed in the apical brush border of 
small intestinal epithelial cells (Shmakov et al., 2000). Employing immunohistochemistry LR 
expression has also been observed in the paranuclear/Golgi apparatus region and in the Paneth cell 
secretory granules (Shmakov et al., 2000). These findings suggest an involvement of LR in both 
secretory and endocytotic functions of human small intestinal epithelium. Moreover, it was speculated 
that the major implication of intestinal expression of the 67kDa LR might be an increased 
susceptibility to an oral infection with prions (Shmakov et al., 2000). It has been demonstrated that the 
oral transmission of infectious prion particles led to a rapid accumulation of PrPSc in Peyer’s patches 
(Maignien et al., 1999). PrPSc has also been detected in enterocytes of the villous epithelium of the 
small intestine in primates after oral exposure to prions (Bons et al., 1999). Enterocytes represent the 
major cell population of the intestinal epithelium (Booth and Potten, 2000) and are known to actively 
participate in endocytosis. Since expression of PrPc was demonstrated to be necessary for prion 
replication, expression of the cellular prion protein in the gastrointestinal tract has been analyzed and 
indeed it has been shown that PrPc is present in human enterocytes (Morel et al., 2004). These results 
led to the hypothesis that enterocytes might play an important role for the uptake of infectious prion 
particles. Very recently, it has been demonstrated that bovine PrPSc is internalized by human 
enterocytes via an LRP/LR-mediated endocytosis (Morel et al., 2005). In this study, the Caco-2/TC7 
cell model system, which is morphologically and functionally similar to normal human enterocytes, 
was used to investigate the PrPSc uptake in human enterocytes. Analysis of the presence of PrPSc after 
supply of prion-contaminated brain homogenate from different sources in Caco-2/TC7 enterocytes 
revealed that BSE prions were specifically internalized and accumulate in human enterocytes, whereas 
murine-adapted scrapie-prions were not endocytosed. Due to the demonstration, that the laminin 
receptor LRP/LR is required for the endocytosis of PrPc and the PrPSc propagation in neuronal cells, 
the involvement of this receptor in the endocytosis of prions in human enterocytes was investigated. 
Immunofluorescence analysis of PrPSc-containing vesicles revealed a co-localization with LRP/LR in 
the sub-apical compartment of Caco-2/TC7 cells after 5 minutes incubation with BSE brain 
homogenate. In addition, blocking of the LRP/LR by an anti-LRP antibody showed a significant 
decrease of PrPSc endocytosis, approving that prion endocytosis in human enterocytes is mediated by 
the 37kDa/67kDa laminin receptor LRP/LR. Interestingly, prions from a mouse-adapted scrapie-strain 
were not internalized, suggesting a specific uptake of bovine BSE prions by human enterocytes (Morel 
et al., 2005). For a role in the uptake of pathogens from the gut, the 37kDa/67kDa LRP/LR must be 
internalized after ligand binding. In terms of internalization, it has been shown that the 67kDa LR 
functioned as the major receptor for virus entry into mammalian cells (Wang et al., 1992). Association 
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of the laminin receptor with glycolipid-enriched microdomains in the cell membrane might lead to a 
clustering with other proteins in this region to provide a mechanism for internalization (Hooper, 1999). 
In summary, understanding the LRP/LR-PrP interaction in human intestine may enlighten the 
pathogenesis of prion diseases since an important role of the 37kDa/67kDa LRP/LR in mediating 
binding and internalization of the prion protein and its involvement in pathological mechanisms was 
demonstrated. 
 
 
7 Therapeutic approaches for the treatment of prion diseases 
 
Since the appearance of variant Creutzfeldt-Jakob disease, numerous strategies and targets have been 
proposed for a therapy of prion diseases, including: 
(i) stabilization of the structure of PrPc to prevent the transconformation from PrPc to 
PrPSc 
(ii) interference of the binding of PrPSc to PrPc 
(iii) inhibition of the formation of the abnormal form of PrP 
(iv) destruction of PrPSc aggregates 
(v) inhibition of the prion protein receptor(s) 
 
The inhibition of the PrPSc accumulation, however, is the most studied target. There are a number of 
compounds which have been shown to efficiently interfere with the PrPSc accumulation, such as Congo 
red (Ingrosso et al., 1995) and analogs (Demaimay et al., 2000), certain cyclic tetrapyrrols such as 
porphyrins and phtalocyanines (Priola et al., 2000) and sulfated polyanions such as dextran sulfate 500 
(Farquhar and Dickinson, 1986), pentosan polysulfate (Caughey and Raymond, 1993) and suramin 
(Gilch et al., 2001). Many other compounds have been identified to have an effect on the formation of 
pathological PrPSc in vitro and in vivo, but only flupirtine, an analgetic, is possibly beneficial in 
humans (Otto et al., 2004). 
To identify novel substances regarding a therapeutic potency, assays for the screening of large 
compound libraries have to be developed. Recently, a high-throughput assay based on the scanning for 
intensely fluorescent targets (SIFT) for the identification of drugs, which interfere with the PrPc/PrPSc 
interaction, was described (Bertsch et al., 2005). A library of 10,000 compounds was screened and a 
new lead structure with favorable pharmacological features has been identified (N’-benzylidene-
benzohydrazides) that represent a novel anti-prion drug. 
 
 
7.1 Chemical compounds  
 
Although several substances have been identified which inhibit PrPSc formation, unfortunately most of 
them show only significant effects when administered long before the clinical onset. At present, there 
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is no therapy for clinically affected TSE patients, so that TSEs usually culminate in death. Up to now 
various prion inhibitors have been identified (Table 8), but the development of potent compounds for 
an in vivo therapy in human TSEs is still required. The development of immune intervention strategies 
on one hand and the use of neuronal stem cells on the other may provide novel approaches for TSEs 
(Dormont, 2003). 
 
Polyanions are highly charged molecules that interact with cell membranes and are known to inhibit 
the entry of several viruses by a non-specific mechanism (Moelling et al., 1989). Certain polyanion 
compounds such as heteropolyanion 23 (HPA23) (Kimberlin and Walker, 1983), Dextran Sulfate 500 
(DS500) (Farquhar and Dickinson, 1986), pentosan polysulfate (PS) (Diringer and Ehlers, 1991; 
Farquhar et al., 1999) and suramin (Gilch et al., 2001) have been shown to be efficient in the treatment 
of TSEs and prolonged the life span of animals inoculated with the scrapie agent. For instance, 
intraperitoneal administration of pentosan polysulfate into scrapie-infected mice has been shown to 
significantly prolong the survival time of these animals, whereas an oral challenge with PS was 
ineffective in delaying disease (Farquhar et al., 1999). Depending on the mouse strain, PS treatment 
increased the mean incubation period of the scrapie strain or even protected mice completely from 
disease (Farquhar et al., 1999). Due to the prion-curing properties of sulfated polyanions in an early 
stage of infection (Caughey and Raymond, 1993) various heparan sulfate mimetics (HMs) have been 
developed and tested for their activity as anti-prion drugs. HM2602 was found to hamper PrPres 
accumulation in vitro and in vivo and prolonged significantly the survival of scrapie infected hamsters 
(Adjou et al., 2003).  
 
The azoic dye Congo red, which specifically binds to amyloid structures, potently inhibits the 
accumulation of PrPres in vitro without affecting the metabolism of the cellular prion protein 
(Caughey and Race, 1992). In scrapie-infected hamsters, treatment with Congo red resulted in a 
prolonged incubation time, depending on the amount of drug administration (Ingrosso et al., 1995). 
The maximal effect was observed, when the scrapie agent and Congo red were co-injected, suggesting 
that the timing of drug administration is a key-determinant.  
 
Polyene antibiotics such as Amphotericin B and its synthetic derivative MS-8209 are antifungal 
agents and have been evaluated as anti-TSE agents in infected hamsters, delaying scrapie disease and 
PrPSc accumulation (Adjou et al., 1995; Pocchiari et al., 1987). These substances are thought to 
interact with cholesterol present in mammalian cell membranes, disturbing the PrPSc endocytosis 
(Bolard, 1986; Taraboulos et al., 1995) or directly affect the conversion of PrPc to PrPSc (Demaimay et 
al., 1997). Another polyene antibiotic, filipin, has also been shown to inhibit PrPres formation in vitro 
(Marella et al., 2002).  
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In contrast to polyene antibiotics, cationic amphiphilic drugs act on the clathrin-dependent pathway 
and inhibit receptor-mediated endocytosis by reducing the number of coated pit-associated receptors at 
the cell surface (Sofer and Futerman, 1995; Wang et al., 1993). It has been demonstrated that 
derivatives of phenothiazines such as promazine, chlorpromazine and azepromazine, are sufficient for 
PrPSc inhibition in cultured cells chronically infected with prions (Korth et al., 2001). Chlorpromazine 
has been used in humans as an antipsychotric drug (treatment of schizophrenia) since the 1950s (Delay 
et al., 1952) and is known to cross the blood-brain-barrier (Korth et al., 2001). Nevertheless, 
combined chlorpromazine and quinacrine therapy in FFI patients did not improve their clinical 
conditions (Benito-Leon, 2004).  
 
Another class of inhibitors of the PrPres accumulation comprises derivatives of acridines/ bis-
acridines, in which quinacrine is the most prominent representative. Quinacrine, an antimalarial drug, 
has been shown to be 10-fold more potent than chlorpromazine in inhibiting PrPSc formation in vitro 
(Korth et al., 2001). In a murine model, oral treatment with quinacrine after intracerebral prion 
inoculation did not lead to any increased survival time compared to control animals (Barret et al., 
2003), which was consistent with the results obtained in CJD patients (Haik et al., 2004). 
 
Tetrapyrrole compounds, which include porphyrins and phtalocyanines, are known to bind 
selectively to proteins and induce conformational changes. Certain molecules have been identified to 
inhibit the formation of PrPres in vitro (Caughey et al., 1998) and increased the survival time of TSE-
infected animals (Priola et al., 2000). Among different tested compounds, phtalocyanine tetrasulfonate 
(PcTS), meso-tetra(4-N-methylpyridyl)porphine iron (III) (TMPP-Fe3+) and deuteroporphyrin IX 2,4-
bis-(ethylene glycol) iron (III) (DPG2-Fe3+) were the most potent inhibitors. Tetrapyrrols have also 
been shown to inhibit PrPres formation in a cell-free conversion reaction, suggesting a direct 
interaction of the tetrapyrrol with PrP molecules (Caughey et al., 1998).   
 
The finding, that transfection of scrapie-infected mouse neuroblastoma (ScN2a) cells using the 
SuperFect reagent, which is a mixture of branched polyamines, reduced the level of pre-existing PrPSc 
led to the testing of several other polyamines for their ability to interfere with the PrPSc propagation in 
chronically infected ScN2a cells (Supattapone et al., 2001). The branched polymers investigated 
include polyethyleneimine (PEI), polypropyleneimine (PPI) and polyamidoamide (PAMAM) 
dentrimers. All these compounds have been demonstrated to eliminate PrPSc in an in vitro assay using 
prion-infected cells. Furthermore, the cationic lipopolyamine DOSPA was shown to interfere with the 
accumulation of PrPSc in scrapie-infected neuroblastoma cells (Winklhofer and Tatzelt, 2000).  
 
Anthracyclins are a class of chemotherapeutic agents normally used to treat a wide range of cancers. 
Administration of a derivative of doxorubicin, 4´-iodo-4´-deoxy-doxorubicin (IDX), in a murine 
model of reactive amyloidosis reduced amyloid deposits (Merlini et al., 1995). In prion diseases, IDX 
CHAPTER I 
___________________________________________________________________________ 
 
 
31 
 
was shown to bind to PrP amyloid and prolonged the survival time of scrapie-infected hamsters, when 
administered intracerebrally at the same time as the scrapie agent (Tagliavini et al., 1997). It has been 
proposed that IDX bind to the abnormal form of PrP, decreasing the availability of template molecules 
for the conversion process of the normal prion protein (Tagliavini et al., 1997). 
 
 
 Class of compounds     Example 
  
polysulfonated, polyanionic substances   dextran sulfate, suramin, 
pentosan polysulfate, heparan sulfate 
mimetics 
 amyloidotropic intercalators    congo red 
 polyene antibiotics     amphotericin B, filipin 
 cyclic tetrapyrrols     porphyrines, phtalocyanines 
 
 polyamines      DOSPA, SuperFect, 
        polyethyleneimine 
 anthracyclines      IDX 
 phenothiazines      chlorpromazine 
 acridines/ bis-acridines     quinacrine, chloroquine 
 designer peptides     β-sheet breaker 
 aptamers      RNA aptamer DP7 
 
 
7.2 Immunotherapy 
 
The absence of detectable immune response during transmissible spongiform encephalopathies is 
likely due to the fact that the prion protein is a self-antigen expressed on the surface of many cells of 
the host. Experimentally, the problem of auto-tolerance was bypassed using PrP0/0 mice to generate 
monoclonal antibodies that recognize PrPc (Krasemann et al., 1996). Exposure of scrapie-infected 
neuroblastoma cells to the monoclonal anti-PrP antibody 6H4 was found to inhibit PrPSc replication 
and even prevent infection of susceptible N2a cells by pre-treatment with the antibody (Enari et al., 
2001). Furthermore, application of Fabs (antibody antigen-binding fragment) to scrapie-infected N2a 
cells dramatically reduced PrPSc formation in prion-infected cells (Peretz et al., 2001). The most 
effective antibody, Fab D18, recognized an epitope between amino acid residues 132 and 156 of 
murine PrP. Surprisingly, this region is well known as an important site for molecular interactions 
modulating PrPc-PrPSc conversion (Korth et al., 1997). To overcome the tolerance against PrPc in vivo, 
genes encoding the heavy chain variable region of 6H4 were expressed in PrP0/0 mice (Heppner et al., 
   Table 8. Chemical compounds exhibiting therapeutic antiprion effects 
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2001). Reintroduction of a single copy of the Prn-p gene resulted in 6H4PrP+/- mice that were 
intraperitoneally challenged with murine scrapie agent. In vivo expression of anti-PrP antibodies were 
found to prevent PrPSc replication in the spleen and the brain, providing immunological protection 
against prion diseases (Heppner et al., 2001).  
Recently, it was demonstrated that passive intraperitoneal immunization with anti-PrP monoclonal 
antibodies dramatically reduced PrPSc levels and delayed the onset of prion disease in scrapie-infected 
mice (White et al., 2003). In contrast, intracerebral injection of PrPc-specific monoclonal antibodies 
was found to trigger neuronal cell death by cross-linking cellular prion protein (Solforosi et al., 2004). 
To avoid that problem, recombinant single-chain antibody (scFv) fragments derived from monoclonal 
anti-PrP antibody 6H4 have been generated. ScFv fragments are small in size (approx. 30kDa) and 
exhibit only a monovalent antigen binding site. Secretion of anti-PrP scFv by mammalian cells has 
been shown to cure chronically prion-infected neuroblastoma cells (Donofrio et al., 2005), suggesting 
scFv as candidates for gene transfer-based immunotherapy of prion diseases. Active immunization 
with synthetic peptides, resembling different portions of the (hamster) prion protein, has been shown 
to prolong the survival time of hamsters infected intraperitoneally with 263K scrapie agent (Magri et 
al., 2005).  
To induce a native PrPc-specific antibody response, a novel strategy has been developed. Retroviral 
PrP-expressing particles were generated and upon intravenous injection in PrP0/0 and wild-type mice, 
PrP retroparticles induced a humoral immune response against the native form of cellular PrPc (Nikles 
et al., 2005). Another effective strategy to overcome the auto-tolerance to PrP in vivo is the use of an 
attenuated Salmonella vaccine strain that express mouse PrP (Goni et al., 2005). It has been 
demonstrated, that oral immunization using Salmonella typhimurium as a delivery and adjuvant 
system led to a humoral immune response against PrP and significantly prolonged the incubation 
period or prevent infection in mice following oral exposure to the prion agent (Goni et al., 2005).  
 
Delivery of antibodies by gene therapy may circumvent the limitations of either passive or active 
immunization by providing a steady antibody supply. Viruses are naturally evolved vehicles that 
efficiently transfer their genes into host cells. Particular viruses such as retroviruses, adenovirus, 
adeno-associated virus (AAV), herpesvirus and poxvirus have been selected as gene delivery vehicles 
because of their capacities to carry foreign genes and their ability to efficiently deliver these genes 
associated with efficient gene expression (Walther and Stein, 2000). Among these vector systems, 
retroviral vectors represent the most prominent delivery system, since these vectors have high gene 
transfer efficiency in both dividing and non-dividing cells and mediate high expression of therapeutic 
genes (Walther and Stein, 2000). 
In respect of the treatment of neurological disorders such as TSEs, recombinant adenovirus and adeno-
associated virus (AAV) are also highly effective vehicles for gene transfer into CNS cells. For the 
treatment of neurodegenerative diseases such as Alzheimer’s disease, AAV-mediated gene delivery 
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has already been investigated (Zhang et al., 2003; Hara et al., 2004; Feng et al., 2004; Sanftner et al., 
2005). The first therapeutic gene delivery attempt for prion diseases was initiated using AAV particles 
expressing an anti-LRP scFv (Rey et al., submitted). Intracerebrally injection of AAV encoding anti-
LRP scFv resulted in expression of the anti-LRP single chain antibodies in mouse brain (Rey et al., 
submitted). Current prion infection experiments will prove if the level of anti-LRP scFv produced in 
the brain is sufficient to delay prion disease and thus, representing a novel therapeutic strategy in the 
treatment of TSEs. 
 
 
7.3 RNA interference (RNAi) and antisense RNA 
 
RNA silencing occurs naturally in several organisms such as plants, fungi and protozoa and is believed 
to evolve as an innate defense mechanism to antagonize viral infection and integration of transposable 
elements. RNA interference (RNAi) is triggered by the presence of double-stranded (ds) RNA in the 
cell and results in the rapid destruction of mRNA containing the identical sequence (Tuschl, 2001) 
(Figure 10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Mechanism of the RNAi mediated gene silencing pathway 
RNAi triggers sequence-specific repression of gene expression. (A) The dsRNA is 
recognized by the cellular machinery and bound by the Dicer-RDE-1 (RNAi deficient-1) 
protein complex, that cleaves long dsRNA in a RNaseIII-like fashion into 19-22bp siRNA 
oligonucleotides. The antisense strand of the siRNA is used by an RNA-induced silencing 
complex (RISC) to guide mRNA cleavage, therefore promoting mRNA degradation. (B) 
In invertebrates the dsRNA-induced gene silencing process can be started via gene-
specific, full-length dsRNA. In mammalian cells, long dsRNA (>30bp) induces an anti-
viral response mechanism leading to non-specific RNA degradation. A gene-specific 
silencing process is started if short siRNAs are introduced into mammalian cells. (adopted 
from www.amaxa.com) 
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The discovery that the introduction of dsRNA longer than 30bp into somatic mammalian cells induced 
the anti-viral interferon-response (Figure 10) led to the application of small interfering RNA (siRNA) 
duplexes, which are specific gene silencing molecules of 19-22 nucleotides that bypass the anti-viral 
response.  
Delivery of siRNAs into mammalian cells was usually achieved via transfection of double-stranded 
(ds) oligonucleotides or plasmids encoding small hairpin RNA (shRNA) (Elbashir et al., 2001), until 
recently, retroviral vectors have been used for the delivery of siRNAs in vitro to reach long-term and 
stable expression of siRNAs. Both adeno-associated viral (AAV) vectors (Tomar et al., 2003) and 
lentiviral vectors (Matta et al., 2003) have been described to be efficient vectors for delivery of 
siRNAs into mammalian cells.  
Recently, a method for in vivo delivery of siRNAs to the liver, spleen, lung, kidney and pancreas of 
mice has been described (Lewis et al., 2002), using rapid injection of synthetically prepared siRNA 
duplexes into the tail vein. As a therapeutic strategy to deliver nucleic acids, cationic-lipid-based 
carriers have emerged as the most popular nonviral method (Sioud and Sorensen, 2003; Sorensen et 
al., 2003). Unfortunately, liposomal carriers localize the encapsulated siRNA complexes mainly to the 
blood compartment, but efficient brain delivery systems need to be developed since neurons are the 
main cells targeted in prion diseases. To address the targeted delivery of RNAi-based therapeutics, 
encapsulation of the shRNA expression plasmids in pegylated immunoliposomes (PILs) bearing 
surface targeting ligands was performed (Zhang et al., 2003a). It has been demonstrated that the PIL 
gene delivery system was effective in primates as well as in rodents (Zhang et al., 2003a; Zhang et al., 
2003b).  
 
Since current treatments do not prevent the appearance of clinical symptoms and death in experimental 
scrapie-infected animals, the development of the siRNA technology offers a promising approach for a 
therapy of prion diseases. Suggesting that suppression of PrP expression might be a potential 
therapeutic strategy against prion diseases (Bueler et al., 1993), the effect of specific Prn-p gene 
silencing using RNAi has been studied (Daude et al., 2003; Tilly et al., 2003). It has been 
demonstrated that transfection of siRNA duplexes corresponding to the murine Prn-p triggered 
specific Prn-p gene silencing in scrapie-infected neuroblastoma cells and caused a rapid loss of their 
PrPres content (Daude et al., 2003). Due to the transient nature of transfection, a long-term effect of 
Prn-p-specific siRNA duplexes on the PrPSc accumulation has not been achieved (Daude et al., 2003). 
A further strategy to interfere with the PrPSc propagation is the knockdown of LRP/LR, which was 
identified as the cell-surface receptor for PrPc (Gauczynski et al., 2001b). In scrapie-infected neuronal 
cells, it has been shown that transfection of LRP-specific siRNAs resulted in a strong reduction of the 
PrPSc level correlated with LRP downregulation (Leucht et al., 2003), demonstrating a requirement of 
LRP/LR for PrPSc propagation in cultured cells. The discovery that (i) knockdown of LRP/LR prevents 
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PrPSc binding and internalization in vitro (Leucht et al., 2003) and (ii) LRP/LR is the receptor for the 
infectious bovine prion protein (Morel et al., 2005) provide a perspective for the treatment of TSEs. 
As demonstrated in an ALS (amyotrophic lateral sclerosis) animal model, lentivirus-mediated RNAi 
represent a promising therapeutic tool to specifically knockdown disease-relevant genes (Ralph et al., 
2005; Raoul et al., 2005). Therefore, a lentivirus-based RNAi gene therapy might be promising for the 
treatment of prion diseases. In vitro studies using HIV-derived vectors expressing LRP-specif siRNAs 
revealed an efficient reduction of the LRP/LR gene expression in neuronal cells (Vana et al., 
submitted). Furthermore, application of vector-encoded LRP-specific siRNAs resulted in a decrease of 
PrPSc levels in scrapie-infected neuronal cells (Vana et al., submitted), confirming an essential role of 
LRP/LR for prion propagation. Injection of lentivirus particles expressing LRP-specific siRNAs into 
mice following prion inoculation will demonstrate if the knockdown of LRP/LR might prolong the 
onset of prion disease in vivo. 
Another strategy interfering with the PrPSc accumulation is the application of antisense RNA targeting 
either PrP or LRP/LR, resulting in gene silencing. Hitherto, no PrP antisense RNA approach has been 
performed, which might be due to the discovery of PrP-specific small interfering RNAs as an effective 
therapeutic tool against prion diseases (Daude et al., 2003; Tilly et al., 2003). However, transfection of 
LRP antisense RNA has been shown to ablate LRP/LR expression and prevent PrPSc propagation in 
scrapie-infected neuronal cells (Leucht et al., 2003), suggesting that the 37kDa/67kDa LRP/LR might 
act as potent target for the development of new therapies against prion diseases.  
 
 
7.4 Trans-dominant negative mutants 
 
Several reports have discussed strategies for inhibiting PrPSc accumulation. One major problem with 
drugs shown to exert anti-scrapie effects is their intrinsic property to induce a wide variety of side 
effects (Priola and Caughey, 1994; Tagliavini et al., 1997). Alternatively, deleted PrP molecules 
inhibiting the accumulation of PrPSc in a trans-dominant fashion were designed (Hölscher et al., 1998). 
Employing scrapie-infected mouse neuroblastoma cells as a model system, it has been shown that a 
deletion of eight amino acids in mouse PrPc (PrPcΔ114-121) abrogates the conversion of the mutant 
protein into PrPSc. In addition, PrPcΔ114-121 overexpression resulted in inhibition of PrPSc 
accumulation (Hölscher et al., 1998). Assuming that any side effects of PrPcΔ114-121 should be 
minimal compared to those of the chemical compounds, an alternative therapeutic approach can be 
envisaged using trans-dominant PrP mutants. 
In vitro, several dominant-negative PrP mutants have been investigated for their therapeutic potential 
in prion diseases and have been shown to prevent PrPSc formation (Kaneko et al., 1997). Further 
studies using transgenic mice expressing dominant-negative PrP mutants (Q167R and Q218K) 
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demonstrated that expression of dominant-negative PrP strongly reduced PrPSc accumulation in vivo 
(Perrier et al., 2002). 
Delivery of PrP containing dominant negative mutations has been achieved using lentiviral gene 
transfer (Crozet et al., 2004). By taking advantage of “prion resistant” polymorphisms that naturally 
exist in sheep and humans (Q171R and E219K), corresponding residues were mutated in the murine 
Prn-p gene (Q167R and Q218K) and subcloned into lentiviral vectors. Transduction of prion-infected 
neuroblastoma cells with lentiviral vectors carrying the dominant negative PrP mutants showed a 
strong expression of the transgene and a potent inhibition of PrPSc accumulation (Crozet et al., 2004). 
Moreover, for the treatment of Alzheimer’s disease a gene therapy strategy has been recently 
evaluated (Marr et al., 2003), suggesting lentiviral vectors as an useful tool in the development of a 
therapeutic approach in prion diseases. 
Because PrPc is a major cellular requirement for the propagation of infectivity (Bueler et al., 1993), it 
represents an attractive therapeutic target. However, identification of the 37kDa/67kDa laminin 
receptor LRP/LR as the receptor for prions (Gauczynski et al., 2001b; Morel et al., 2005) led to an 
alternative target for the development of TSE therapeutics. Recently, it has been shown that a LRP 
mutant encompassing only the extracellular domain of LRP/LR (LRP102-295::FLAG) might act in a 
trans-dominant negative manner as a decoy by trapping PrP molecules (Vana and Weiss, 2006). In 
vitro studies revealed that the LRP mutant is able to reduce the PrPSc accumulation in scrapie-infected 
neuronal cells (Vana and Weiss, 2006) and thus, might have potential for the development of a TSE 
therapy. In vivo prion inoculation studies in transgenic mice expressing LRP102-295::FLAG 
brainspecifically will verify if the trans-dominant negative LRP mutant can interfere with the PrPSc 
formation and prolong the onset of prion disease (Vana and Weiss, submitted). 
 
Creutzfeldt-Jakob disease and other transmissible spongiform encephalopathies are fatal and to date, 
there is no effective treatment to cure prion diseases. However, there are a number of potential 
treatments in development or under consideration. Nevertheless, no treatment has been shown to slow 
down or halt the disease process in CJD patients. Laboratory findings are only simply indications of 
the possible therapeutic value. Therefore, further work is essential to establish treatments that 
efficiently medicate prion diseases. 
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Prionkrankheiten sind neurodegenerative, stets tödlich verlaufende Erkrankungen, die zur 
Gruppe der spongiformen, übertragbaren Enzephalopathien zählen. Dazu gehören BSE bei 
Rindern, die Traberkrankheit (Scrapie) bei Schafen und Ziegen sowie die Creutzfeldt-Jakob 
Erkrankung (CJD) beim Menschen. BSE trat erstmals in Großbritannien Mitte der achtziger 
Jahre auf und gegenwärtig geht man davon aus, dass durch den Konsum von BSE-
kontaminierten Produkten die neue Variante der Creutzfeldt-Jakob Krankheit (vCJD) beim 
Menschen ausgelöst wurde. Diskutiert werden neue Therapiemöglichkeiten zur Behandlung 
menschlicher Prionerkrankungen und die Risiken an BSE zu erkranken. 
 
Durch einen EU-weiten Beschluß ist seit Januar 2001 für alle kranken und verhaltensauffälligen 
Rinder über 30 Monate ein BSE-Test verpflichtend (in Deutschland werden BSE-Tests ab einem Alter 
von 24 Monaten durchgeführt). Aufgrund eines solchen Tests wurde am 24. November 2000 erstmals 
bei einer in Deutschland geborenen Kuh BSE diagnostiziert. Seitdem sind in Deutschland 382 Rinder 
(Stand 29.09.2005) erkrankt (Abb. 1). Die Gesamtzahl der seit 1986 registrierten BSE-Fälle in 
Großbritannien ist mit 180837 beachtlich (Stand 29.09.2005) (Abb. 2). BSE zeigt Inkubationszeiten 
von 4-6 Jahren und verursacht Störungen des Verhaltens, der Bewegung und der Sensibilität. Trotz des 
Auftretens von klinischen Symptomen ist bis dato eine eindeutige Diagnose nur post mortem durch 
eine Hirnbiopsie möglich, in der ein charakteristisches, mit der Krankheit assoziiertes Protein, das 
Scrapie-Prion-Protein (PrPSc), nachgewiesen wird. 
 
Das Prion-Protein 
 
PrP kommt in zwei Konformationen vor: einer zellulären (PrPc) und einer abnormalen Isoform (PrPSc). 
PrPc wird in jedem Säugetier exprimiert, wobei seine physiologische Funktion bisher noch unklar ist. 
PrPc bindet Kupfer und spielt bei synaptischen Übertragungen und der Regulation von zirkadianer 
Aktivität eine Rolle. Durch die Umwandlung der zellulären Form PrPc in die pathologische Form PrPSc 
kommt es zur Aggregat-Bildung im Gehirn und zur Entstehung der Prionerkrankungen. PrPSc ist 
extrem hitze- und druckbeständig und resistent gegenüber Proteasen. Im Laufe der Erkrankung kommt 
es zu Ablagerungen von Amyloiden im Zentralnervensystem, zum Anschwellen von Hirnzellen 
(Astrogliose) und zur vermehrten Bildung von Vakuolen durch abgestorbene Zellen (Spongiose).  
 
Therapieansätze zur Behandlung von Prionerkrankungen 
 
Trotz intensiver Forschung gibt es bislang keine effektiven Behandlungsmöglichkeiten für 
Prionerkrankungen, welche deswegen stets letal sind. Hinweise auf einen Anti-Prion Effekt einiger 
Substanzen in vivo erhielten Forscher, nachdem sie Hamster mit DMSO (Dimethylsulfoxid) 
behandelten und eine Infektion mit PrPSc erschwert wurde (Shaked et al., 2003). Auch in 
Tierversuchen mit Heparansulfatanaloga konnte gezeigt werden, dass die Bildung des pathologischen 
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Prion-Proteins reduziert war (Adjou et al., 2003). Ein Nachteil der Behandlung mit diesen Substanzen 
ist jedoch, dass die Manifestation der Erkrankung nur verzögert, aber nicht verhindert wird. Große 
Hoffnung wurde deswegen in die Entwicklung von Impfstoffen gesetzt, die anfangs allerdings 
enttäuscht wurde, da das zelluläre Prion-Protein ein körpereigenes Protein und deswegen nur schwach 
immunogen ist. Dennoch ist es gelungen, Antikörper gegen PrPc zu generieren. Dazu wurden 
verschiedene Strategien entwickelt, um eine Immunität der Versuchstiere gegenüber einer 
Prioninfektion zu erreichen. In transgenen Mäusen, welche Anti-PrP-Antikörper produzierten, konnte 
gezeigt werden, dass eine humorale Immunantwort gegen PrP einen protektiven Effekt gegenüber 
einer Prioninfektion hat (Heppner et al., 2001). Neuere Therapieansätze fokussieren auf Vakzine aus 
rekombinanten retroviralen Partikeln, um die Toleranz des Körpers gegenüber dem zellulären Prion-
Protein zu überwinden. Erste Untersuchungen in Mäusen haben gezeigt, dass es möglich ist, 
autoreaktive spezifische PrP-Antikörper zu generieren (Nikles et al., 2005). Weiterführende Studien 
sollen prüfen, ob die induzierte Antikörpermenge in einem Organismus ausreichend ist, um eine 
Prioninfektion zu verhindern.  
 
Moderne Therapiemöglichkeiten 
 
Aussichtsreich scheint bei der Entwicklung neuer Therapien gegen Prionerkrankungen der Befund, 
dass Prionen einen Rezeptor benötigen, um internalisiert zu werden. Wir konnten den 37kDa/67kDa 
Laminin-Rezeptor (LRP/LR) als Rezeptor für das Prion-Protein identifizieren und zeigen, dass der 
Rezeptor auch für die Vermehrung von infektiösen Prionen in Zellkultur essentiell ist. Sowohl 
antisense LRP RNA als auch small interfering RNAs (siRNAs), welche gegen die LRP mRNA, und 
Antikörper, die gegen den 37kDa/67kDa LRP/LR gerichtet sind, inhibierten eine Akkumulation von 
PrPSc in Zellkultur (Leucht et al., 2003). Anschließende in vivo Studien sollen nun zeigen, ob 
transgene Tiere, die antisense-LRP RNA bzw. anti-LRP-siRNAs exprimieren, vor einer Prioninfektion 
geschützt sind. Alternative Therapiemöglichkeiten bestehen auch im Einsatz von dominant-negativ 
wirkenden LRP/LR Mutanten, die nach Sekretion durch ein Abfangen des pathogenen Prion-Proteins 
ein Fortschreiten der Erkrankung verhindern können („Lockvogel“- oder „Decoy“- Effekt) (Vana and 
Weiss, 2006). Eine Weiterentwicklung der klassischen Antikörper-Therapie stellt die Generierung von 
sogenannten Anti-LRP-Einzelketten-Antikörpern dar. Einzelketten-Antikörper (scFv) bestehen nur aus 
den variablen Regionen der leichten (VL) und schweren Kette (VH) eines Immunglobulins, welche 
durch einen Peptidlinker kovalent miteinander verknüpft sind. Kürzlich gelang es in Mäusen durch 
eine orale Immunisierung mit PrP-exprimierenden Salmonella-Bakterien den Ausbruch einer Prionose 
zu verhindern. Immunisierte Mäuse zeigten im Vergleich zur Kontrollgruppe 500 Tage nach der 
Prioninfektion keine klinischen Symptome einer Prionerkrankung. PrPSc konnte weder im Gehirn noch 
in der Milz nachgewiesen werden (Goni et al., 2005). Eine Immunisierung gegen PrP scheint damit 
ein sehr vielversprechender therapeutischer Ansatz zur Bekämpfung von Prionosen zu sein (Abb. 3) 
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und könnte die Behandlung von menschlichen TSEs, wie der durch die Übertragung von BSE auf den 
Menschen induzierte neue Variante der Creutzfeldt-Jakob-Erkrankung (vCJD) ermöglichen. 
 
Die neue Variante der Creutzfeldt-Jakob Erkrankung 
 
Die neue Variante der CJD unterscheidet sich von der klassischen (sporadischen) Erkrankung 
insbesondere hinsichtlich des Alters der Betroffenen (mittleres Alter: 27) und der sehr langsamen 
Progressivität der Erkrankung. Sie beginnt meist mit psychiatrischen Symptomen wie Ängstlichkeit 
und Depressionen. Später treten dann neurologische Störungen mit dem Verlust intellektueller 
Fähigkeiten auf. Die Beobachtung, dass alle vCJD-Patienten eine genetische Disposition an der 
Position 129 des vom Prion-Gen (Prn-p) kodierten Prion-Protein besitzen, führte zur Entwicklung 
eines kommerziellen genetischen Tests, mit dessen Hilfe überprüft werden kann, welche Aminosäure 
an der Position 129 des Prion-Proteins eingebaut wurde (www.medigenomix.de). Alle vCJD Patienten 
kodierten auf beiden Allelen des Prion-Gens Prn-p für die Aminosäure Methionin an Position 129 des 
Prion-Proteins, waren also homozygot für Methionin (Tabelle 1). Diese Variante ist in der 
kaukasischen Bevölkerung mit einem Anteil von 39% vertreten. 11% der Bevölkerung hingegen sind 
homozygot für die Aminosäure Valin und 50% der kaukasischen Bevölkerung zeigen eine Methionin- 
Valin Heterozygotie (Tabelle 1). 
 
 
 
 
 
 
 
 
 
Das Ergebnis der Sequenzanalyse liefert jedoch keinen Beweis für eine Immunität gegenüber einer 
Prioninfektion, da Personen, welche Met/Val heterozygot oder Val/Val homozygot sind, die Krankheit 
möglicherweise später entwickeln könnten als Menschen mit Met/Met Homozygotie. In einer 
aktuellen Studie untersuchten Züricher Forscher den Einfluß dieser verschiedenen Allelvarianten des 
Prion-Protein-Gens auf die Gedächtnisleistung. Dabei wurde entdeckt, dass sich sowohl Träger der 
homozygoten als auch der heterozygoten Methionin-Variante durchschnittlich 17 Prozent mehr 
Informationen merken konnten als die Personen, welche die homozygote Valin-Variante trugen 
(Papassotiropoulos et al., 2005). Die Forscher nehmen deswegen an, dass das Prion-Protein eine 
wichtige Rolle in der Ausbildung des Langzeitgedächtnisses spielen könnte und nicht nur für die 
neurodegenerativen Erkrankungen bei Mensch und Tier verantwortlich ist. In Deutschland ist bisher 
noch kein Fall der neuen Variante der Creutzfeldt-Jakob-Erkrankung aufgetreten, dennoch kommt der 
Tab.1: Der Codon 129 Polymorphismus des Prion-Protein-Gens (Prn-p) 
Aminosäuren, welche vom 
Codon 129 exprimiert werden 
Verteilung in der 
Bevölkerung 
Vorkommen bei 
sCJD 
Vorkommen bei 
vCJD 
Met/Met 39% 80% 100% 
Met/Val 50% 8% 0% 
Val/Val 11% 12% 0% 
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Entwicklung empfindlicher Tests und wirksamer Therapien gegen Prionerkrankungen eine wichtige 
Aufgabe zu.  
 
Suszeptibilität und Übertragbarkeit von Prionen - Aktuelle Forschung 
 
Auch wenn die BSE-Fallzahlen in Europa sinken wird die Problematik der Prionerkrankungen in den 
nächsten Jahren weiterhin öffentliche Beachtung finden. Französische Forscher nehmen an, dass 
Kinder und Jugendliche besonders anfällig für die neue Variante der Creutzfeldt-Jakob-Erkrankung 
sein könnten. Ursächlich könnte ein übermäßiger Konsum von Rindfleisch sein, aber auch eine 
besonders hohe Durchlässigkeit des Darms für Prionen im Jugendalter schließen die Wissenschaftler 
nicht aus (Boelle et al., 2004). In einer soeben veröffentlichten Studie konnten wir zusammen mit 
Französischen Kollegen zeigen, dass menschliche Enterozyten im Darm den BSE-Erreger innerhalb 
weniger Minuten aufnehmen können, wobei der Lamininrezeptor eine essentielle Rolle spielt (Morel 
et al., 2005). Interessanterweise konnten Scrapie-Prionen des Schafes nicht von den menschlichen 
Dünndarmzellen aufgenommen werden, was erklären könnte warum BSE, nicht aber Schaf-Scrapie 
auf den Menschenübertragbar ist (Morel et al., 2005). Obwohl menschlichen Prionerkrankungen 
gering verbreitet sind, so handelt es sich dennoch um stets tödlich verlaufende Erkrankungen, welche 
im Fall der vCJD besonders junge Menschen betrifft. Um das Leben der Betroffenen zu retten, suchen 
Forscher intensiv nach Behandlungsmöglichkeiten, um Prionerkrankungen effizient zu bekämpfen. 
Eine Heilung von CJD beim Menschen ist nach heutigem Wissenstand zwar noch nicht möglich, 
scheint aber im Lichte der aktuellen Therapieforschung in naher Zukunft realisierbar.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Abb. 1: BSE-Fälle in Deutschland seit Einführung der Meldepflicht 
für BSE-Fälle durch die EU 1990 
geschätzte Anzahl der BSE-Fälle für 2005 
tatsächliche BSE-Fälle bis September 2005 (25 Fälle) 
 BSE-Fälle in Deutschland 2000 - 2005 
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BSE-Fälle in Großbritannien 
Abb. 2: BSE-und vCJD-Fälle in Großbritannien im Vergleich 
Die BSE- und vCJD-Statistik (Inset) zeigt alle bis Dezember 2004 
bestätigten Fälle in Großbritannien (gesamt 180837, Stand 29.09.05). 
Die Zahlen für 2005 entsprechen den bis September 2005 erfassten 
Fällen: 126 BSE-Fälle und 2 vCJD Erkrankungen. 
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  Abb. 3: Mögliche Therapieansätze gegen Prionerkrankungen 
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The accumulation of PrPSc in scrapie-infected neuronal cells has been prevented by three approaches: 
(i) transfection of ScMNB cells with an antisense laminin receptor precursor (LRP) RNA-expression 
plasmid, (ii) transfection of ScN2a cells and ScGT1 cells with small interfering RNAs (siRNAs) 
specific for the LRP mRNA, and (iii) incubation of ScN2a cells with an anti-LRP/LR antibody. LRP 
antisense RNA and LRP siRNAs reduced LRP/LR expression and inhibited the accumulation of PrPSc 
in these cells. The treatment also reduced PrPc levels. The anti-LRP/LR antibody, W3, abolished PrPSc 
accumulation and reduced PrPc levels after seven days of incubation. Cells remained free of PrPSc after 
being cultured for 14 additional days without the antibody, whereas the PrPc level was restored. Our 
results demonstrate the necessity of the laminin receptor (LRP/LR) for PrPSc propagation in cultured 
cells and suggest that LRP/LR-specific antibodies could be used as powerful therapeutic tools in the 
treatment of transmissible spongiform encephalopathies. 
 
Introduction 
 
Transmissible spongiform encephalopathies (TSEs) are a group of neurodegenerative disorders which 
include Creutzfeldt-Jakob disease (CJD) in humans, bovine spongiform encephalopathy (BSE) in 
cattle, and scrapie in sheep (Aguzzi and Weissmann, 1998; Lasmezas and Weiss, 2000; Prusiner et al., 
1998; Weissmann, 1999). The main pathogenic event in the development of TSEs is the conversion of 
PrPc to PrPres. A main feature of PrPSc is its partial resistance to proteases, which makes it 
biochemically distinguishable from PrPc (Caughey and Raymond, 1991). Recently, we identified the 
37kDa/67kDa laminin receptor (LRP/LR) as the cell surface receptor for the cellular prion protein 
(PrPc) (Gauczynski et al., 2001b). Heparan sulfate proteoglycans (HSPGs) have been shown to 
function as cofactors or co-receptors for the binding of PrPc to LRP/LR (Hundt et al., 2001b). The 
LRP/LR laminin receptor has been shown to interact directly with the prion protein in the yeast two-
hybrid system (Rieger et al., 1997). This interaction was confirmed by pull down assays in 
cotransfected COS-7 cells and co-infected insect cells (Rieger et al., 1997). Furthermore, increased 
levels of LRP were found in the brain, spleen and pancreas of scrapie infected mice and hamsters as 
well as in scrapie infected neuroblastoma cells, a well characterized in vitro model for scrapie 
infection (Rieger et al., 1997). These data suggest a link between the 37kDa/67kDa laminin receptor 
and prion propagation. The non-integrin LRP/LR laminin receptor represents a multifunctional protein 
required for cell differentiation, movement and growth (for review see (Gauczynski et al., 2001a)). Its 
cDNA encodes a 37 kDa protein, also known as p40, and has been cloned from different species by 
several groups. This protein has been reported to be ribosome associated, to bind to histones H2A, 
H2B and H4 and to be the precursor of the metastasis-associated 67kDa mature high-affinity laminin 
receptor (for a review see (Gauczynski et al., 2001a), Leucht & Weiss 2002). The 67kDa LR is 
consistently upregulated in aggressive carcinoma suggesting a role in cell homeostasis and cohesion. 
The amino acid sequence of the receptor is extremely well conserved through evolution with at least 
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98.3% homology between mouse, human and bovine sequences and 99% homology between rat and 
human sequences (for review, see (Gauczynski et al., 2001a), Leucht & Weiss, 2002). Published data 
suggest the existence of at least six LR genes in the mouse genome, one of these is localized on 
chromosome nine and at least two copies are thought to be functional (Douville and Carbonetto, 
1992). Using TRIBE-MCL, an algorithm for detection of protein families (Enright et al., 2002), five 
LRP/LR genes were identified when the program was used to search the latest mouse draft genome 
sequence (Mouse Genome Sequencing Consortium, 2003, available at http://www.ensembl.org). The 
LRP gene on chromosome 9 has seven exons and six introns, in contrast with earlier results (Douville 
and Carbonetto, 1992), no LRP/LR gene on chromosome six has been identified. Interestingly, genes 
that affect susceptibility to prions have been identified on mouse chromosome nine (Stephenson et al., 
2000). PrP specific antibodies have successfully been used in preventing prion propagation in vitro 
and in vivo as follows: first, the accumulation of PrPSc in scrapie infected neuroblastoma cells was 
inhibited by PrP-specific antibodies (Peretz et al., 2001), second, scrapie infection was abolished by 
transgenic expression of PrP-specific antibodies in mice (Heppner et al., 2001). The epitope 
recognized by the antibody that has the most potent effect on PrPSc, D18, consists of amino acid 
residues 132-156 of PrP, which includes helix A (residues 145-155). Because PrP residues 144-179 
has been shown to constitute a binding site for the LRP/LR (Hundt et al., 2001a), we investigated 
whether an antibody directed against LRP/LR, the cellular receptor for PrPc (Gauczynski et al., 
2001b), can also be used to interfere with the metabolism of PrPSc. To ablate LRP/LR expression from 
all putative LRP/LR-encoding genes, we used an antisense RNA and a small interfering RNA (siRNA) 
approach. We investigated whether these strategies had an effect on prion propagation in several 
scrapie-infected cell systems. 
 
Results and Discussion 
 
Antisense LRP RNA prevents PrPSc propagation 
 
To produce LRP antisense messenger RNA, we cloned a region of LRP complementary DNA from 
nucleotide positions 65 to 901 into the expression plasmid pCI-neo in the antisense orientation to 
produce the pCI-neo-asLRP plasmid. After transient transfection of pCI-neo-asLRP into ScMNB cells 
we confirmed antisense LRP RNA expression in these cells (Fig. 1A). The level of LRP mRNA was 
greatly reduced 48 h after transfection (Fig. 1B). Using phosphorimaging, the reduction was quantified 
and LRP mRNA levels were found to be 80-85% of normal LRP/LR mRNA expression levels. A 
similar reduction in target mRNA levels has been shown in other studies that have used the antisense 
RNA method to downregulate the expression of the myelic basic protein (Katsuki et al., 1988), and 
Wnt-1 (Erickson et al., 1993). At the level of protein expression, no LRP protein was detected by 
western blotting 48 h after transfection (Fig. 1C). Levels of PrPSc were unaffected in cells transfected
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with pCI-neo as compared with untransfected cells (Fig. 1D). In ScMNB cells we were able to detect 
only the diglycosylated form of PrP using the SAF70 antibody, whereas in ScN2a and ScGT1 cells we 
observed the classic three-band pattern. We observed a reduction in PrPc level after antisense LRP 
RNA transfection (Fig. 1D), which might be caused by an altered PrPc metabolism. Previous studies 
have indicated that PrPc internalization is highly dependent on the presence of the LRP/LR at the cell 
surface (Gauczynski et al., 2001b), where the LRP/LR binds PrPc through two distinct domains: the 
octapeptide region and the region encompassing amino acids 144-179 of PrPc (Hundt et al., 2001a). 
This is consistent with a recent study, in which it was found that the octapeptide region is essential for 
internalization of PrPc (Nunziante et al., 2003). Hence, the altered PrPc levels seen in this study are 
likely to be due to perturbed metabolism of the protein. 
 
LRP-specific siRNAs prevent PrPSc propagation 
 
SiRNAs were used to verify the results obtained using the LRP antisense RNA construct. This method 
has been used successfully in other studies to knock-down target-gene expression levels (Elbashir et 
al., 2001). We tested four different LRP-specific siRNAs for their ability to repress LRP expression in 
ScN2a cells. All of them repressed LRP synthesis (Fig. 2A). Figure 2B shows data from a time-course 
experiment carried out to analyze the effect of siRNA-LRP3 on PrPSc propagation in ScN2a cells. 
Seventy-hours after transfection, PrPSc propagation was completely abolished by siRNA-LRP3, 
whereas siRNA-LRP1, siRNA-LRP4 and a control siRNA (lamin A/C, described in Elbashir et al., 
2001) had a smaller effect (siRNA-LRP1 + siRNA-LRP4) or no effect (control) on PrPSc levels. PrPc 
levels were reduced in the presence of siRNA-LRP3. The same effects were observed with LRP 
antisense RNA 72 h after transfection. In contrast to PrPSc, PrPc levels increased 96 h after 
transfection, probably due to a decrease in siRNA effectiveness with time. We also tested the 
efficiency of the reduction of LRP expression using siRNAs in ScGT1 cells, which show a robust 
PrPSc phenotype (that is, these cells propagate PrPSc over a long period of time). The results were 
consistent with those obtained in ScN2a cells, with a strong reduction of PrPSc correlated with LRP 
downregulation (Fig. 2C). 
 
Anti-LRP/LR antibody W3 prevents PrPSc accumulation 
 
LRP/LR specific antibodies have been used successfully to compete with recombinant prion protein 
for binding to the LRP/LR in different mammalian cell types (Gauczynski et al., 2001b), showing that 
the LRP/LR has a crucial role in the metabolism of PrPc. Using the LRP/LR specific antibody W3 
(Rieger et al., 1997) in ScN2a cells we observed a reduction of PrPSc to a undetectable level (Fig. 3A, 
B). The antibody was used at concentrations of 6- 64 µg ml-1. At a concentration of 12 µg ml-1 a 
reduction in PrPSc level was observed. At a higher concentrations (64 µg ml-1), PrPSc accumulation was 
completely abolished after incubation for three days, indicating a dose dependent effect (Fig. 3A). In a 
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time-course experiment, we found a complete clearance of PrPSc after incubation for one week, using 
an antibody concentration of 32 µg ml-1 (Fig. 3B). These results are consistent with a previous study, 
in which different anti-PrP antibodies were used to reduce PrPSc in cultured cells (Peretz et al., 
2001),Table I). In that study, PrP antibody concentrations of 1.2 µg/ml to 10 µg ml-1 were sufficient to 
clear PrPSc from ScN2a cells after one week of incubation (Table I). We also incubated ScN2a cells in 
which PrPSc had been previously cleared by W3 for a further two weeks without any antibody, and 
showed that no PrPSc reappeared (Fig. 3B). PrPc levels in W3-treated cells were reduced after seven 
days of incubation with W3, but were completely restored after a further two-week incubation in the 
absence of the antibody (Fig. 3B). 
 
Table I. Efficacy of anti-PrP and anti-LRP antibodies in clearance of PrPSc 
from ScN2a cells  
Antibody anti-LRP/LR anti-PrP1 
Incubation time 1 week 1 week 
Antibody W3 D18 D13 R1 R2 
Effective Concentration  
[µg ml-1] 
 
32 
 
1.2 
 
2.5 
 
10 
 
10 
1 Data taken from Peretz et al., 2001 
 
Role of the LRP/LR in PrPSc propagation in cultured cells 
 
The knock down of the LRP/LR on the cell surface by LRP antisense RNAs or by siRNAs, and the 
blockage of LRP/LR binding sites by the W3 anti LRP/LR antibody are most likely to interfere with 
PrP levels by blocking the PrP internalization process. However, some PrPc can still be synthesized 
and transported through the secretory pathway to the cell surface (Figs 1D, 2B and 3). Conversion of 
PrPc to PrPSc is thought to take place either at the cell membrane or in the endocytic pathway. Thus, it 
is possible that due to the lack of PrPc within the endocytic pathway no PrPSc can be formed, resulting 
in a time-dependent reduction of PrPSc (Figs 2B and 3B). It is also possible that the LRP/LR has a 
function in the conversion of PrPc to PrPSc, and that the absence of the LRP/LR from the cell surface 
affects PrPSc formation. PrPSc propagation cannot be restored after cessation of the incubation with anti 
LRP/LR antibody (Fig. 3B) due to the absence of any PrPSc to re-initiate the conversion process. In 
contrast, PrPc levels were completely restored after cessation of incubation with the anti LRP/LR 
antibody (Fig. 3B). Furthermore, depletion or blockage of the LRP/LR on the cell surface might 
directly prevent PrPSc binding and internalization. In summary, our results show that the LRP/LR is 
not only involved in PrPc metabolism, as demonstrated in previous reports (Gauczynski et al., 2001b; 
Hundt et al., 2001), but also has a crucial role in prion propagation. The fact that LRP/LR-specific 
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antibodies are able to clear PrPSc from neuroblastoma cells provides possibilities for the development 
of new experimental therapies for TSEs. 
 
Methods 
 
Construction of pCI-neo-asLRP. Bases 65-901 of the LRP cDNA were amplified by PCR with 
reverse transcription (RT-PCR) from total RNA isolated from N2a cells, introducing the restriction 
sites NheI and SmaI. The LRP cassette was cloned in an antisense orientation into the plasmid pCI-neo 
using the NheI and SmaI sites to produce pCI-neo-asLRP. Cloning was confirmed by sequencing. 
 
Cell culture. ScMNB and ScN2a cells (both lines are neuroblastoma cells chronically infected with 
scrapie) were grown in DMEM, 10% fetal bovine serum, 2 mM Glutamax (Invitrogen), 100 units ml-1 
penicillin and 10 µg ml-1 streptomycin sulfate, at 37°C with 5% CO2. ScN2a cells were produced as 
described previously (Bosque & Prusiner, 2000). ScGT1-7 cells (GT1 hypothalamic neuronal cells, 
chronically infected with the Chandler scrapie isolate) were provided by S.Lehmann, and were 
cultured as described previously (Mange et al., 2000), with the exception that DMEM was replaced 
with Opti-MEM (Gibco LifeSciences). 
 
Inhibition studies using the W3 antibody. ScN2a cells (1x106) were incubated in normal growth 
medium (DMEM, 10% fetal bovine serum, 2 mM Glutamax) supplemented with the purified 
polyclonal anti LRP/LR antibody, W3, at varying concentrations. After incubation with the antibody, 
the cells were harvested, lyzed and analyzed by western blotting.  
 
Inhibition studies using small interfering RNAs. Four pairs of complementary 21-nucleotide RNAs 
corresponding to regions of the LRP cDNA were made (Ambion). As a control, the lamin A/C RNA 
duplex was used (Elbashir et al., 2001). The single-stranded complementary RNAs were annealed in 
annealing buffer (provided by the manufacturer) for 1 min at 90°C, followed by incubation for 1 h at 
37°C. The RNA duplexes were transfected into ScN2a cells (cultured in Opti-MEM medium, 
Invitrogen) using Oligofectamine (Invitrogen) in accordance with the manufacturer’s instructions. 
ScGT1-7 cells were seeded in 60-mm petri dishes (5x105 cells per dish) and transfected the following 
day with 10 µg of each of the 21-nucleotide RNA pairs using Exgen 500 (Fermentas) in accordance 
with the manufacturer’s instructions. 
 
Ribonuclease protection assays. Total RNA was purified from transfected ScMNB cells and used in 
a Ribonuclease Protection Assay using the RPA III kit (Ambion). An antisense riboprobe was made by 
in vitro transcription from pCI-neo-asLRP, following linearization of the plasmid with EcoRI, in the 
presence of [α-32P]-UTP. The antisense riboprobe was combined with the total RNA and the mixture 
was then precipitated. The precipitates were dissolved in hybridization buffer, denatured and 
hybridized with the total RNA. This was followed by incubation with RNase for 30 min at 37°C, 
followed by inactivation of the RNase and ethanol precipitation of the RNA. Protected RNA 
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fragments were separated on a 5% acrylamide/ urea gel and visualized using a Storm 860 
phosphorimager equipped with ImageQuant software. 
 
Reverse-transcriptase-PCR. Total RNA was purified from transfected ScMNB cells and cDNA 
synthesis was carried out using oligo(dT) primer in a RT reaction. The resulting cDNA was then 
amplified by PCR using a 5’-oligodeoxyribonucleotide corresponding to the 3’-end of the 
cytomegalovirus promoter and a 3’-oligodeoxyribonucleotide corresponding to a sequence in the 5’-
region of the simian virus 40 polyadenylation signal. PCR products were separated on 1% agarose gels 
and stained with ethidium bromide. 
 
Western blotting. Cytoplasmic lysats were made using a buffer containing 10 mM Tris/HCl pH 7.5, 
100 mM NaCl, 10 mM EDTA, 0.5 % Triton X-100, 0.5 % sodium desoxycholate. After centrifugation, 
the total protein content of the lysats was measured (BCA-Protein Assay, Pierce) and equal amounts of 
protein from each lysate were analyzed. For PrPSc detection, cell lysates digested with proteinase K 
(20 µg ml-1)  for 1 h at 37°C . The reaction was stopped by the addition of Pefabloc (1mM) and the 
proteins were denatured using 6 M guanidine hydrochloride. Samples were boiled in SDS sample 
buffer and analyzed on an SDS-polyacryamide gel containing 12.5% acrylamide. For PrPc and PrPSc 
detection (from ScN2a cells), 10% Bis-Tris gels with MES running buffer (NuPAGE, Invitrogen) 
were used. Proteins were blotted on a polyvinylidene difluoride membrane, blocked and incubated 
overnight with the monoclonal antibodies SAF70, SAF32 or SAF84 (diluted 1:5000 in blocking 
solution) or A7 (diluted 1:2,500 in blocking solution) for PrP detection. The polyclonal anti LRP/LR 
antibody W3 (Rieger et al., 1997) (1:2,000), or the monoclonal antibody 43512 (1 µg ml-1) were used 
for LRP/LR detection and anti-β-actin antibody (Chemicon) (1:5,000) for β-actin detection. After 
washing with TBS/0.05 % Tween 20 the blot was incubated for 1 hour with a peroxidase-conjugated 
secondary antibody (Sigma) (1:2,500). Detection was carried out by enhanced chemiluminescence 
(Western Lightning, NEN). 
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Fig.1 | Abolition of PrPSc propagation using laminin receptor precursor (LRP) antisense RNA. (A) Analysis 
by PCR with reverse transcription of total RNA extracts from transfected ScMNB cells. 
Oligodesoxythymidine-primed complementary DNA was amplified by PCR using specific primers for the 
pCI-neo plasmid. This gave a 322-bp cDNA fragment for the pCI-neo transfected cells and a 1,115-bp 
cDNA fragment for the pCI-neo-asLRP transfected cells. (B) A ribonuclease protection assay was carried 
out on total RNA from cells transfected with either pCI-neo or pCI-neo-asLRP; the RNA was then 
separated using a 5% acrylamide/ urea gel. 5 µg or 10 µg of total RNA was used, and in both cases the 
level of LRP messenger RNA was reduced by 80-85% in cells transfected with pCI-neo-asLRP (quantified 
by phosphorimaging). (C) Western blot analysis of cell lysates from pCI-neo and pCI-neo-asLRP-
transfected ScMNB cells assayed 48 hours after transfection. LRP was detected using the polyclonal anti-
LRP/LR antibody, W3. β-actin was detected using an anti β-actin antibody as loading control. (D) ScMNB 
cells were transfected with pCI-neo and pCI-neo-asLRP. The PrPSc content of ScMNB cells was analysed 
72 h after transfection. The monoclonal anti-PrP antibody SAF70 was used for PrPSc detection and the 
SAF32 antibody were used for detection of PrPc. 
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Fig.2 | Inhibition of PrPSc propagation using small interfering RNAs. (A) Western blot analysis of ScN2a 
cells transfected with small interfering RNAs (siRNAs). Cells were analyzed 72 h after transfection using 
the polyclonal anti-laminin receptor (LRP/LR) antibody W3. (B) The effect of siRNAs on PrPSc 
propagation was assayed 72 h after transfection (left panel). The time-dependent effect of siRNA-LRP3 on 
PrPSc propagation (right panel) was analyzed using the SAF70 antibody; PrPc was detected with the SAF32 
antibody. β-actin was detected using an anti β-actin antibody as a loading control. (C) Western blot 
analysis of siRNA-transfected ScGT1 cells at 72 h after transfection. The cells were analyzed using the 
monoclonal antibodies LR43512 (lower panel) and SAF84 (upper panel). All samples were normalized to 
equal protein concentrations. 
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Fig.3 | The effect of the W3 anti-laminin receptor (LRP/LR) antibody on PrPSc propagation. (A) ScN2a 
cells were incubated with W3 at varying concentrations. The PrPSc content was determined after 72h 
incubation with W3. An anti-VLA-6 (integrin-type laminin receptor) antibody was used as a control. PrPSc 
was detected using the A7 polyclonal antibody; PrPc was detected with the SAF32 antibody. (B) ScN2a 
cells were incubated with W3 at 32 µg ml-1 for varying durations. The last lane shows W3-treated ScN2a 
cells after an additional 2-week incubation without any antibody. PrPSc was detected with SAF70 antibody, 
PrPc was detected with the SAF32 antibody. β-actin was detected using an anti-β-actin antibody as a 
loading control. 
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Abstract 
 
The 37-kDa/67-kDa laminin receptor (LRP/LR) plays a major role in the propagation of PrPSc, the 
abnormal form of the prion protein. In order to ablate the expression of LRP/LR in mouse brain we 
generated transgenic mice ectopically expressing antisense LRP RNA in the brain under control of the 
neuron-specific enolase (NSE) promoter. Hemizygous transgenic mice TgN(NSEasLRP)2 showed a 
significant reduction of LRP/LR protein levels in hippocampal and cerebellar brain regions. These 
mice might act as powerful tools to investigate the role of the laminin receptor in scrapie pathogenesis. 
 
Transmissible spongiform encephalopathies (TSEs) are neurodegenerative diseases thought to be 
caused by prions (proteinaceous infectious particles) which occur in humans and animals. The human 
TSEs include Creutzfeldt-Jakob-Disease (CJD), fatal familiar insomnia (FFI), Gerstmann-Sträussler-
Scheinker syndrome (GSS) and Kuru, whereas bovine spongiform encephalopathy (BSE) affects 
cattle, chronic wasting disease (CWD) elk and deer, and scrapie sheep and goat, respectively 
(Lasmézas and Weiss, 2000; Weissmann and Aguzzi, 1997). The infectious agent, termed prion, is 
thought to consist of an abnormal protein as the main if not the sole infectious component. The key 
event in pathogenesis of prion diseases is the conversion of the cellular prion protein (PrPc) to its 
homolog PrPSc (scrapie form of the prion protein). The latter represents an abnormally folded, 
infectious isoform of the host-encoded and naturally expressed PrPc (Prusiner, 1998). PrPSc and its 
proteinase K resistant form PrP27-30, which is 142 amino acids in length (in case of hamster PrP), are 
present predominantly in brains or lymphoreticular organs of humans or animals suffering from prion 
diseases where they accumulate, sometimes in the form of amyloid plaques (McKinley et al., 1991). 
Recently, we showed that the 37-kDa/67-kDa laminin receptor (LRP/LR), originally identified as an 
interactor for PrPc (Rieger et al., 1997) acts as the cellular receptor for the prion protein (Gauczynski 
et al., 2001b; Hundt et al., 2001) (for review: (Gauczynski et al., 2001a; Leucht and Weiss, 2002)). 
More recently, we showed that the LRP/LR is required for PrPSc-propagation in prion-infected 
neuronal cells (Leucht et al., 2003). The propagation of the protease resistant prion protein has been 
inhibited by transient transfection of short interfering RNAs specific for LRP/LR mRNA into scrapie-
infected N2a and GT1 cells (Leucht et al., 2003). Moreover, the transient expression of laminin 
receptor precursor (LRP) antisense-RNA interfered with PrPSc accumulation in ScMNB cells (Leucht 
et al., 2003). The 37-kDa/67-kDa laminin receptor has two major isoforms, the mature 67-kDa laminin 
receptor and the 37-kDa laminin receptor precursor. Both forms have been shown to locate in the 
plasma membrane of neuronal cells (Gauczynski et al., 2001b). However, four PrP-binding isoforms 
were identified in mouse brain, including a 60-kDa and a 220-kDa form (Simoneau et al., 2003). Five 
genes of LRP/LR have been identified (Leucht et al., 2003), therefore we aimed to establish transgenic 
mice that exhibit a lower level of LRP/LR by antisense RNA technology rather than producing a 
LRP/LR knock-out mouse.  
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Here we report on the generation of hemizygous transgenic mice that express LRP/LR antisense RNA 
under the control of the neuron-specific enolase (NSE) promoter from rat and show reduced LRP/LR 
levels in the cerebellum and hippocampus. This is the first example of a successful antisense RNA 
transgene expression ectopically in the brain employing the NSE-promoter. 
 
The NSE promoter was amplified from the plasmid pNSElacZ by PCR using the primers 5´-
GAAGATCTGAGCTCCTCCTCTGCTCGCCCAATC-3´ (forward) and 5´-
GCGCCTCTCTTAAGGTAGCAGCGCGGGCGGGGGGT-3´ (reverse). The resulting 1.8 kb 
fragment was used to replace the CMV I.E. enhancer/ promoter in the plasmid pCI-neo-asLRP (Leucht 
et al., 2003) using the restriction enzymes BglII and I-Ppo-I. The resulting plasmid pCI-NSE-asLRP 
was linearized using the restriction enzyme BglII. The linearized plasmid was microinjected into 
pronuclei of mouse zygotes (B6D2F2) and then transferred into oviducts of pseudopregnant female 
NMRI mice.  
The offspring were routinely screened by PCR to identify transgenic animals. The transgene copy 
number was evaluated by Southern blotting. Ten micrograms of genomic DNA from transgenic 
animals were digested with SacI, analyzed on an 0.6 % agarose gel and blotted by capillary transfer to 
a positively charged Hybond-N+ membrane (Amersham). The membrane was probed with alpha-32P 
random labeled fragments (Rediprime II, Amersham) derived from the BglII/BamHI digested pCI-
NSE-asLRP 4312 bp fragment. For quantitative analysis the obtained signals were measured by 
phosphor imaging and compared with blotted standard amounts of DNA derived from the plasmid 
pCI-NSE-asLRP. 
The expression of the antisense RNA was monitored by RT-PCR using the specific primers 5’-
AGAAGTTGGTCGTGAGGCAC-3’ (forward) and 5’-TGTATCTTATCATGTCTGCTCGAAG-3’ 
(reverse). The RT-PCR reaction was done in one step employing the Superscript One-Step RT-PCR 
kit (Invitrogen). For protein analysis homogenates from cortex, cerebellum and hippocampus were 
prepared in homogenization buffer (0.32 M sucrose, 10 mM HEPES pH 7.4, 2 mM EDTA plus 
protease inhibitors) from transgenic and control (non-transgenic littermates) animals. Four animals per 
transgenic line were analyzed. For the isolation of crude membranes the homogenates were 
centrifuged at 800g for 15 minutes. The supernatant was centrifuged at 120,000g for 90 minutes. The 
resulting pellet was resuspended in hypotonic lysis buffer (50 mM HEPES pH 7.4, 2 mM EDTA, 0.1% 
Triton X-100 plus protease inhibitors). Fifteen micrograms of each solubilized membrane preparation 
were subjected to SDS-PAGE. The gel was blotted onto a PVDF membrane (Millipore), blocked with 
5% non-fat dry milk and probed with different antibodies diluted in TBST (0.05% Tween 20 in TBS). 
The proteins were visualized by enhanced chemiluminescence (Renaissance, NEN). Stripping of the 
blots was carried out using the Restore Western blot stripping buffer (Pierce). 
CHAPTER IV 
___________________________________________________________________________ 
 
 
56 
 
For densitometric measurements the blots were scanned and the bands were quantified employing 
NIH-Image software. The intensity of all relevant bands was normalized with respect to the β-actin 
signal to circumvent loading inaccuracies. 
 
We could establish four transgenic lines (out of 7 founder animals) harboring the LRP-antisense 
construct in their genome, which were analyzed by Southern blot (Figure 1). The genomes of mice 
TgN(NSEasLRP)2, TgN(NSEasLRP)3 and TgN(NSEasLRP)5 contain approximately the same 
transgene copy numbers (101-116), whereas TgN(NSEasLRP)4 have only about 16 copies in their 
genome (Figure 1). 
We further analyzed transgene expression by RT-PCR (Figure 2 (A)) and monitored for a possible 
antisense-effect on LRP/LR mRNA expression by Western blotting (Figure 2 (B)). All analyzed mice 
showed transgene expression in distinct brain regions (Figure 2 (A), data not shown for 
TgN(NSEasLRP)3, TgN(NSEasLRP)4 and TgN(NSEasLRP)5). TgN(NSEasLRP)2 showed LRP/LR 
antisense expression in the cerebellum and the hippocampus and no or only marginal expression in the 
cortex (Figure 2 (A)). TgN(NSEasLRP)3-5 showed a weaker expression compared to 
TgN(NSEasLRP)2 in the hippocampus and the cerebellum (data not shown). We also observed a 
stronger antisense LRP mRNA expression in the cortex of TgN(NSEasLRP)3 and TgN(NSEasLRP)5 
compared to TgN(NSEasLRP)2 (data not shown), possibly indicating that the transgene is susceptible 
to position efffects. These data demonstrate that the NSE promoter can be active in all examined brain 
tissues. However, the strong expression of antisense LRP mRNA predominantly in the hippocampus 
and cerebellum of TgN(NSEasLRP)2 was surprising since equal expression levels in all brain sections 
were exprected (Forss-Pett et al., 1990). Since only weak or marginal activity of the NSE promoter 
was described in non-neuronal tissue (Mouse Genome Informatics (MGI) Accession ID: MGI: 
1199209) we restricted our examinations to the central nervous system. Only TgN(NSEasLRP)2 
showed a significant LRP/LR reduction in the brain (Figure 2 (B)), whereas no LRP/LR reduction was 
observed in the other transgenic mice (data not shown). Densitometric analysis revealed a reduction of 
~60% in the hippocampus and ~20% in the cerebellum (Figure 2 (C)). No reduction was observed in 
the cortex (Figure 2 (C)) due to the lack of antisense RNA expression (Figure 2 (A)). The lack of 
LRP/LR reduction in TgN(NSEasLRP)3-5 is most likely due to the weaker expression of antisense 
LRP RNA in the examined brain tissues. The simultaneously measured PrPc content showed no 
significant differences to control mice (Figure 2 (B)). This observation is in contrast with our recent 
finding that the PrPc level is reduced in neuroblastoma cells expressing antisense LRP RNA (Leucht et 
al., 2003). It can be explained by the fact that the complex mechanism of the regulation of PrPc 
expression might be better compensated in vivo than in cultured cell lines. Transgenic mice did not 
show abnormal behavior compared to control mice. This is the first example of successful antisense 
transgenesis in mouse brain using the NSE-promoter. However, significant downregulation of the type 
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II glucocorticoid-receptor by antisense RNA in specific brain regions was achieved using the 
neurofilament L promoter (Pepin et al., 1992). 
In summary, we showed that transgenic expression of an antisense construct derived from the LRP 
cDNA under the control of the NSE promoter is able to reduce the LRP/LR protein level in the 
cerebellum and hippocampus of  transgenic mice. The cerebellum and the hippocampus represent 
brain regions where lesions occur in mice challenged with experimental scrapie (Fraser and Dickinson, 
1967). Therefore, the transgenic mice will be used in scrapie infection studies to investigate if the 
accumulation of the abnormal prion protein is delayed or prevented in cerebellar and hippocampal 
brain regions due to a reduced level of LRP/LR. These mice might act as promising tools to elucidate 
the role of the LRP/LR in scrapie pathogenesis in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Southern blot analysis of 10 µg of SacI digested genomic DNA 
derived from TgN(NSEasLRP) mice. The membrane was probed with alpha-32P 
labeled fragments derived from pCI-NSE-asLRP. SacI digestion results in two 
major bands of 2832 and 2361 bp, respectively, due to tandem integration of 
the transgene. 
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Figure 2. (A) The expression of LRP/LR antisense RNA in TgN(NSEasLRP)2 was monitored by a one-
step RT-PCR reaction with primers specific for the transgene. This resulted in a 1115 bp DNA band 
detectable in cerebellum and hippocampus. (B) Representative Western blot of crude membrane 
preparation of cortical, cerebellar and hippocampal brain regions of TgN(NSEasLRP)2. The membrane 
was probed simultaneously with the monoclonal anti-PrP antibody SAF32 and the monoclonal anti-
LRP/LR antibody 43506. As a loading control the stripped blot was incubated with a monoclonal anti-β-
actin antibody. (C) Relative intensities of the LRP-bands in different brain regions compared to control 
brains. Four individual blots of four individual animals were analyzed. Student’s t-test p-values: * <0.05, 
** <0.005. We calculated the standard variation of the LRP/LR level in control animals to ± 9% by 
densitometrical measurements of Western blot signals (data not shown). 
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The 37kDa/67kDa laminin receptor (LRP/LR) has been identified as a cell surface receptor for cellular 
and infectious prion proteins. Here, we show that a N-terminally truncated LRP mutant encompassing 
the extracellular domain of the LRP/LR (LRP102-295::FLAG) reduces the binding of (i) recombinant 
cellular huPrP to mouse neuroblastoma cells, (ii) infectious moPrP27-30 to BHK cells and (iii) 
interferes with the PrPSc propagation in scrapie-infected neuroblastoma cells (N2aSc+). A cell free 
binding assay demonstrated the direct binding of the LRP102-295::FLAG mutant to both PrPc and 
PrPSc. These results together with the finding that endogenous LRP levels remain unaffected by the 
expression of the mutant indicate that the secreted LRP102-295::FLAG mutant may act in a trans-
dominant negative manner as a decoy by trapping PrP molecules. The LRP mutant might represent a 
potential therapeutic tool for the treatment of TSEs. 
 
Introduction 
 
Prion diseases are a group of fatal and transmissible neurodegenerative disorders (TSEs) which 
include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and Creutzfeldt-Jakob 
disease (CJD) in humans (Aguzzi and Weissmann, 1998; Prusiner et al., 1998; Weissmann, 1999). A 
hallmark of all prion diseases is the accumulation of an abnormal, proteinase-resistant isoform (PrPSc) 
of the cellular prion protein (PrPc) which is a cell-surface glycosylphosphatidylinositol (GPI) anchored 
protein that is highly conserved among mammalian species (Schätzl et al., 1995; Wopfner et al., 
1999). The fundamental step in the pathogenesis of TSEs is the conversion of the cellular PrP into the 
PrPSc isoform that involves a conformational change (Prusiner, 1994). We previously showed that the 
37kDa/67kDa laminin receptor (LRP/LR) acts as the cell surface receptor for the cellular PrP 
(Gauczynski et al., 2001b). The findings that (i) BSE prions become internalized by human 
enterocytes via the LRP/LR (Feraudet et al., 2005) and (ii) the binding of mouse PrP27-30 to 
mammalian cells is dependent on LRP/LR (Gauczynski et al., submitted) suggests that LRP/LR acts as 
a receptor for infectious prions. Heparan sulfate proteoglycanes (HSPGs) act as co-factors/co-
receptors for PrPc (Hundt et al., 2001). Recently, we demonstrated that accumulation of PrPSc in 
scrapie-infected neuronal cells (N2aSc+) can be prevented by (i) the transfection of a antisense LRP 
RNA-expression plasmid, (ii) transfection with small interfering RNAs (siRNAs) specific for LRP 
mRNA and (iii) incubation with the anti-LRP/LR antibody W3 (Leucht et al., 2003). 
Various isoforms corresponding to different maturation states of the non-integrin laminin receptor 
LRP/LR have been isolated from mouse brains and found to bind to PrP (Simoneau et al., 2003). 
Therefore, a physiological role of the laminin receptor/PrP interaction in the brain and its relevance for 
transmissible spongiform encephalopathies is suggested. 
At present, there is no approved therapy for prion diseases. Several anti-prion agents exist, including 
polyphenol inhibitors, anti-malaria drugs, antihistamines or phenothiazine derivates (Kocisko et al., 
2003). Chemically designed compounds such as heparan sulfate mimetics were shown to abolish prion  
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propagation (Adjou et al., 2003). Anti-PrP antibodies can antagonize prion propagation in vitro (Peretz 
et al., 2001) and in vivo (Heppner et al., 2001) which is probably due to a global effect on PrP 
trafficking and/or transconformation processes (Feraudet et al., 2005). A trans-dominant negative 
mutant approach targeting PrPc showed that the accumulation of PrPSc was blocked, raising the 
possibility to render animals and humans resistant to prion diseases (Hölscher et al., 1998). 
Since we have shown that a transmembrane deletion mutant of LRP/LR (LRPdelTMD::FLAG), which 
lacks the proposed transmembrane domain of amino acid residues 86-101 (Castronovo et al., 1991), 
was secreted to the medium and prevented PrPc binding and internalization in BHK21 cells 
(Gauczynski et al., 2001b), in this study we investigated the effect of a N-terminally truncated LRP 
mutant (LRP102-295::FLAG), which represents only the extracellular domain of the LRP/LR, in 
normal and scrapie-infected neuroblastoma cells (N2a/N2aSc+). Cell culture experiments exhibit the 
secretion of the LRP102-295::FLAG mutant into the medium of both N2a and N2aSc+ cells. We show 
that secretion of LRP102-295::FLAG mutant is able to significantly decrease the binding of 
recombinant PrP to N2a cells. Furthermore, expression of the LRP102-295::FLAG mutant led to a 
reduced PrP27-30 binding to BHK cells and a reduction of the PrPSc accumulation in chronically 
scrapie-infected mouse neuroblastoma cells. Furthermore, we show that the mutant binds to both PrPc 
and PrPSc, and conclude that the N-terminally truncated LRP102-295::FLAG mutant might have a 
trans-dominant negative effect and might have potential for the development of a TSE therapy. 
 
Results 
 
Secretion of the LRP102-295::FLAG mutant reduces binding of GST::huPrP to N2a cells 
 
Western blot analysis of the crude lysate and the supernatant of N2a cells transfected with pCIneo-
LRP102-295::FLAG and pCIneo-LRP::FLAG, respectively, revealed that the LRP102-295::FLAG 
mutant is secreted to the medium of N2a cells, whereas LRP::FLAG is detectable only in the cell 
lysates of N2a cells (Figure 1a). The LRP102-295::FLAG mutant with a calculated molecular weight 
of approx. 22.3 kDa, migrated with approx. 32kDa on a SDS polyacrylamide gel. Recently, we 
showed that a transmembrane deletion mutant of LRP/LR (LRPdelTMD::FLAG) was secreted to the 
medium and prevented PrPc binding and internalization in BHK21 cells (Gauczynski et al., 2001b). 
Therefore, the possibility that the N-terminally truncated LRP102-295::FLAG mutant has the potency 
to interfere with PrPc binding by intercepting PrP molecules before entering the cell was investigated 
using a cell binding assay. Here, transfected cells were incubated with recombinant GST::huPrP. 
Owing to the fact, that N2a and N2aSc+ cells exhibit endogenous LRP on the cell surface, the anti-
FLAG antibody M2 was used to discriminate between endogenous LRP, LRP102-295::FLAG and 
LRP::FLAG, respectively. Quantitative analysis of western blot signals (Figure 1b) revealed a 
reduction of approximately 60% of GST::huPrP binding to N2a cells expressing the LRP102-
295::FLAG mutant compared to LRP::FLAG expressing N2a cells (Figure 1c). To investigate whether 
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the LRP102-295::FLAG mutant can act as a decoy, we analyzed whether the endognous LRP level is 
influenced upon LRP mutant expression. The fact that the expression of LRP102-295::FLAG did not 
affect endogenous LRP levels (Figure 1a, middle panel) suggests that LRP102-295::FLAG might act 
in a trans-dominant negative manner. 
 
LRP102-295::FLAG reduces the binding of PrP27-30 to BHK cells 
 
To investigate the potential inhibitory effect of the LRP102-295::FLAG mutant on the binding of 
moPrP27-30 to BHK21 cells, which express low levels of endogenous LRP, we transfected SFV-
LRP::FLAG and SFV-LRP102-295::FLAG RNA, respectively, into BHK21 cells resulting in 
expression of both corresponding proteins (Figure 2a, upper panel). BHK21 cells expressing 
LRP::FLAG exhibit higher PrP27-30 binding compared to SFV-1 transfected cells (control), 
confirming an involvement of LRP/LR in the binding of PrP27-30 (Figure 2b, c and Gauczynski et al., 
submitted). In contrast, expression of LRP102-295::FLAG reduced PrP27-30 binding to 
approximately 40% (Figure 2c), suggesting that the mutant traps PrP27-30 molecules and prevents 
their binding and internalization. 
 
Expression of the LRP102-295::FLAG mutant interferes with the PrPSc propagation in N2aSc+ 
cells 
 
To investigate whether the LRP102-295::FLAG mutant also interferes with PrPSc propagation in 
scrapie-infected N2a cells, N2aSc+ were transfected with pCIneo-LRP102-295::FLAG and pCIneo-
LRP::FLAG, respectively, resulting in the expression of LRP102-295::FLAG and LRP::FLAG (Figure 
3a, upper panel). Whereas the mutant was secreted to the medium (Figure 3a, lower panel), 
LRP::FLAG has been solely detected cell associated. Ninety hours post transfection, PrPSc levels were 
reduced up to approximately 35% (mean approximately 45%) (Figure 3b, c). In contrast, expression of 
LRP::FLAG showed no significant effect on PrPSc levels compared to pCIneo (mock) transfected cells 
(Figure 3c). Furthermore, we analyzed PrPc levels in N2aSc+ cells transfected with the LRP102-
295::FLAG mutant and LRP::FLAG, respectively, and found that cellular PrP levels remain 
unaffected in the presence of both LRP102-295::FLAG and LRP::FLAG (data not shown). This 
finding was expected since the endogenous LRP levels remain unaffected by expression of 
LRP::FLAG or LRP102-295::FLAG (data not shown). 
 
LRP102-295::FLAG binds to GST::PrPc and PrP27-30 in a cell free binding assay 
 
To prove whether the LRP102-295::FLAG mutant is able to bind directly PrPc and PrP27-30, a cell-
free binding assay was performed. (i) GST::huPrP-coupled (Figure 4a) and (ii) PrPSc-coupled immuno-
magnetic beads (Figure 4b) were incubated with the supernatant and cell lysates of transfected N2a 
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cells. Expression and secretion of the LRP102-295::FLAG mutant and expression of LRP::FLAG, 
respectively, was tested prior to the binding experiment (data not shown). Western blot analysis of 
bound protein complexes revealed a distinct binding of the LRP102-295::FLAG mutant, expressed in 
the cells (CL) and secreted from these cells (SN), to recombinant GST::huPrP (Figure 4a) and PrPSc 
(Figure 4b), respectively, whereas supernatants of pCIneo (mock) transfected N2a cells showed no 
binding to recombinant GST::huPrP and PrPSc (Figure 4a).  
 
Discussion 
 
The fact that the prion protein is the central determinant in prion diseases has led to many efforts to 
find a strategy for the treatment of TSEs. A variety of anti-prion compounds have been reported, 
mostly targeting the prion protein itself and interfering with the conversion of PrPc into the pathogenic 
isoform PrPSc. Identification of the 37kDa/67kDa laminin receptor (LRP/LR) as a cell surface receptor 
for the cellular (Gauczynski et al., 2001b) and the infectious prion protein (Morel et al., 2005) opened 
a further direction for the development of new TSE-therapeutics. 
Trans-dominant negative mutants targeting PrP have been investigated for their therapeutic potential 
in prion diseases (Kaneko et al., 1997) In vivo studies with transgenic mice expressing PrP with either 
the Q167R or Q218K mutation alone or in combination with wild-type PrP showed that expression of 
the dominant-negative PrP strongly reduced PrPSc formation (Perrier et al., 2002). Moreover, these 
dominant-negative PrP mutants were not converted into PrPSc. The effect of a non-
glycosylphosphatidylinositol (GPI)-anchored recombinant PrP with a Q218K (rPrP-Q218K) mutation 
revealed that rPrP-Q218K inhibits the PrPSc replication in N2aSc+ cells and was more efficient than 
quinacrine (Kishida et al., 2004). Given the knowledge that these mutations (Q167R, Q218K) are 
naturally occurring polymorphic variants of PrP that render resistance to prion disease, gene therapy 
with transdominant negative mutants might be a promising tool in the therapy of TSEs. 
In this manuscript, we investigate a trans-dominant negative LRP/LR mutant and its effect on PrPc, 
PrPSc binding and PrPSc propagation as well as its ability to interact directly with PrPc and PrPSc as a 
prerequisite for its decoy function. We further analyze the influence of the mutant on the endogenous 
LRP/LR levels to proof its possible trans-dominant negative effect. 
 
Secretion of the LRP102-295::FLAG mutant interferes with the binding of GST::huPrP and 
PrP27-30 
 
In order to investigate a possible therapeutic effect of a LRP-mutant encompassing only the 
extracellular domain of the LRP/LR (LRP102-295::FLAG), we employed mouse neuroblastoma (N2a) 
cells as an in vitro model. Due to the fact that mouse neuroblastoma cells exhibit endogenous LRP on 
the cell surface (Gauczynski et al., 2001b), a possible decoy effect of the LRP102-295::FLAG mutant 
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can be investigated in this cell system. Mapping analysis identified amino acid residues 161-179 as a 
direct PrP-binding site on LRP (Hundt et al., 2001). Therefore, this binding site is still intact in the 
LRP102-295::FLAG mutant, so that a binding to cellular PrP is conceivable upon secretion to the cell 
culture medium.  
The N-terminally truncated LRP102-295::FLAG mutant comprises the ability to interfere with the 
binding of recombinant huPrP (Figure 1) and PrP27-30 (Figure 2) to mammalian cells. Binding of 
GST::huPrP to N2a cells is not totally blocked by the secretion of the LRP102-295::FLAG mutant, 
presumably due to the presence of functional LRP/LR receptor molecules on the surface of N2a cells 
capable to bind to PrP. Moreover, we did not observe an enhancement of the binding of recombinant 
GST::huPrP upon expression of LRP::FLAG, which might be explained by the relative high 
expression level of endogenous LRP in these cells (Figure 1). Upon transfection, LRP levels remain 
unaffected, suggesting that transfection did not influence the binding capacity of GST::huPrP in 
LRP::FLAG expressing cells. In contrast, BHK cells express only low levels of endogenous LRP 
(Figure 2). Nevertheless, addition of PrP27-30 to SFV1-transfected cells (control) resulted in a weak 
binding signal (Figure 2). The recent finding that sulfated glycans such as heparan sulfate act as a 
cellular receptor for purified infectious prions (Horonchik et al., 2005) might explain this result. Thus, 
the binding of PrP27-30 to SFV1-transfected BHK cells might represent binding to surface heparan 
sulfates or heparan sulfate proteoglycanes (HSPGs) and to endogenous LRP/LR. Recent experiments 
demonstrate that the binding of mouse PrP27-30 to LRP::FLAG expressing BHK cells can be blocked 
by preincubation of the cells with the LRP/LR specific antibody W3, demonstrating an LRP/LR-
specific binding of the scrapie prion protein (Gauczynski et al., submitted).  
In BHK cells, hyperexpression of full-length LRP::FLAG enhanced the binding of recombinant 
GST::huPrP compared to SFV1-transfected cells (Figure 2). These findings are consistent with the 
publication by Morel et al., showing that bovine prions are endocytosed by human enterocytes via the 
37kDa/67kDa LRP/LR (Morel et al., 2005). In contrast, BHK cells expressing the LRP102-
295::FLAG mutant revealed a significant reduced binding of PrP27-30 compared to LRP::FLAG 
hyperexpressing cells (Figure 2), demonstrating that the LRP102-295::FLAG mutant can interfere 
with the PrP27-30 binding in vitro. BHK cells reveal a weaker expression of the LRP102-295::FLAG 
mutant compared to N2a cells, which might be explained by an intracellular regulatory process within 
BHK cells. The observation that different LRP102-295::FLAG expression levels in N2a and BHK 
cells caused approximately 60% reduction of the PrPc (N2a) and the PrP27-30 binding (BHK), 
respectively, might be due to different amounts of GST::huPrP (20 µg) and PrP27-30 (2 µg), 
respectively, utilized in the binding assays. Therefore, an approximately 10 fold reduced LRP102-
295::FLAG expression level in BHK cells compared to N2a cells resulted in approximately the same 
reduction of PrP binding since also 10 fold less PrP27-30 was utilized in BHK cells compared to N2a 
cells. The fact that the secreted LRP102-295::FLAG mutant efficiently reduces GST::huPrP binding to 
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N2a cells (Figure 1 b), which encompass high levels of LRP (Figure 1 a), suggests that the mutant 
binds more efficiently to PrP as the endogenous LRP, confirming its trans-dominant negative capacity. 
Taken together, these results show that the LRP102-295::FLAG mutant interferes with the binding of 
both PrPc and PrP27-30 to mammalian cells and confirm that LRP/LR acts as a receptor for cellular 
(Gauczynski et al., 2001b) and infectious prions (Gauczynski et al., submitted; Morel et al., 2005). 
 
LRP102-295::FLAG hampers PrPSc propagation in neuroblastoma cells 
 
We showed that expression of the LRP102-295::FLAG mutant hampers the PrPSc propagation in 
scrapie-infected neuronal cells (N2aSc+) (Figure 3). Since we demonstrated that expression of the 
LRP102-295::FLAG mutant in BHK cells hampers PrPSc binding (Figure 2), we suppose that N2aSc+ 
cells might loose PrPSc due to the trapping effect of the mutant in the extracellular space acting in a 
trans-dominant negative fashion and preventing PrPSc binding and internalization. In addition, 
considerable amounts of the mutant were detected cell associated possibly due to a trapping 
mechanism in the cytosol or an unspecific binding to the cell (Figure 1a, 3a). Although the mutant is 
capable to bind to PrPc (Figure 4), intracellular expression of the mutant, however, did not influence 
PrPc levels (data not shown), suggesting no interference of the LRP mutant with the cellular PrP 
metabolism. 
We cannot exclude, however, that the intracellularly expressed LRP mutant might bind to PrPSc within 
the endocytic pathway trapping here PrPSc molecules and enhancing the trapping effect of the mutant in 
the extracellular space. Finally, the mutant might interfere with the PrPc/PrPSc conversion process 
which occurs either at the cell surface or within endocytotic compartments via binding to PrPc and 
PrPSc. 
 
LRP102-295 ::FLAG might act in a trans-dominat negative fashion by trapping cellular and 
scrapie prion proteins 
 
Mouse neuroblastoma (N2a) cells express LRP and PrP endogenously and in vitro-assays revealed a 
LRP/LR-dependent binding and -internalization of recombinant huPrP in mouse neuroblastoma cells 
(Gauczynski et al., 2001b). The LRP102-295::FLAG mutant is secreted to the extracellular space and 
might trap exogenously added recombinant huPrP, resulting in a reduced binding of huPrP to the cell 
surface, as shown in Figure 1. In scrapie-infected neuroblastoma cells, secreted LRP102-295::FLAG 
interferes with PrPSc propagation by trapping PrPSc molecules (Figure 3), circumventing their binding 
to the cell surface. The latter hypothesis was confirmed by our finding that secretion of the LRP102-
295::FLAG mutant strongly reduced binding of PrP27-30 to BHK cells (Figure 2). 
To support the model of a trans-dominant negative inhibition of the LRP102-295::FLAG mutant, the 
binding ability of the mutant to both PrPc and PrPSc was investigated employing a cell-free binding 
assay. Incubation of LRP102-295::FLAG containing supernatants with immunomagnetic beads 
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coupled to recombinant huPrP and PrP27-30, respectively, revealed a direct binding of the LRP102-
295::FLAG mutant to both huPrP and PrP27-30 (Figure 4). The direct binding of LRP::FLAG to 
PrP27-30, which we demonstrated in this manuscript for the first time, is supported by the finding that 
BSE prions and LRP/LR co-localize in early endosomes of human enterocytes (Morel et al., 2005). 
The proof of direct interactions between the LRP mutant and PrPc and PrP27-30, respectively, suggests 
that the mutant might act in a trans-dominant negative manner as a decoy by trapping both PrPc (Figure 
5b) and PrPSc molecules (Figure 5c) and prevent their binding and internalization. The LRP mutant 
might also trap PrPSc molecules within the endocytic pathway  and  might interfere with the PrPc-PrPSc 
conversion process either on the cell surface or within endocytic compartments. 
 
In conclusion, the ability of the LRP102-295::FLAG mutant (i) to interfere with PrPc and PrPSc 
binding and (ii) to reduce PrPSc propagation in scrapie propagating cells recommends the mutant 
which might act in a trans-dominant negative manner as a alternative promising tool for the treatment 
of prion diseases.  
 
Materials and Methods 
 
Recombinant pCIneo Plasmid Constructions. The PCR method was used to amplify the mouse 
laminin receptor (moLRP) using the pSVF1-LRP::FLAG (Gauczynski et al., 2002) plasmid DNA as 
template. NotI- and NheI- restriction sites were used to subclone the moLRP::FLAG into the pCIneo 
mammalian expression vector. To generate the pCIneo-LRP102-295::FLAG plasmid, the C-terminal 
part of the mouse laminin receptor was amplified by PCR using the pCIneo-moLRP::FLAG plasmid 
DNA as template. The correctness of LRP102-295::FLAG was proven by agarose gel electrophoresis 
and confirmed by dideoxy sequencing. The plasmid DNA pCIneo-LRP102-295::FLAG was amplified 
in Escherichia coli and purified by using a plasmid maxi kit (Qiagen) according to the manufactures 
instructions and stored at –20°C. 
 
Recombinant pSFV1 Plasmid Constructions. The pSFV1-LRP::FLAG plasmid was constructed as 
described previously (Gauczynski et al., 2002). The LRP102-295::FLAG fragment was amplified by 
PCR using pSFV1-LRP::FLAG plasmid DNA as a template and subcloned into the pSFV1 vector via 
BamHI and SmaI restriction sites. The cloning was confirmed by dideoxy sequencing. The plasmid 
DNA LRP102-295::FLAG was amplified in E.coli and purified by using a plasmid maxi kit (Qiagen) 
according to the manufacturer’s instructions. 
 
Cell cultures. Mouse neuroblastoma cells (N2a) were grown in DMEM with GlutaMAX™I (Gibco) 
containing 10% fetal calf serum (Gibco), 1x MEM non-essential amino acids (Gibco), 100U/ml 
penicillin and 100µg/ml streptomycin (Gibco) at 37°C in 5% CO2. Scrapie-infected mouse 
neuroblastoma cells (N2aSc+) were provided by S. Lehmann. N2aSc+ cells were cultured in DMEM 
with GlutaMAX™I containing 10% fetal calf serum, 1x MEM non-essential amino acids, 100 U/ml 
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penicillin, 100 µg/ml streptomycin and 0.5 mg/ml geneticin (Invitrogen) at 37°C in 5% CO2. Baby 
hamster kidney cells (BHK21) were cultured in DMEM with GlutaMAX™ containing 10% fetal calf 
serum, 1x MEM non-essential amino acids, 100U/ml penicillin and 100µg/ml streptomycin at 37°C in 
5% CO2. During transfection cells were always cultured in their normal growth medium omitting 
penicillin and streptomycin (transfection medium). 
 
In vitro transcription and cell transfections (SFV-System). DNAs pSFV1, pSFV1-LRP::FLAG and 
pSFV1-LRP102-295::FLAG were linearized with SpeI following purification by phenol-chloroform 
extraction. Transcriptions were carried out in a total volume of 50 µl containing 1.5 µg linearized 
plasmid DNA, 10x SP6 transcription buffer (0.4 M Tris-HCl, pH 8.0 at 20°C; 60 mM MgCl2; 100 mM 
dithiothreitol; 20 mM spermidine), 1 mM of each ATP, CTP and UTP, 500 µM of GTP, 1 mM of 
m7G(5')ppp(5')G, 50 units of RNasin and 50 units of SP6 RNA polymerase and incubated for 2 hours 
at 37°C. The correct length of the transcripts was verified by agarose gel electrophoresis.  
Transfections of BHK21 cells using recombinant SFV1 RNAs were performed according to 
Gauczynski et al. (Gauczynski et al., 2002). Transfection efficiency as determined by transfecting 
SFV3-lacZ RNA followed by X-gal staining was approximately 100%. 
 
Cell transfections with pCIneo plasmids. The day before transfection, cells (N2a, N2aSc+) were 
plated in normal growth medium in a 6-well tissue culture test plate to a confluency of 50%. On the 
day of transfection the normal growth medium was removed and replaced with 1 ml of transfection 
medium. Both N2a and N2aSc+ cells were transfected with pCIneo, pCIneo-LRP::FLAG and pCIneo-
LRP102-295::FLAG, respectively, using the Geneporter™2 transfection reagent (Peqlab) in 
accordance with the manufacturer’s instructions. Transfection efficiency using pCIneo plasmids was 
approximately 60%. 
 
Preparation of supernatants and cell lysates. 72-90 hours post transfection the supernatant and the 
crude cell lysate of N2a, N2aSc+ and BHK21 cells were collected.  
The supernatant was centrifuged for one minute at 40,000 g followed by protein concentration by 
overnight methanol-precipitation at –20°C. Precipitated proteins were centrifuged for 10 minutes at 
40,000 g and pellets were resuspended in 5x SDS-loading buffer, boiled for 5 minutes and subjected to 
SDS-PAGE. Cells were washed with D-PBS (Invitrogen) and lyzed for 10 minutes at 4°C in lysis 
buffer (10 mM Tris/ HCl pH 7.5 containing 100 mM NaCl, 10 mM EDTA, 0.5% Nonidet P40 and 
0.05% sodium deoxycholat) and centrifuged for 5 minutes at 40,000 g to obtain the crude cell lysate 
that was mixed with 5x SDS-loading buffer, boiled for 5 minutes and applied on a polyacrylamide gel. 
For detection of PrP27-30 (N2aSc+ cells) samples were digested with 20 µg/ml Proteinase K of total 
protein for 30 minutes at 37°C. The digestion was stopped by adding phenylmethylsulfonylfluoride 
(PMSF, 2 mM) for 5 minutes at room temperature and subsequently, PK-resistant proteins were 
precipitated by methanol at –20°C overnight. Samples were then centrifuged for 10 minutes at 40,000 
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g and pellets were resuspended in 5x SDS-loading buffer, boiled for 5 minutes and loaded on a 12% 
polyacrylamide (PAA) gel.  
 
Western blotting. Proteins were separated by SDS-PAGE and blotted on a polyvinylidenedifluoride 
(PVDF) membrane (Peqlab). Membranes were blocked with a solution containing 20% horse serum in 
TBS/0.2% Tween20 for at least 1 hour, and incubated overnight with the appropriate primary antibody 
(diluted in 5% horse serum in TBS/0.2% Tween20) at 4°C followed by incubation with the suitable 
secondary antibody for 1 hour. For detection of FLAG-tagged proteins, the monoclonal anti-flag M2 
antibody (1:5,000) was used. Endogenous LRP levels were detected using the LRP-specific single 
chain antibody N3 (1:1000) and the polyclonal anti-LRP antibody W3 (1:5000), respectively. 
Detection of PrP27-30 was carried out using anti-PrP antibodies A7 (1:5,000) and SAF83 (1:5,000), 
respectively. β-Actin was detected using the monoclonal anti-β-actin antibody (1:5,000). Blots were 
developed using an enhanced chemiluminescence system (Perkin Elmer) and exposed on 
chemiluminescense films (Hyperfilm, Amersham). Stripping of the membranes was carried out using 
stripping buffer (100 mM glycine, 1% SDS, 0.1% Nonidet P40; pH 2.2) followed by blocking as 
described and incubation with the sufficient antibody. Quantification of the Western Blot signals were 
performed by densitometric measurements using the NIH-software. 
 
Generation of recombinant prion protein (GST::huPrP). Recombinant GST::huPrP 23-230 was 
generated as described previously (Gauczynski et al., 2001b) and expressed in the baculovirus system. 
Proteins were purified to homogeneity as described for hamster GST::PrP fusions and dialyzed against 
PBS. Until usage recombinant GST::huPrP was stored at –20°C. 
 
GST::huPrP cell binding assay. Seventy two hours post transfection, recombinant GST::huPrP (20 
µg) was added to N2a cells. After 16-19 hours of incubation at 37°C in 5% CO2, supernatants were 
collected. Cells were washed twice with D-PBS (Invitrogen) and cell lysates were prepared following 
western blot analysis.  
 
Preparation of murine PrP27-30. PrP27-30 (PrP27-30 cell binding assay) was extracted from 20% 
mouse brain homogenate derived from 6PB4 (mouse-adapted BSE strain) infected mice (C.Lasmézas, 
Fontenay-aux-Roses, France). Brain homogenates were Proteinase K digested (20 µg/ml, 30 minutes, 
37°C) followed by stopping the reaction with 2 mM PMSF (5 minutes, room temperature). After 
density gradient centrifugation (10% sarcosyl in 10 mM Tris/HCl pH 7.5) for 4 hours, the pellet was 
dried and sonified in 50 mM Hepes pH7.5. Different sonication steps were necessary to dissolve the 
pellet completely. To determine the PrP27-30 concentration a BCA protein assay (Perbio) was used. 
For the cell-free binding assay PrP27-30 was isolated from 10% mouse brain homogenate derived 
from RML (mouse-adapted scrapie strain) and Proteinase K digested as described previously followed 
by a methanol precipitation. After centrifugation (40,000 g, 10 minutes) pellets were resuspended in 
5x SDS-loading buffer, boiled for 5 minutes and subjected to SDS-PAGE.  
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PrP27-30 cell binding assay. Twenty-four hours post transfection, PrP27-30 (2 µg) was added to the 
culture growth medium of BHK21 cells and incubated for 16-19 hours at 37°C in 5% CO2. Cells were 
washed twice with D-PBS (Invitrogen) and cell lysates were prepared as described and analyzed by 
western blot. 
 
Cell-free binding assay (Dynabeads). Immunomagentic beads (Dynabead®ProteinG, Dynal Biotech; 
50 µl per reaction) were coupled with polyclonal anti-PrP antibody A7 for 30 minutes at room 
temperature. For isolation of A7-coupled beads, the test tubes were placed in the Dynal Magnetic 
Particle Concentrator (MPC) for 2 minutes. During this time immunomagnet beads were attracted to 
the wall of the test tube. Supernatants were removed while the beads were held in place by the 
magnetic field of the Dynal MPC. Test tubes were removed from the magnet and beads were 
resuspended in 100 µl PBS and reinserted into the Dynal magnet. Binding of recombinant GST::huPrP 
(2 µg) and PrP27-30 (50 µg), respectively, to A7-coupled beads was performed for 1 hour at 4°C. 
Supernatant (3 ml) and crude cell lysate (400 µg), respectively, from transfected N2a cells was then 
added to the complex and incubated for 1 hour at 4°C. After each incubation step, PBS washing was 
carried out three times. Finally, beads were resuspended in 30 µl SDS-sample buffer and protein 
complexes were released from the immunomagnetic beads by incubation at 95°C for 5 minutes. Test 
tubes were placed into the MPC and supernatants were removed and subjected to SDS-PAGE. 
Immunomagnetic beads were washed three times in 250 mM sodium acetate pH 5.0 and were stored at 
4°C for re-use. 
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Figure 1. Effect of the LRP102-295::FLAG mutant on the binding of GST::huPrP to N2a cells. (a) Western 
blot of transfected N2a cells. Ninety hours post transfection supernatants (SN) and crude cell lysates (CL) 
were prepared and loaded on a 12% PAA gel. LRP102-295::FLAG and LRP::FLAG, respectively, were 
detected using monoclonal anti-flag M2 antibody. The blot was stripped and re-probed with the single chain 
antibody N3 to detect the cellular LRP/LR level. In the lower panel the blot was incubated with the 
monoclonal anti-β-actin antibody. Molecular weight markers in kilodalton (kDa) are indicated on the left. (b) 
The day after transfection 20 µg recombinant GST::huPrP was added to the cell culture medium and incubated 
overnight. Cell lysates were prepared and western blot analysis were performed using the anti-PrP 3B5 
antibody. Figures were digitally arranged. (c) Densitometry analysis using the NIH IMA GE software. The 
results of three individual experiments are shown and expressed as a percentage of control levels ±s.e.m. 
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Figure 2. Effect of LRP102-295::FLAG mutant on the binding of PrP27-30 in BHK21 cells. (a) Cells 
were transfected with SFV1, SFV1-LRP::FLAG and SFV1-LRP102-295::FLAG, respectively, and cell 
lysates were analyzed by western blotting. Expression of LRP::FLAG and LRP102-295::FLAG was 
detected using the monoclonal anti-flag M2 antibody (upper panel). Endogenous LRP levels were 
detected using the polyclonal anti-LRP/LR antibody W3 (lower panel). β-actin was used as a loading 
control (middle panel). Molecular weight markers in kilodalton (kDa) are indicated on the left. (b) 
Twenty four hours post transfection, PrP27-30 was added to the cells and after overnight incubation 
lysates were analyzed by western blotting. PrP27-30 was detected using polyclonal anti-PrP A7 
antibody. The three-band pattern represent the di-, mono- and unglycosylated form of PrP. As a positive 
control 5 µg purified PrP27-30 was loaded. Figures were digitally arranged. (c) Densitometry analysis 
using the NIH IMA GE software. The binding of PrP27-30 to SFV1-transfected BHK cells (control) was 
set to 100% to illustrate the effect of the LRP102-295::FLAG mutant. The results of three individual 
experiments are shown and expressed as a percentage of control levels ±s.e.m.  
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Figure 3. Influence of the LRP102-295::FLAG mutant expression on the PrPSc propagation in N2aSc+ 
cells. (a) Representative western blot of transfected N2aSc+. Ninety hours post transfection, 
supernatants (SN) and crude cell lysates (CL) were prepared. LRP102-295::FLAG and LRP::FLAG, 
respectively, were detected using monoclonal anti-flag M2 antibody. β-actin was used as a loading 
control. Molecular weight markers in kilodalton (kDa) are indicated on the left. (b) PK-digested cell 
lysates (150 µg) were subjected to SDS-PAGE and PrPSc was detected using SAF83 antibody. Figures 
were digitally arranged. (c) Densitometry analysis employing NIH IMAGE software. The results of four 
independent experiments are shown and expressed as a percentage of control levels ±s.e.m. 
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Figure 4. Cell-free binding assay of LRP102-295::FLAG mutant to GST::huPrP and PrP27-30. 
Polyclonal anti-PrP-antibody A7-coupled immunomagnetic beads were bound to (a) recombinant 
GST::huPrP and (b) to PrP27-30 and incubated with supernatants (SN) and cell lysates (CL) of 
transfected N2a cells. Expression and secretion of LRP102-295::FLAG mutant and expression of 
LRP::FLAG, respectively, was checked prior to the experiment. Loaded beads were isolated by 
using a magnetic field and bound proteins were released from the beads by a denaturation step at 
95°C. Protein complexes were loaded on a 12% PAA gel and analyzed by western blotting. 
LRP102-295::FLAG and LRP::FLAG, respectively, were detected using monoclonal anti-flag 
M2 antibody (upper panels). The blots were stripped and re-probed with (a) monoclonal anti-PrP 
antibody 3B5 and (b) anti-PrP SAF83 antibody to detect the recombinant GST::huPrP and 
PrP27-30, respectively. Molecular weight markers in kilodalton (kDa) are indicated on the left. 
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Figure 5. Model for the mode of action of the LRP 102-295::FLAG mutant. (a) Mouse neuroblastoma 
(N2a) cells express LRP/LR and PrP endogenously on the cell surface. Addition of recombinant 
exogeneous PrP (GST::huPrP) results in binding and internalization of PrP (Gauczynski et al., 2001). (b) 
Upon transfection, the N-terminally truncated LRP 102-295::FLAG mutant, representing the extracellular 
domain of LRP/LR, secretes to the cell culture medium. Addition of exogenous PrP (GST::huPrP) results 
in a reduction of PrP binding to N2a cells due to the trapping of exogenous PrP by the LRP 102-
295::FLAG mutant („decoy effect“). (c) Scrapie-infected mouse neuroblastoma (N2aSc+) cells express 
LRP/LR and PrP on the cell surface. Following transfection, the LRP 102-295::FLAG mutant secretes to 
the cell culture medium. We hypothesize that the LRP 102-295::FLAG mutant is able to interfere with the 
PrPSc propagation by trapping free PrPSc molecules before entering the cell (“decoy effect”). The LRP 
mutant might in addition trap PrPSc molecules within compartments of the endocytic pathway  and  might 
hamper the PrPc-PrPSc conversion process either on the cell surface or within endocytic compartments. 
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Abstract 
 
The 37kDa/67kDa laminin receptor (LRP/LR) was identified to act as a cell surface receptor for prion 
proteins. In vitro studies demonstrated that the LRP102-295::FLAG mutant reduced the binding of 
both recombinant cellular huPrP and infectious PrP27-30 and interfered with the PrPSc propagation in 
mouse neuronal cells. These results indicate that the LRP102-295::FLAG mutant may act in a trans-
dominant negative manner as a decoy by trapping PrP molecules. In order to test the potential of the 
LRP mutant in vivo in respect of delay or prevention of prion disease, transgenic animals were 
generated expressing LRP102-295::FLAG ectopically in the brain. Animals showed no phenotype and 
transgene expression was detected in cortical and cerebellar brain regions. An intracerebral prion 
inoculation of these mice will prove, if the expression of the LRP102-295::FLAG mutant can impair 
the PrPSc accumulation in the brain and thus, can act as an alternative therapeutic tool in prion 
diseases. 
 
Prion diseases are neurodegenerative disorders found in mammals, naturally in many ruminants 
(scrapie, BSE), deer (CWD) and mink (TME), as well as humans (Aguzzi and Weissmann, 1998; 
Prusiner et al., 1998; Weissmann, 1999) and are characterized by the accumulation of an abnormal, 
partially protease-resistant isoform of the cellular prion protein (PrPc). The infectious isoform of the 
prion protein (PrPSc) tend to aggregate in brains of affected humans and animals (McKinley et al., 
1991). All prion diseases show long incubation periods but are typically rapidly progressive. In the 
CNS, neuropathological changes, including spongiosis, astrogliosis and neuronal loss (Fraser, 1976), 
are prominent features of prion diseases.  
The 37kDa/67kDa laminin receptor (LRP/LR) was identified as the cell surface receptor for cellular 
PrP (Gauczynski et al., 2001b; Hundt et al., 2001) and for infectious prions (Morel et al., 2005). 
LRP/LR is implicated in a wide variety of biological processes including neuronal cell adhesion, 
differentiation, migration and neurite outgrowth and it has been shown that several isoforms of the 
LRP/LR are present in mouse brain (Simoneau et al., 2003). Recently, we demonstrated that the 
LRP/LR is required for the prion propagation in scrapie-infected neuronal cells (Leucht et al., 2003) 
and showed that secretion of LRP102-295::FLAG mutant, which represents the extracellular domain 
of the LRP/LR, led to a reduction of the PrPSc accumulation in chronically scrapie-infected 
neuroblastoma cells (Vana and Weiss, 2006). Moreover, the LRP102-295::FLAG mutant reduced the 
binding of PrPc and PrP27-30 to cells, indicating that the LRP102-295::FLAG mutant may act in a 
trans-dominant negative manner as a decoy by trapping PrP molecules (Vana and Weiss, 2006). In 
addition, the finding that bovine prions are endocytosed in a LRP/LR dependent manner (Morel et al., 
2005) raised the possibility that the use of LRP/LR as a therapeutic target represent an alternative 
strategy in the development of a TSE treatment. 
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Here we report on the generation of hemizygous transgenic mice expressing the LRP102-295::FLAG 
mutant ectopically in mouse brain under the control of the rat neuron specific enolase (NSE) promoter 
to investigate the decoy effect of the LRP mutant in vivo. Assuming that the NSE promoter-containing 
construct is more efficient in various neuronal cell types than in non-neuronal tissues (Leucht et al., 
2004) we concentrated on the analysis of distinct parts of the central nervous system (CNS). 
Previously, trans-dominant negative mutants targeting PrP (Q167R, Q218K) have been investigated 
for their therapeutic potential in prion diseases (Kaneko et al., 1997) and showed a strong effect on the 
reduction of PrPSc formation in vivo (Perrier et al., 2002). These studies encouraged us to use the trans-
dominant negative LRP102-295::FLAG mutant of the prion protein receptor LRP/LR (Vana and 
Weiss, 2006) as a therapeutic approach in vivo. 
 
NheI and NotI restriction sites were used to subclone the LRP102-295::FLAG (Vana and Weiss, 2006) 
into the pCIneo-NSE plasmid (Leucht et al., 2004) to generate the plasmid pCIneo-NSE-LRP102-
295::FLAG. The pCIneo-NSE-LRP102-295::FLAG plasmid was digested using BglII and BamHI, 
purified by gel extraction (Genomed) following microinjection into pronuclei of mouse zygotes and 
transfer into oviducts of female recipient mice. The offspring were routinely screened by PCR using a 
specific LRP102-295::FLAG-specific primer pair to identify transgenic animals.  
To analyze the expression of the LRP102-295::FLAG protein, cortical and cerebellar brain regions 
were homogenized using homogenization buffer (0.32 M sucrose, 10 mM HEPES pH 7.4, 2 mM 
EDTA plus protease inhibitors) and centrifuged at 750 x g for 15 minutes. Supernatants were 
subjected to SDS-PAGE followed by blotting the gel on a polyvinylidenedifluoride (PVDF) 
membrane (Peqlab). Membranes were blocked with a solution containing 20% horse serum in 
TBS/0.2% Tween20 and incubated with the monoclonal anti-flag M2 antibody (1:5000) and 
monoclonal anti-β-actin antibody (1:5000), respectively. Endogenous LRP and PrP levels were 
detected using the single chain anti-LRP antibody S18 (1:1000) and the anti-PrP antibody SAF32 
(1:5000), respectively. Blots were developed using an enhanced chemiluminescence system (Perkin 
Elmer) and exposed on chemiluminescense films (Hyperfilm, Amersham). Stripping of the 
membranes was carried out using stripping buffer (100 mM glycine, 1% SDS, 0.1% Nonidet P40; pH 
2.2).  
 
Three transgenic lines (TgN(NSE_LRP102-295::FLAG)1, TgN(NSE_LRP102-295::FLAG) 2 and 
TgN(NSE_LRP102-295::FLAG) 3) were established (Figure 1 (A)) and the offspring were monitored 
for the expression of the LRP102-295::FLAG construct by PCR (Figure 1 (B), data not shown for 
TgN(NSE_LRP102-295::FLAG) 2 and TgN(NSE_LRP102-295::FLAG) 3). Transgenic LRP102-
295::FLAG mice were compared with wild-type mice for variations in body size and body weight and 
showed no visible phenotype. Furthermore, behavioral screening tests were performed and resulted in 
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no obvious alterations. The expression of the LRP102-295::FLAG mutant in different brain areas was 
analyzed by western blotting. In TgN(NSE_LRP102-295::FLAG) 1 mice, transgene expression was 
detected in cortex and cerebellum (Figure 2, upper panel) to equal levels as expected (Forss Petter et 
al., 1990). In contrast, no expression of the LRP102-295::FLAG mutant was observed in non-
transgenic littermates (data not shown). Analysis of endogenous PrP levels showed that expression of 
LRP102-295::FLAG in the brain of TgN(NSE_LRP102-295::FLAG) 1 mice resulted in a PrPc 
upregulation in the cortical brain region compared to the cerebellum (Figure 2, middle panel). This is 
in contrast to our recent finding that the PrPc level is unaltered upon expression of the LRP102-
295::FLAG mutant in mouse neuronal cells (Vana and Weiss, 2006). This contradictory result might 
be explained by a complex regulatory mechanism of the PrPc expression in vivo. In addition, due to the 
direct binding capacity of the LRP102-295::FLAG mutant to both PrPc and PrPSc (Vana and Weiss, 
2006), we cannot exclude that the mutant might trap cellular PrP molecules and thus, might enhance 
PrP synthesis. 
Examination of endogenous LRP levels in TgN(NSE_LRP102-295::FLAG) 1 mice revealed no 
change in cortical and cerebellar brain areas upon expression of the LRP102-295::FLAG mutant 
(Figure 2, middle panel). This observation is consistent with our in vitro results showing that the 
expression of LRP102-295::FLAG mutant did not affect endogenous LRP levels (Vana and Weiss, 
2006). Intracerebral (i.c.) prion inoculation studies in these transgenic TgN(NSE_LRP102-
295::FLAG) mice will verify, whether the LRP120-295::FLAG mutant has the ability to delay or 
prevent prion disease in vivo.  
The development of transmissible spongiform encephalopathies in experimental animal models 
depends on two major factors: the intracerebral PrPSc accumulation and the existence of different 
strains of the agent. Previously, it was demonstrated that although intracerebellar prion injections gave 
the lowest yield of PrP27-30, the mice injected into the cerebellum had the shortest incubation period, 
reinforcing the proposal that only the strain of agent influence the pattern of distribution and the yield 
of PrP27-30 (Casaccia-Bonnefil et al., 1993). In addition, mouse-adapted scrapie-strains have been 
characterized showing clear late stage neuropathological differences (Cunningham et al., 2005). 
Nevertheless, in vivo prion infection studies will prove the hypothesis that the LRP mutant might act 
in a trans-dominant negative manner as a decoy by trapping PrP molecules and thus prevent their 
binding and internalization (Vana and Weiss, 2006).  
In conclusion, the present manuscript showed successful transgenic LRP102-295::FLAG expression in 
specific mouse brain region using the NSE-promoter. Assuming that the CNS represent a major organ 
affected by prion diseases, the ectopic expression of a decoy LRP mutant in the brain might display an 
alternative strategy for the development of a TSE therapy. 
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Figure 1. (A) PCR analysis of genomic DNA derived from founder animals of TgN(NSE_LRP102-
295::FLAG) 1, TgN(NSE_LRP102-295::FLAG) 2 and TgN(NSE_LRP102-295::FLAG) 3. Genomic 
DNA was isolated from mouse tail samples and PCR was carried out using a specific primer pair for the 
transgen. This resulted in a 631bp DNA band detected on a 1.5% agarose gel. As a positive control, a 
vector containing LRP102-295::FLAG was used as a template for PCR reaction. Fragment size markers in 
basepairs (bp) are indicated on the left. (B) PCR analysis of genomic DNA derived from 
TgN(NSE_LRP102-295::FLAG) 1 offspring. Five animals were analyzed and two of them carried the 
LRP102-295::FLAG transgen as detected by the 631bp DNA band. Fragment size markers in basepairs 
(bp) are indicated on the left.  
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Figure 2. Representative Western blot of cortical (Co) and cerebellar (Ce) brain region 
preparations of TgN(NSE_LRP102-295::FLAG) 1 mice. LRP102-295::FLAG was 
detected using monoclonal anti-flag M2 antibody. The membrane was stripped and re-
probed simultaneously with the single chain anti-LRP antibody S18 and the monoclonal 
anti-PrP antibody SAF32. β-Actin was used as a loading control. Molecular weight 
markers in kilodalton (kDa) are indicated on the left. 
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The 37kDa/67kDa laminin receptor (LRP/LR) functions as a receptor for prions and represents a novel 
target for a therapeutic intervention in prion diseases. Here, we examined a therapeutic approach using 
lentivirus-based packaging of RNAi targeting the LRP mRNA. We report that VSV-G pseudotyped 
HIV-derived vectors expressing LRP-specific siRNAs strongly downregulate the cellular LRP level in 
different neuronal cell lines. In chronically scrapie-infected neuronal cells, we demonstrate that LRP 
downregulation leads to a reduction of prion-replication. Therefore, this study provides a promising 
therapeutic strategy for the treatment of prion diseases. 
 
Introduction 
 
Transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative disorders affecting 
animals and humans. TSEs are characterized by the accumulation of an “abnormal” pathogenic 
isoform (PrPSc) of the host-encoded cellular prion protein (PrPc) in the brain of affected individuals 
(Prusiner et al., 1998). According to the “protein-only” hypothesis, the conversion of PrPc to PrPSc is 
the pivotal event in the etiology of TSEs (Prusiner et al., 1990).  
Since there is no efficient TSE-treatment available, great expenses have been driven to discover anti-
prion drugs and to develop a vaccination against prion diseases. Due to possible side effects of drugs 
(e.g. toxicity, kidney damage, high blood pressure etc.) and the limitation of either passive or active 
immunization strategies, gene therapy approaches evolved.  
Previously, experimental introduction of RNA was described as a system to interfere with the function 
of an endogenous gene later termed as RNA interference (RNAi). Long-lasting RNAi-mediated gene 
knockdown can be achieved using lentiviral vectors that express the siRNAs. Recently, in an animal 
model of amyotrophic lateral sclerosis (ALS), which is a neurological disease that attacks motor 
neurons, it has been shown that an intraspinal injection of lentiviral vectors led to a substantial delay in 
the onset and progression of the disease (Ralph et al., 2005; Raoul et al., 2005). ). The advantage of 
lentiviral vectors lays in their ability to transduce dividing, non-dividing and terminally differentiated 
cells such as neurons (Blomer et al., 1997; Naldini et al., 1996b). Because neurons are the main target 
cells in prion diseases, the use of lentivirus-mediated RNAi displays a novel strategy to prolong 
disease or even prevent prion replication. 
In order to evaluate a gene transfer therapeutic TSE strategy, we used lentiviral gene transfer, which 
has previously been reported to inhibit PrPSc formation in scrapie-infected neuroblastoma cells (Crozet 
et al., 2004).  
In the present study, human immunodeficiency virus (HIV)-derived vectors that enable the expression 
of short hairpin RNA (shRNA) directed against the LRP mRNA were developed and characterized. 
Subsequently these vectors were applied onto scrapie-infected and non-infected mouse neuronal cells, 
respectively, and the effects on the cellular LRP levels were monitored. Furthermore, we examined the 
PrPSc level in scrapie-infected cells to investigate the influence of the LRP/LR downregulation on the 
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PrPSc propagation in neuronal cells. Our results demonstrate an efficient reduction of 37kDa/67kDa 
LRP/LR protein expression in neuronal cells upon both transient transfection of siRNA containing 
plasmids and genomic integration of lentiviral vectors. Downregulation of LRP gene expression in 
scrapie-infected N2a (N2aSc+) cells resulted in a decrease of PrPSc levels in these cells, indicating an 
essential requirement of LRP/LR for prion propagation in vitro.  
 
Materials and Methods 
 
Cell lines. Mouse neuroblastoma (N2a) and 293FT cells were grown in DMEM with GlutaMAX™I 
(Invitrogen) supplemented with 10% fetal calf serum, 1x MEM non-essential amino acids, 100U/ml 
penicillin and 100µg/ml streptomycin (Invitrogen) at 37°C in 5% CO2. 293FT cells are a fast-growing 
293 cells that stably expresses the large T antigen of SV40. Scrapie infected mouse neuroblastoma 
cells (N2aSc+) were provided by S.Lehmann. N2aSc+ cells were cultured in DMEM with 
GlutaMAX™I containing 10% fetal calf serum, 1x MEM non-essential amino acids, 100 U/ml 
penicillin, 100 µg/ml streptomycin and 0.5 mg/ml geneticin (Invitrogen) at 37°C in 5% CO2. 
Hypothalamic neuronal cells (GT1) were kindly provided by C.Lasmézas and were cultivated in 
OptiMEM (Invitrogen) containing 5% horse serum, 5% fetal calf serum, 100 U/ml penicillin and 100 
µg/ml streptomycin (Invitrogen) at 37°C in 5% CO2. HT1080 cells (human fibrosarcoma cells, ATCC 
No. CCL121) were cultivated in DMEM with GlutaMAX™I (Invitrogen) supplemented with 10% 
fetal calf serum, 1x MEM non-essential amino acids, 100 U/ml penicillin and 100 µg/ml streptomycin 
(Invitrogen) at 37°C in 5% CO2. 
During transfection all cells were cultured in their according growth medium omitting penicillin and 
streptomycin (transfection medium).  
 
Generation of HIV-based lentiviral RNAi vectors. Using the BLOCK-it™ Lentiviral RNAi 
Expression System (Invitrogen), lentiviral RNAi vectors encoding siRNAs directed against the LRP 
mRNA were generated. Target sequences in the LRP mRNA for the RNAi were chosen according to 
the published guidelines (www.invitrogen.com). Double-stranded DNA-oligonucleotides were cloned 
into the pENTR/U6 vector (Invitrogen) to create an entry clone, which can be used to check the 
efficiency of gene silencing by transfection method. The replication-incompetent lentiviral vectors 
containing LRP mRNA-directed siRNAs were produced in 293FT cells according to the 
manufacturer’s instructions. The viral vectors were concentrated (Burns et al., 1993) and the vector 
titer of concentrated stocks was determined by crystal-violet staining of blasticidin selected colonies 
according to the manufacturer´s protocol. 
 
Transfection. The day before transfection, cells were plated into their normal growth medium in a 6-
well tissue culture test plate to a confluency of 50%. On the day of transfection the normal growth 
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medium was removed and replaced with 1 ml of transfection medium. Cells were transfected using the 
Geneporter™2 transfection reagent (Peqlab) in accordance with the manufacturer’s instructions.  
 
Virion production. VSV-G pseudotyped HIV-derived lentiviral vectors (LVV) expressing siRNAs 
directed against the LRP mRNA were produced in 293FT cells using BLOCK-iT Lentiviral RNAi 
Expression System (Invitrogen) according to the manufacturer’s guidelines. 
 
In vitro lentivirus transduction. The day before transduction, target cells were plated into 6-well 
plates and were subsequently transduced with various multiplicities of infection (MOI) ranging from 
0.1 to 10 in the presence of 6 µg/ml polybrene (Invitrogen). The culture media was changed 5 h to 24 
h post transduction and cells were analysed 24 h to 72 h post transduction. To examine long-term 
influence of integrated siRNA coding sequences cells were treated with culture medium supplemented 
with 8 µg/ml blasticidin two days post transduction. Transduced cells were selected for 10 to 14 days 
in blasticidin containing culture medium to obtain stably transduced cell lines. Transduced cells were 
subsequently analyzed by Western Blot and preparation of genomic DNA as described below. 
 
Preparation of cell lysates. Cells were washed with D-PBS (Invitrogen) and lyzed for 10 minutes at 
4°C in lysis buffer (10 mM Tris/ HCl pH 7.5 containing 100 mM NaCl, 10 mM EDTA, 0.05% 
Nonidet P40 and 0.5% sodium deoxycholat) and centrifuged for 5 minutes at 14,000 g to obtain the 
crude cell lysate that was mixed with 5x SDS-loading buffer, boiled for 5 minutes and applied on a 
polyacrylamide gel. For detection of PrPSc samples were digested with 20 µg/ml Proteinase K of total 
protein for 30 minutes at 37°C. The digestion was stopped by adding phenylmethylsulfonylfluoride (2 
mM) for 5 minutes at room temperature and subsequently, PK-resistant proteins were precipitated by 
methanol at –20°C. Then, samples were centrifuged for 10 minutes at 14000 g and the pellets were 
resuspended in 5x-SDS-loading buffer, boiled for 5 minutes and loaded on a 12% PAA gel.  
 
Western blotting. Proteins were separated by SDS-PAGE and blotted on a polyvinylidenedifluoride  
(PVDF) membrane (Peqlab). Membranes were blocked with a solution containing 20% horse serum in 
TBS/ 0.1% Tween 20 for 3 hours, and incubated overnight with the appropriate primary antibody 
(diluted in 5% horse serum in TBS/ 0.1% Tween 20) at 4°C followed by incubation with the suitable 
secondary antibody (1:5,000) for 1 hour. Endogenous LRP levels were detected using the LRP-
specific single chain antibody N3 (1:1,000) and the polyclonal anti-LRP-antibody W3 (1:5,000). 
Detection of PrPSc was carried out using anti-PrP antibody SAF83 (1:5,000). β-Actin was detected 
using the monoclonal anti-β-actin antibody (1:5,000). Blots were developed using an enhanced 
chemiluminescence system (Perkin Elmer) and exposed on chemiluminescence films (Hyperfilm, 
Amersham). 
 
DNA preparation and subsequent PCR reaction. Genomic DNA was prepared using the DNeasy 
tissue kit (Qiagen) according to the manufacturer´s instructions. PCR reaction was carried out using 2 
µg genomic DNA as template and the primer pair U6 forward (5´-GGACTATCATATGCTTACCG-
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3´) and V5 reverse (5´-ACCGAGGAGAGGGTTAGGGAT -3´) to test for vector integration and 
universal ß-actin primer pair (forward 5´-CACACCTTCTACAATGAGCTG-3´, reverse 5´-
GGAGGAGCAATGATCTTGATC-3´) to standardize samples, respectively. PCR cycles (1 min 95 
°C, 2 min 55 °C, 2 min 72 °C; 30 cycles) were carried out using the taq DNA polymerase (Invitrogen) 
and according buffers and conditions. PCR products were subsequently analyzed on a 1.5% 
agarose/TBE gel. 
 
RNA preparation and analysis. Total RNA out of cultured cells was prepared using the Trizol 
reagent (Invitrogen) according to the manufacturer´s instructions. Briefly, 1 × 106 cells were lyzed in 
200 µl Trizol and 50 µl of chloroform was added. After centrifugation at full speed in an Eppifuge 
(4°C, 10 min) the upper phase was treated with one volume of isopropanol and pelleted RNA was 
washed with 70% of ethanol and air-dried to reveal 0.2-1 µg of total RNA. Subsequently, RNA was 
reverse transcribed into cDNA using the reverse transcriptase RT enzyme (Invitrogen). Reaction setup 
was carried out as described in the according manual using 0.1 µg of total RNA and a poly-dT primer 
for reverse transcription. The sample was incubated at 80 °C for 1 min and subsequently cooled down 
on ice. Then, 20 mM dNTPs (Promega), 5 units RT enzyme per reaction were added and the mixture 
was incubated at 37 °C for 1 h. For subsequent PCR reactions, 2 µl of the cDNA sample were used as 
template. PCR was carried out as described above for genomic DNA except the primer pair, which 
was LRP-specific (forw: 5´-ATG TCC GGA GCC CTT GAC GTC CTG-3´; rev:5´-GGA CCA CTC 
AGT GGT GGC TCC AAC C-3´). 
 
Results 
 
Vector-encoded siRNAs targeting the LRP mRNA repress the LRP synthesis in neuronal cells. 
In order to analyze the efficiency of several siRNA target sequences within the LRP mRNA 
transfections of siRNA-encoding vectors (pENTR) were performed using two different neuronal cell 
lines (Fig. 1). All of the three tested siRNAs repressed the LRP-synthesis in both mouse hypothalamic 
(GT1) and mouse neuroblastoma (N2a) cells 72 hours post transfection compared to control (pENTR-
siRNA Lamin A/C) transfected cells (Fig. 1). In GT1 cells pENTR-siRNA 7 showed the strongest 
effect (Fig. 1a and b), whereas in N2a cells pENTR-siRNA 9 was most potent (Fig. 1c and d). In both 
cell lines the maximal reduction of the LRP level was approx. between 40-60%. In contrast, in scrapie-
infected mouse neuroblastoma (N2aSc+) cells LRP levels were reduced up to approx. 40% by pENTR-
siRNA 4 and pENTR-siRNA 9 (Fig. 2a, upper panel and b). These results demonstrate that in different 
neuronal cell lines different siRNA target sequences are effective. 
 
Vector-encoded LRP-specific siRNAs hamper PrPSc propagation in scrapie-infected cells. 
Recently, it has been shown that LRP-specific RNA oligonucleotide duplexes prevent PrPSc 
propagation in scrapie-infected neuronal cells (Leucht et al., 2003). Due to the instability of RNA 
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duplexes, we generated lentiviral encoded siRNAs, which have the ability to integrate into the genome 
of the target cells and lead to a longlasting silencing effect. Therefore, we investigated whether vector-
encoded LRP-specific siRNAs can interfere with the PrPSc propagation in scrapie-infected cells. In 
both N2aSc+ and ScGT1 cells, seventy-two hours post transfection, the PrPSc levels were reduced (Fig. 
2a and c, middle panels). Employing pENTR-siRNA 4 in N2aSc+ cells we observed a downregulation 
of both LRP and PrPSc of approx. 60% (Fig. 2c). In ScGT1 cells, all three LRP-specific siRNAs 
showed an effect (Fig. 2c, middle panel and d). pENTR-siRNA Lamin A/C used as control showed no 
influence on the cellular LRP levels in both neuronal cell lines (Fig. 2). The downregulation of the 
PrPSc propagation correlated with the reduction of the cellular LRP level (Fig.2), confirming the 
requirement of LRP/LR for prion propagation. 
 
Lentiviral-encoded LRP-specific siRNAs are integrated into the genome of neuronal cells. Virion 
particles expressing LRP-specific siRNAs (pLENTI) were produced by transfecting 293FT cells using 
the BLOCK-iT lentiviral expression system (Invitrogen). Viral supernatants were concentrated by 
ultracentrifugation (Burns et al., 1993; Naldini et al., 1996a) and vector titers were determined on 
HT1080 target cells by crystal violet staining ranging from 1 to 7 × 107 TU/ml. 
To evaluate whether vector particles were able to efficiently integrate into the genome of target cells 
and express the LRP-specific siRNAs, N2a cells were transduced with virion preparations with a MOI 
of 1. As demonstrated by PCR analysis, the transduced cells express the LRP-specific siRNAs (Fig. 
3a). In addition, transduction of HT1080 cells, which represent an important component in the titering 
step of the virus particles, revealed expression of LRP-specific siRNAs (data not shown). But, 
transduction of HT1080 cells with a MOI of 1 did not influence the LRP mRNA level in these cells 
(Fig. 3b), suggesting the necessity of a MOI greater than 1 to obtain visible RNAi effects. 
 
Lentiviral particles expressing LRP-specific siRNAs downregulate the cellular LRP level in 
neuronal cells 
To investigate the RNAi-potential of lentiviral particles expressing LRP-specific siRNAs, mouse 
neuronal cells were transduced with MOIs of 1, 5 and 10, respectively. Twenty-four hours post 
transduction, cell lysates of mouse neuroblastoma cells (N2a) were analyzed (Fig. 4a). Expression of 
both pLENTI-siRNA 9 and pLENTI-siRNA 7 resulted in a decrease of LRP levels, whereas the 
pLENTI-siRNA Lamin A/C (control) had no influence on the cellular LRP level (Fig. 4a). In mouse 
hypothalamic cells (GT1), the cell lysates were collected 4, 5 and 6 days post transduction and 
analyzed by western blot (Fig. 4b, upper panel). Four days post transduction, pLENTI-siRNA 7 
resulted in an approx. 50-80% reduction of the LRP level (Fig. 4c). The LRP level is further reduced 5 
days post transduction, reaching approx. 30-10% (Fig. 4c). More than 5 days post transduction, the 
LRP level reached a plateau and no further decrease of the LRP synthesis was observed (Fig. 4c). To 
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confirm the specificity of the effect of the LRP-pLENTI-siRNA 7, transduction was performed using a 
control siRNA (pLENTI-siRNA Lamin A/C). Western blot analysis revealed no change in the cellular 
LRP level after expression of pLENTI-siRNA Lamin A/C in GT1 cells (Fig. 4d, upper panel), 
suggesting a specific effect of siRNAs directed against the LRP mRNA. 
 
Discussion 
 
Transient transfection of PrP-specific siRNA duplexes in scrapie-infected neuroblastoma cells has 
been shown to trigger specific Prn-p gene silencing and caused a rapid loss of its PrPres content 
(Daude et al., 2003), suggesting a promising strategy for a therapy of prion diseases. For a non-
transient expression of siRNAs within mammalian cells, several retroviral-based vectors have been 
developed (Brummelkamp et al., 2002; Devroe and Silver, 2002; Matta et al., 2003; Tomar et al., 
2003) and showed high potential for a therapeutic application.  
Lentivirus-mediated RNAi is a promising therapeutic tool to specifically knockdown disease-relevant 
genes as demonstrated in an ALS animal model (Ralph et al., 2005; Raoul et al., 2005). Lentivirus-
based gene therapy has been developed for various human diseases such as Diabetes mellitus (Oh et 
al., 2005), Parkinson’s disease (Lo Bianco et al., 2004) and Alzheimer’s disease (Marr et al., 2003). In 
mouse models of amyloidosis, intracerebral injection of lentiviral vectors expressing neprilysin, which 
is the major Aβ-degrading enzyme in the brain, reduced amyloid-beta deposits by about 50% (Marr et 
al., 2003), suggesting a potential of gene transfer approaches for the development of alternative 
therapies. Thus, the ability of lentiviruses encoding siRNA to silence genes specifically provide a 
beneficial tool for a TSE therapy. 
Recently, lentiviral gene transfer of PrP containing dominant negative mutations was performed and 
resulted in an inhibition of PrPSc formation in chronically scrapie-infected neuronal cells (Crozet et al., 
2004). Furthermore, in vivo the distribution of lentiviral vectors using intracerebral and intravenous 
routes was examined, demonstrating a transduction of brain and spleen cells (Crozet et al., 2004). 
In vitro, the 37kDa/67kDa LRP/LR has been shown to act as the cell surface receptor for PrP 
(Gauczynski et al., 2001b; Morel et al., 2005) and has been found to be present in the murine central 
nervous system in different maturation states (Simoneau et al., 2003). In addition, it was reported that 
that the 67kDa LR is the major receptor form in adult rat brain and spinal cord (Baloui et al., 2004). 
Furthermore, it was demonstrated that the distribution of LR correlated well with that reported for 
laminin-1 but also with brain regions classically associated with prion-related neurodegeneration 
(Baloui et al., 2004). The 37kDa LRP is thought to be the precursor of the mature 67kDa laminin 
receptor (LR) (Buto et al., 1998), but the exact molecular structure of the 67kDa LR remain unknown 
so far.  
Moreover, it has been shown that LRP/LR is required for PrPSc propagation in scrapie-infected 
neuroblastoma cells (Leucht et al., 2003). In natural scrapie, the gastrointestinal tract is considered to 
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be the major route of infection (Hadlow et al., 1982; Pattison et al., 1972). The involvement of the 
37kDa/67kDa laminin receptor (LRP/LR) in the endocytosis of prions has been recently investigated 
using human enterocytes, which are epithelial cells of the intestine and seem to act as antigen-
presenting cells (Morel et al., 2005). Immunofluorescence analysis revealed that LRP/LR specifically 
mediates the endocytosis of bovine PrPSc into human enterocytes. Interestingly, scrapie prions were 
not found to be internalized, suggesting a specific uptake of bovine BSE prions by human enterocytes 
(Morel et al., 2005). Taken together, these studies encouraged us to assess a further therapeutic 
approach for prion diseases targeting LRP/LR.  
In this study, we used an in vitro system to investigate whether lentivirus-based RNAi directed against 
the 37kDa/67kDa LRP mRNA is able to interfere with the PrPSc propagation in scrapie-infected 
neuronal cells due to a downregulation of LRP/LR expression. Assuming that not all siRNAs directed 
against a target gene are equally effective in suppressing target gene expression (Harborth et al., 
2003), in a pre-experiment we confirmed in both non-infected N2a and GT1 cells that all three 
siRNAs were active and suppressed the cellular LRP synthesis. We observed that in both cell lines a 
different siRNA showed the greatest effect, namely pENTR-siRNA 7 in GT1 cells and pENTR-siRNA 
9 in N2a cells, respectively. Interestingly, in GT1 cells all three siRNAs result in a comparable LRP 
downregulation, whereas in N2a cells a strong variation in the RNAi effect was detected. Both cell 
lines are of neuronal origin and vary in the RNAi response, pointing out the importance of testing an 
assortment of siRNAs to discover the one with the maximal silencing effect.  
In prion diseases, the accumulation of the abnormal, infectious isoform of the cellular prion protein is 
the pivotal step. In the present study, we used the RNAi technology to target the prion protein receptor 
LRP/LR to interfere with the PrPSc propagation in chronically scrapie-infected neuronal cells. Our 
results demonstrate that in both N2aSc+ and ScGT1 cells lentiviral siRNAs targeting the LRP mRNA 
are able to reduce the PrPSc level in these cells and PrPSc reduction correlates with the LRP/LR 
downregulation, suggesting a LRP/LR-dependent PrPSc propagation. In contrast, a siRNA targeting 
Lamin A/C showed no effect on both cellular LRP and PrPSc levels.  
Since there is no LRP/LR-knockout mouse available, RNAi directed against LRP mRNA may provide 
a potential tool to study the role of LRP/LR in vivo. To further enlighten the role of LRP/LR in prion 
diseases, injection of recombinant LRP-specific RNA interference (RNAi) lentiviral particles into 
mice using an intracerebral (i.c.) or intraperitoneal (i.p.) route is projected. Subsequent prion 
inoculation in these mice will prove whether the knockdown of LRP/LR by RNAi might prolong the 
onset or even prevent prion disease.  
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FIG. 1. Effect of pENTR vectors encoding siRNAs directed against the LRP mRNA in neuronal 
cells. (a) Western blot of transfected GT1 cells. Seventy-two hours post transfection crude cell 
lysates were analyzed using the single chain anti-LRP antibody N3 (upper panel). The blot was 
stripped and re-probed with the monoclonal anti-β-actin antibody (lower panel). Molecular weight 
markers in kilodalton (kDa) are indicated on the left. (b) Densitometry analysis using the NIH 
IMAGE software. The results of three individual experiments are shown and expressed as a 
percentage of control levels ±s.e.m. (c) Western blot of transfected N2a cells. The effect of LRP-
specific siRNAs on cellular LRP levels was assayed 65 hours post transfection. Endogenous LRP 
was detected using the single chain anti-LRP antibody N3 (upper panel). β-actin was used as 
loading control (lower panel). Molecular weight markers in kilodalton (kDa) are indicated on the 
left. (d) Densitometry analysis using the NIH IMAGE software. The experiment was performed six 
times and the results are shown as a percentage of control levels ±s.e.m.  
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FIG. 2. Influence of pENTR vectors encoding LRP-specific siRNAs on the PrPSc propagation in scrapie-
infected neuronal cells. (a) Western blot of transfected N2aSc+ cells. Seventy-two hours post transfection 
crude cell lysates were prepared and subjected to SDS-PAGE. Cellular LRP was detected using the single 
chain anti-LRP antibody N3 (upper panel). The blot was stripped and re-probed with the monoclonal anti-β-
actin antibody (lower panel). PK-digested cell lysates were analyzed using anti-PrP SAF83 antibody (middle 
panel). Molecular weight markers in kilodalton (kDa) are indicated on the left. (b) Densitometry analysis 
using the NIH IMAGE software. (c) Western blot of transfected ScGT1 cells. The effect of LRP-specific 
siRNAs on cellular LRP levels was assayed using the single chain anti-LRP antibody N3 (upper panel). 
PrPSc was detected using the SAF83 antibody (middle panel). β-actin was used as loading control (lower 
panel). Molecular weight markers in kilodalton (kDa) are indicated on the left. (d) Densitometry analysis 
using the NIH IMAGE software.  
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FIG. 3. Detection of the integration of lentiviral vectors expressing LRP-specific siRNAs and their 
effect on the mRNA level. (a) PCR analysis of transduced mouse neuroblastoma cells.  N2a cells were 
transduced with virion preparations with a MOI of 1 and genomic DNA was prepared. PCR reaction 
was carried out and PCR products were analyzed on an agarose/TBE gel. The expression of the LRP-
specific siRNAs was tested using the primer pair U6 forward and V5 reverse, giving a band of 250 bp 
(upper panel). To standardize samples, a β-actin primer pair was used resulting in a band of 600 bp 
(lower panel). The specificity of the PCR signal for the siRNAs was proven using genomic DNA 
(gDNA) of non transduced N2a cells as a template for the PCR reaction. (b) mRNA levels in HT1080 
cells after transduction with lentiviral vectors expressing siRNAs directed against the LRP mRNA. 
HT1080 cells were transduced with a MOI of 1 and were selected for 5 days in blasticidin containing 
medium following isolation of total cellular RNA. The cDNA resulting from the reverse transcription 
was amplified in a PCR reaction using a LRP-specific primer pair. PCR products were separated on an 
agarose/ TBE gel and visualized using ethidium bromide staining. The LRP-specific signal resulted in a 
800 bp pair band (upper panel). As a control, cDNA from non transduced HT1080 cells was used. To 
standardize samples, a β-actin primer pair was used resulting in a band of 600 bp (lower panel).  
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FIG. 4. Effect of lentiviral vectors expressing LRP-specific siRNAs in neuronal cells. (a) Western blot 
of N2a cells transduced with virion particles (MOI=10) expressing LRP-specific siRNA 4, 7, 9 and 
control siRNA Lamin A/C, respectively (upper panel). Cells lysates were analyzed one day post 
transduction using the anti-LRP-antibody W3. As a loading control β-actin was used (lower panel). 
Molecular weight markers in kilodalton (kDa) are indicated on the left. (b) Western blot of GT1 cells 
transduced with pLENTI-siRNA 7. Cells were transduced using MOI of 0, 5 and 10, respectively. Four, 
five and six days post transduction crude cell lysates were prepared and analyzed using the single chain 
anti-LRP antibody N3 (upper panel). The blot was stripped and re-probed with the monoclonal anti-β-
actin antibody (lower panel). Molecular weight markers in kilodalton (kDa) are indicated on the left. (c) 
Densitometry analysis using the NIH IMAGE software. (d) Western blot of GT1 cells transduced with 
pLENTI-Lamin A/C. Four, five and six days post transduction crude cell lysates were prepared and 
subjected to SDS-PAGE. The effect on cellular LRP levels was assayed using the single chain anti-LRP 
antibody N3 (upper panel). β-actin was used as loading control (lower panel). Molecular weight 
markers in kilodalton (kDa) are indicated on the left.  
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1-character code for amino acids    3-character code for amino acids 
A alanine       Asn asparagine 
D aspartic acid      Cys cysteine 
E glutamic acid      Leu leucine 
F phenylalanine      Met methionine 
G glycine       Phe phenylalanine 
H histidine      Ser serine 
K lysine       Thr threonine 
L leucine       Val valine 
N asparagine 
P proline  
Q glutamine 
R arginine 
S serine 
T threonine 
Y tyrosine 
 
%      percentage 
°C      degree Celsius 
37kDa LRP     37kDa laminin receptor precursor 
67kDa LR     67kDa laminin receptor 
[α-32P]-UTP     uridine 5´-alpha 32P triphosphate 
aa      amino acid 
AAV      adeno associated virus 
AD      Alzheimer’s disease 
ALS      amyotrophic lateral sclerosis 
ApoEe4     apolipoprotein E type epsilon 4 
approx.      approximately 
asLRP      antisense laminin receptor precursor 
BBB      blood-brain barrier 
BSE      bovine spongiform encephalopathie 
cAMP      cyclic adenosinemonophosphat 
CaCo-2/TC7     human colon carcinoma cells 
cDNA      complementary deoxyribonucleic acid 
CHO      chinese ovary hamster cells 
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CJD (sCJD, vCJD, fCJD, iCJD) Creutzfeldt-Jakob disease (sporadic, variant, familiar,  
iatrogenic form of CJD) 
CLD caveolae-like domain 
CNS central nervous system 
Cos-7 african green monkey kidney cells 
CPEB cytoplasmic polyadenylation element binding protein 
C-terminal carboxyterminal 
Cu2+ copper (II) ion 
CWD chronic wasting disease 
Dicer-RDE-1 Dicer-RNAi deficient-1 
DIG detergent insoluble glycosphingolipid-rich membrane 
domain 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
Dpl doppel protein 
DPG2-Fe3+ deuteroporphyrin IX 2,4-bis-(ethylene glycol) iron 
(III) 
DY drowsy (TME prion strain) 
ds double-stranded 
DS500 dextran sulfate 500 
EDTA ethylenediaminetetraacetic acid 
ER endoplasmatic reticulum 
EU European Union 
EUE exotic ungulate encephalopathy 
FFI fatal familial insomnia 
FGF fibroblast growth factor 
FSE feline spongiform encephalopathy 
GAG glycosaminoglycan 
GPI glycosyl phosphatidyl inositol 
Grb2 growth factor receptor-bound protein-2 
GSS Gerstmann-Straussler-Scheinker syndrome 
GST gluthation-S-transferase 
GT1 hypothalamic neuronal cells 
h hour 
HEPES 2-(4-(2-Hydroxyethyl)-1piperazinyl) ethanesulfonic 
acid sodium salt 
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hGH human growth hormon 
hGNH human gonadotropin 
HM heparansulfate mimetic 
HPA23 heteropolyanion 23 
Hsp heat shock protein 
HSPG heparansulfate proteoglycan 
HSV herpes simplex virus 
HY hyper (TME prion strain) 
IDX 4´-iodo-4´-deoxy-doxorubicin 
kb kilobase 
kDa kilodalton 
M molar 
mM millimolar 
MCF-7 human breast adenocarcinoma cells 
µg microgram 
mg milligram 
ml milliliter 
mRNA messenger RNA 
N2a mouse neuroblastoma cells 
N2aSc+ scrapie-infected mouse neuroblastoma cells 
NaCl sodiumchloride 
NMR nuclear magnetic resonance 
NSE neuron specific enolase 
N-terminal aminoterminal 
PAA polyacrylamide 
PAMAM  polyamidoamide 
PCR polymerase chain reaction 
PcTS phtalocyanine tetrasulfonate 
PEI polyethyleneimine 
PK proteinase K 
PIL pegylated immunoliposomes 
PKA proteinkinase A 
PPI polypropyleneimine 
Prn-d prion protein gene 
Prn-p prion protein dublet  
Prn-p-/-/ Prn-p0/0 PrP knock out 
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PrP prion protein 
CtmPrP/ NtmPrP transmembrane forms of the prion protein 
PrP 27-30 protease-resistent core of the prion protein 
PrPc cellular prion protein 
PrPres protease-resistant form of the prion protein 
PrPSc pathogenic isoform of the cellular prion protein 
PS pentosan polysulfate 
PSE primate spongiform encephalopathy 
PVDF polyvinylidenedifluoride 
rER rough endoplasmatic reticulum 
RISC RNA-induced silencing complex 
RNA ribonucleic acid 
RNAi RNA interference 
RT-PCR reverse transcriptase polymerase chain reaction 
SAF scrapie associated fibril 
scFv single chain variable fragment 
ScGT1 scrapie-infected hypothalamic neuronal cells 
ScMNB scrapie-infected mouse neuroblastoma cells 
SDS sodiumdodecylsulfate 
SDS-PAGE SDS polyacrylamide gelelectrophoresis 
sFI sporadic familial insomnia 
shRNA short hairpin RNA 
SIFT scanning for intensely fluorescent targets 
siRNA small interfering RNA 
STI1 stress-inducible protein-1 
Sup35p* prion form of Sup35p 
TBE tris-borate-EDTA 
TBS tris buffered saline 
TBST tris buffered saline/ tween 20 
tg trangenic/ transgene 
TGF-β transforming growth factor-β 
TME transmissible mink encephalopathy 
TMPP-Fe3+ meso-tetra(4-N-methylpyridyl) porphine iron (III) 
TNF tumor necrosis factor 
TSE transmissible spongiform encephalopathy 
UK United Kingdom 
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Ure2p* prion form of Ure2p 
US/ USA United States of America 
VH, VL variable region immunoglobulin heavy, light chain 
VEE Venezuelan equine encephalitis virus  
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